<!DOCTYPE html>
 <!--[if lt IE 7]> <html dir="ltr" lang="en-US" class="aui ltr no-js lt-ie9 lt-ie8 lt-ie7"> <![endif]--> <!--[if IE 7]> <html dir="ltr" lang="en-US" class="aui ltr no-js lt-ie9 lt-ie8"> <![endif]--> <!--[if IE 8]> <html dir="ltr" lang="en-US" class="aui ltr no-js lt-ie9"> <![endif]--> <!--[if gt IE 8]><!--> <html class="aui ltr" dir="ltr" lang="en-US" prefix="og: http://ogp.me/ns#"> <!--<![endif]--> <head> <title>Anticholinergic medication for antipsychotic‐induced tardive dyskinesia - Bergman, H - 2018 | Cochrane Library</title> <meta content="Anticholinergic medication for antipsychotic‐induced tardive dyskinesia - Bergman, H - 2018 | Cochrane Library" property="og:title"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD000204.pub2/full" property="og:url"/> <meta content="article" property="og:type"/> <meta content="https://www.cochranelibrary.com/cochrane-theme/images/cochrane_circulargraphic.png" property="og:image"/> <meta content="summary_large_image" name="twitter:card"/> <meta content="Anticholinergic medication for antipsychotic‐induced tardive dyskinesia - Bergman, H - 2018 | Cochrane Library" name="twitter:title"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD000204.pub2/full" name="twitter:url"/> <meta content="https://www.cochranelibrary.com/cochrane-theme/images/cochrane_circulargraphic.png" name="twitter:image"/> <meta content="initial-scale=1.0, width=device-width" name="viewport"/> <meta content="10.1002/14651858.CD000204.pub2" name="dc.identifier" scheme="DOI"/> <meta content="Anticholinergic medication for antipsychotic‐induced tardive dyskinesia" name="citation_title"/> <meta content="Hanna Bergman" name="citation_author"/> <meta content="Cochrane" name="citation_author_institution"/> <meta content="hbergman@cochrane.org" name="citation_author_email"/> <meta content="Karla Soares‐Weiser" name="citation_author"/> <meta content="Cochrane" name="citation_author_institution"/> <meta content="Cochrane Database of Systematic Reviews" name="citation_journal_title"/> <meta content="John Wiley &amp; Sons, Ltd" name="citation_publisher"/> <meta content="1" name="citation_issue"/> <meta content="10.1002/14651858.CD000204.pub2" name="citation_doi"/> <meta content="2018" name="citation_date"/> <meta content="2018/01/17" name="citation_online_date"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD000204.pub2/abstract" name="citation_abstract_html_url"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD000204.pub2/full" name="citation_fulltext_html_url"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD000204.pub2/pdf/full" name="citation_pdf_url"/> <meta content="1465-1858" name="citation_issn"/> <meta content="en" name="citation_language"/> <meta content="Antipsychotic Agents [*adverse effects]; Biperiden [adverse effects, therapeutic use]; Cholinergic Antagonists [adverse effects, *therapeutic use]; Dyskinesia, Drug‐Induced [*drug therapy, etiology]; Isocarboxazid [adverse effects, therapeutic use]; Procyclidine [adverse effects, therapeutic use]; Randomized Controlled Trials as Topic; Schizophrenia [drug therapy]; Withholding Treatment" name="citation_keywords"/> <link href="https://fonts.googleapis.com/css?family=Source+Sans+Pro:400,700,600,900" rel="stylesheet"/> <script src="https://cmp.osano.com/AzZdRbSORDOOzF9W/d594efc1-9663-477d-9528-6576640e64fd/osano.js"></script> <style> .osano-cm-widget{display: none;} </style> <script src="https://static.addtoany.com/menu/page.js"></script> <script async="" charset="utf-8" src="https://platform.twitter.com/widgets.js"></script> <script async="async" src="//script.crazyegg.com/pages/scripts/0056/6375.js" type="text/javascript"></script> <script type="text/javascript">window.dataLayer={};var xtend=function(){var a={};var b=false;var c=0;var d=arguments.length;if(Object.prototype.toString.call(arguments[0])==="[object Boolean]"){b=arguments[0];c++}var f=function(g){for(var h in g){if(Object.prototype.hasOwnProperty.call(g,h)){if(b&&Object.prototype.toString.call(g[h])==="[object Object]"){a[h]=xtend(true,a[h],g[h])}else{a[h]=g[h]}}}};for(;c<d;c++){var e=arguments[c];f(e)}return a};</script> <!-- Global site tag (gtag.js) - Google Analytics --> <script src="https://www.googletagmanager.com/gtag/js?id=UA-189672-63&amp;l=gDataLayer"></script> <script>window.gDataLayer=window.gDataLayer||[];function gtag(){gDataLayer.push(arguments)}gtag("js",new Date());gtag("config","UA-189672-63");</script> <script type="text/javascript">var o={auth:{customerIds:[],individualId:null,brandedCustomer:null,roles:["Guest"]}};window.dataLayer=xtend(true,window.dataLayer,o);</script> <script type="text/javascript">var o={page:{siteSection:"Content",languageCode:"en",cms:{pageTitle:"Content"}}};window.dataLayer=xtend(true,window.dataLayer,o);</script> <meta content="text/html; charset=utf-8" http-equiv="content-type"/> <link href="https://www.cochranelibrary.com/cochrane-theme/images/favicon.ico" rel="Shortcut Icon"/> <link href="https://www.cochranelibrary.com/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD000204.pub2&amp;doi=10.1002/14651858.CD000204.pub2&amp;type=cdsr&amp;contentLanguage=" rel="canonical"/> <link href="https://www.cochranelibrary.com/zh/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD000204.pub2&amp;doi=10.1002/14651858.CD000204.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="zh-HANS" rel="alternate"/> <link href="https://www.cochranelibrary.com/zh_HANT/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD000204.pub2&amp;doi=10.1002/14651858.CD000204.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="zh-HANT" rel="alternate"/> <link href="https://www.cochranelibrary.com/hr/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD000204.pub2&amp;doi=10.1002/14651858.CD000204.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="hr-HR" rel="alternate"/> <link href="https://www.cochranelibrary.com/nl/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD000204.pub2&amp;doi=10.1002/14651858.CD000204.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="nl-NL" rel="alternate"/> <link href="https://www.cochranelibrary.com/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD000204.pub2&amp;doi=10.1002/14651858.CD000204.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="x-default" rel="alternate"/> <link href="https://www.cochranelibrary.com/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD000204.pub2&amp;doi=10.1002/14651858.CD000204.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="en-US" rel="alternate"/> <link href="https://www.cochranelibrary.com/fr/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD000204.pub2&amp;doi=10.1002/14651858.CD000204.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="fr-FR" rel="alternate"/> <link href="https://www.cochranelibrary.com/de/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD000204.pub2&amp;doi=10.1002/14651858.CD000204.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="de-DE" rel="alternate"/> <link href="https://www.cochranelibrary.com/hi/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD000204.pub2&amp;doi=10.1002/14651858.CD000204.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="hi-HI" rel="alternate"/> <link href="https://www.cochranelibrary.com/hu/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD000204.pub2&amp;doi=10.1002/14651858.CD000204.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="hu-HU" rel="alternate"/> <link href="https://www.cochranelibrary.com/in/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD000204.pub2&amp;doi=10.1002/14651858.CD000204.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="in-ID" rel="alternate"/> <link href="https://www.cochranelibrary.com/ja/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD000204.pub2&amp;doi=10.1002/14651858.CD000204.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="ja-JP" rel="alternate"/> <link href="https://www.cochranelibrary.com/ko/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD000204.pub2&amp;doi=10.1002/14651858.CD000204.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="ko-KR" rel="alternate"/> <link href="https://www.cochranelibrary.com/ms/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD000204.pub2&amp;doi=10.1002/14651858.CD000204.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="ms-MY" rel="alternate"/> <link href="https://www.cochranelibrary.com/fa/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD000204.pub2&amp;doi=10.1002/14651858.CD000204.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="fa-IR" rel="alternate"/> <link href="https://www.cochranelibrary.com/pl/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD000204.pub2&amp;doi=10.1002/14651858.CD000204.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="pl-PL" rel="alternate"/> <link href="https://www.cochranelibrary.com/pt/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD000204.pub2&amp;doi=10.1002/14651858.CD000204.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="pt-PT" rel="alternate"/> <link href="https://www.cochranelibrary.com/ro/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD000204.pub2&amp;doi=10.1002/14651858.CD000204.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="ro-RO" rel="alternate"/> <link href="https://www.cochranelibrary.com/ru/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD000204.pub2&amp;doi=10.1002/14651858.CD000204.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="ru-RU" rel="alternate"/> <link href="https://www.cochranelibrary.com/es/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD000204.pub2&amp;doi=10.1002/14651858.CD000204.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="es-ES" rel="alternate"/> <link href="https://www.cochranelibrary.com/ta/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD000204.pub2&amp;doi=10.1002/14651858.CD000204.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="ta-IN" rel="alternate"/> <link href="https://www.cochranelibrary.com/th/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD000204.pub2&amp;doi=10.1002/14651858.CD000204.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="th-TH" rel="alternate"/> <link class="lfr-css-file" href="https://www.cochranelibrary.com/cochrane-theme/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1738734064000" rel="stylesheet" type="text/css"/> <link class="lfr-css-file" href="https://www.cochranelibrary.com/cochrane-theme/css/aui.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1738734064000" rel="stylesheet" type="text/css"/> <link href="/html/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1739772874000" rel="stylesheet" type="text/css"/> <link href="https://www.cochranelibrary.com/scolaris-content-display/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" rel="stylesheet" type="text/css"/> <link href="https://www.cochranelibrary.com/notifications-portlet/notifications/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1739772751000" rel="stylesheet" type="text/css"/> <link href="https://www.cochranelibrary.com/html/portlet/login/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1739772901000" rel="stylesheet" type="text/css"/> <script type="text/javascript">var Liferay={Browser:{acceptsGzip:function(){return false},getMajorVersion:function(){return 80},getRevision:function(){return"537.36"},getVersion:function(){return"80.0"},isAir:function(){return false},isChrome:function(){return true},isFirefox:function(){return false},isGecko:function(){return true},isIe:function(){return false},isIphone:function(){return false},isLinux:function(){return true},isMac:function(){return false},isMobile:function(){return false},isMozilla:function(){return false},isOpera:function(){return false},isRtf:function(){return true},isSafari:function(){return true},isSun:function(){return false},isWap:function(){return false},isWapXhtml:function(){return false},isWebKit:function(){return true},isWindows:function(){return false},isWml:function(){return false}},Data:{NAV_SELECTOR:"#navigation",isCustomizationView:function(){return false},notices:[null]},ThemeDisplay:{getLayoutId:function(){return"7"},getLayoutURL:function(){return"https://www.cochranelibrary.com/en/content"},getParentLayoutId:function(){return"0"},isPrivateLayout:function(){return"false"},isVirtualLayout:function(){return false},getBCP47LanguageId:function(){return"en-US"},getCDNBaseURL:function(){return"https://www.cochranelibrary.com"},getCDNDynamicResourcesHost:function(){return""},getCDNHost:function(){return""},getCompanyId:function(){return"20155"},getCompanyGroupId:function(){return"20195"},getDefaultLanguageId:function(){return"en_US"},getDoAsUserIdEncoded:function(){return""},getLanguageId:function(){return"en_US"},getParentGroupId:function(){return"20182"},getPathContext:function(){return""},getPathImage:function(){return"/image"},getPathJavaScript:function(){return"/html/js"},getPathMain:function(){return"/en/c"},getPathThemeImages:function(){return"https://www.cochranelibrary.com/cochrane-theme/images"},getPathThemeRoot:function(){return"/cochrane-theme"},getPlid:function(){return"20757"},getPortalURL:function(){return"https://www.cochranelibrary.com"},getPortletSetupShowBordersDefault:function(){return true},getScopeGroupId:function(){return"20182"},getScopeGroupIdOrLiveGroupId:function(){return"20182"},getSessionId:function(){return""},getSiteGroupId:function(){return"20182"},getURLControlPanel:function(){return"/group/control_panel?refererPlid=20757"},getURLHome:function(){return"https\x3a\x2f\x2fwww\x2ecochranelibrary\x2ecom\x2fweb\x2fcochrane"},getUserId:function(){return"20159"},getUserName:function(){return""},isAddSessionIdToURL:function(){return false},isFreeformLayout:function(){return false},isImpersonated:function(){return false},isSignedIn:function(){return false},isStateExclusive:function(){return false},isStateMaximized:function(){return false},isStatePopUp:function(){return false}},PropsValues:{NTLM_AUTH_ENABLED:false}};var themeDisplay=Liferay.ThemeDisplay;Liferay.AUI={getAvailableLangPath:function(){return"available_languages.jsp?browserId=other&themeId=cochrane_WAR_cochranetheme&colorSchemeId=01&minifierType=js&languageId=en_US&b=6210&t=1513679709000"},getCombine:function(){return true},getComboPath:function(){return"/combo/?browserId=other&minifierType=&languageId=en_US&b=6210&t=1513679709000&"},getFilter:function(){return"min"},getJavaScriptRootPath:function(){return"/html/js"},getLangPath:function(){return"aui_lang.jsp?browserId=other&themeId=cochrane_WAR_cochranetheme&colorSchemeId=01&minifierType=js&languageId=en_US&b=6210&t=1513679709000"},getStaticResourceURLParams:function(){return"?browserId=other&minifierType=&languageId=en_US&b=6210&t=1513679709000"}};Liferay.authToken="xcg9958b";Liferay.currentURL="\x2fweb\x2fcochrane\x2fcontent\x3ftemplateType\x3dfull\x26urlTitle\x3d\x2fcdsr\x2fdoi\x2f10\x2e1002\x2f14651858\x2eCD000204\x2epub2\x26doi\x3d10\x2e1002\x2f14651858\x2eCD000204\x2epub2\x26type\x3dcdsr\x26contentLanguage\x3d";Liferay.currentURLEncoded="\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD000204\x2epub2\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD000204\x2epub2\x2526type\x253Dcdsr\x2526contentLanguage\x253D";</script> <script src="/html/js/barebone.jsp?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;colorSchemeId=01&amp;minifierType=js&amp;minifierBundleId=javascript.barebone.files&amp;languageId=en_US&amp;b=6210&amp;t=1513679709000" type="text/javascript"></script> <script type="text/javascript"></script> <script type="text/javascript">var o={database:"CDSR",page:{pageType:"Article Full Text HTML"},article:{availableLanguage:["en","es","de","fa","zh_HANS"],languageCode:"en",accessStatus:"delayed-free",doi:"10.1002/14651858.CD000204.pub2",title:"Anticholinergic medication for antipsychotic\\u2010induced tardive dyskinesia",firstPublishedDate:"Jan 17, 2018 12:00:00 AM",isCurrentVersion:true,editorialGroup:"Cochrane Schizophrenia Group",availableParts:["PDF Full","PDF Standard","PDF Abstract","HTML","Comments","Information","References","Stats","Related Content"]}};window.dataLayer=xtend(true,window.dataLayer,o);</script> <link class="lfr-css-file" href="https://www.cochranelibrary.com/cochrane-theme/css/custom.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1738734064000" rel="stylesheet" type="text/css"/> <style type="text/css"></style> <script async="" src="https://assets.adobedtm.com/59640f9fa510/7cad07cf7779/launch-a215d9c51521.min.js"></script> <!--[if lt IE 9]> <script src="/cochrane-theme/vendor/respond/dest/respond.min.js?t=1738734064000" type="text/javascript"></script> <![endif]--> </head> <body class="yui3-skin-sam controls-visible guest-site signed-out public-page site"> <div class="site-container"> <a href="#main-content" id="skip-to-content">Skip to Content</a> <div class="cookie-message cookie-message--hidden system-message-container" id="js-cookie-message"> <div class="container"> <a aria-label="Close cookies message" class="fa fa-times js-cookie-close pull-right" href="#"></a> <div class="system-message-wrapper container"> <i aria-hidden="true" class="fa fa-exclamation-triangle"></i> <div class="system-message-title">Cookies</div> <div class="system-message-description"> <p> Our site uses cookies to improve your experience. You can find out more about our use of cookies in About Cookies, including instructions on how to turn off cookies if you wish to do so. By continuing to browse this site you agree to us using cookies as described in <a href="http://olabout.wiley.com/WileyCDA/Section/id-813473.html">About Cookies</a>. </p> <a class="btn secondary js-cookie-close js-cookie-accept" href="#">I accept</a> </div> </div> </div> </div> <script>document.body.className=document.body.className+" js_enabled";</script><header> <div class="container"> <div class="branding"> <h1 class="brand-container"> <a href="https://www.cochranelibrary.com/en/"> <span class="brand-name">The Cochrane Library</span> <img alt="Cochrane Library logo" class="brand-logo" src="https://www.cochranelibrary.com/cochrane-theme/images/en-US_logo.png" title="Cochrane Library"/> </a> </h1> <span class="additional-branding"> <p class="brand-message"> <em>Trusted evidence.</em> <em>Informed decisions.</em> <em>Better health.</em> </p> </span> </div> <div class="desktop-search basic-search-container"> <div class="desktop-search-form"> <div class="portlet-boundary portlet-boundary_scolarissearchportlet_WAR_scolarissearch_ portlet-static portlet-static-end" id="p_p_id_scolarissearchportlet_WAR_scolarissearch_"> <span id="p_scolarissearchportlet_WAR_scolarissearch"></span> <section class="portlet" id="portlet_scolarissearchportlet_WAR_scolarissearch"> <header class="portlet-topper"> <h1 class="portlet-title"> <span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Search\x20Portlet')"> <img alt="" id="owel__null__null" src="/scolaris-search/icon.png"/> <span class="taglib-text hide-accessible">Scolaris Search Portlet</span> </span> <span class="portlet-title-text">Scolaris Search Portlet</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolarissearchportlet_WAR_scolarissearch" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="header-search"> <form action="https://www.cochranelibrary.com/en/content?p_auth=xcg9958b&amp;p_p_id=scolarissearchportlet_WAR_scolarissearch&amp;p_p_lifecycle=1&amp;p_p_state=normal&amp;p_p_mode=view&amp;_scolarissearchportlet_WAR_scolarissearch_scolarisAction=redirectSearchResult" method="post"> <input name="searchType" type="hidden" value="basic"/> <input name="facetDisplayName" type="hidden" value=""/> <input name="facetQueryTerm" type="hidden" value=""/> <input name="facetQueryField" type="hidden" value=""/> <input name="facetCategory" type="hidden" value=""/> <fieldset class="fieldset"> <legend class="sr-only">Basic Search</legend> <div class="select search-by"> <select aria-label="Search by options" class="custom-select-enabled search-type" name="searchBy" title="Search by options"> <option value="1">Title Abstract Keyword</option> <option value="2">Record Title</option> <option value="3">Abstract</option> <option value="4">Author</option> <option value="5">Keyword</option> <option value="6">All Text</option> <option value="7">Publication Type</option> <option value="8">Source</option> <option value="9">DOI</option> <option value="14">Language</option> <option value="10">Accession Number</option> <option value="11">Trial Registry Number</option> <option value="12">Cochrane Group</option> <option value="13">Cochrane Topic</option> </select> </div> <div class="search-select-crg-container select" style="display: none;"> <select class="search-select-crg-list"></select> </div> <div class="search-select-topic-container select" data-topic-list-url="https://www.cochranelibrary.com/en/content?p_p_id=scolaristopics_WAR_scolaristopics&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=topics-list&amp;p_p_cacheability=cacheLevelPage" style="display: none;"> <select class="search-select-topic-list"></select> </div> <div class="search-select-cl-container select" style="display: none;"> <select class="search-select-cl-list"></select> </div> <div class="search-text-container"> <div class="control-group control-group-inline search-input-wrapper"> <input aria-label="Enter search term" class="field browser-search search-text ui-autocomplete-input" id="searchText" name="searchText" placeholder="Search" size="30" type="text" value=""/>
<div id="autocomplete-results"></div>
</div>
<div class="control-group control-group-inline search-button-wrapper">
<button aria-label="Search" class="searchByBtn" type="submit">
<i aria-hidden="true" class="fa fa-search"></i>
</button>
</div>
</div>
</fieldset>
</form>
</div>
<script>
    window.displayResultURL = 'https://www.cochranelibrary.com/en/content?p_p_id=scolarissearchportlet_WAR_scolarissearch&p_p_lifecycle=2&p_p_state=normal&p_p_mode=view&p_p_resource_id=getSuggestions&p_p_cacheability=cacheLevelPage&_scolarissearchportlet_WAR_scolarissearch_templateType=full&_scolarissearchportlet_WAR_scolarissearch_urlTitle=%2Fcdsr%2Fdoi%2F10.1002%2F14651858.CD000204.pub2&_scolarissearchportlet_WAR_scolarissearch_contentLanguage=&_scolarissearchportlet_WAR_scolarissearch_type=cdsr&_scolarissearchportlet_WAR_scolarissearch_doi=10.1002%2F14651858.CD000204.pub2';
    window.searchByOption = '';
</script>
</div>
</div>
</div>
<div style="display:none">
<input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
<div class="search-tools-nav">
<a class="btn secondary" href="/en/browse-by-topic">Browse</a>
<a class="btn primary advanced-search-button" href="/en/advanced-search">Advanced search</a>
</div>
</div>
<a class="toggle-menu-switch" href="#"><i aria-hidden="true" class="fa fa-bars"></i> <div class="toggle-menu-text">Open menu</div></a>
</div>
<div class="auxiliary-container">
<div class="container">
<div class="header-auxiliary-menu">
<div class="auxiliary-menu-item language-selector">
<div class="portlet-boundary portlet-boundary_scolarislanguageselector_WAR_scolarislanguageportlet_ portlet-static portlet-static-end" id="p_p_id_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header_">
<span id="p_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header"></span>
<section class="portlet" id="portlet_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Language\x20Selector')">
<img alt="" id="bvrs__null__null" src="/scolaris-language-portlet/icon.png"/> <span class="taglib-text hide-accessible">Scolaris Language Selector</span> </span> <span class="portlet-title-text">Scolaris Language Selector</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="language-display" data-content-languages="[de, en, es, fa, fr, hi, hr, id, ja, ko, hu, ms, nl, pl, pt, ru, ro, ta, th, zh_HANT, zh_HANS]"> <a class="open-language-modal" href="#" title="Select your preferred language"> <i class="fa fa-file-text"></i> Review language : English </a> <a class="open-language-modal" href="#" title="Select your preferred language"> <i class="fa fa-globe"></i> Website language : English </a> </div> <div class="language-selector-modal-content" data-modal-title="Language selection" data-size="large" style="display: none;"> <div class="form-content language-selector-modal"> <div class="row-fluid"> <div> <table class="mytable" style="border: 1px solid #f0f0f0" width="90%"> <tbody> <tr class="row-box"> <td><i class="fa fa-file-text icon-size"></i></td> <td><h3>Cochrane review language</h3> <p>Select your preferred language for Cochrane reviews and other content. Sections without translation will be in English.</p> </td> <td> <div> <select id="contentLanguageSelector" onchange="updateLang(this.value)"> <option class="content-language-option" data-languagecode="de" value="de"> Deutsch </option> <option class="content-language-option" data-languagecode="en" selected="" value="en"> English </option> <option class="content-language-option" data-languagecode="es" value="es"> Español </option> <option class="content-language-option" data-languagecode="fa" value="fa"> فارسی </option> <option class="content-language-option" data-languagecode="fr" value="fr"> Français </option> <option class="content-language-option" data-languagecode="hi" value="hi"> हिन्दी </option> <option class="content-language-option" data-languagecode="hr" value="hr"> Hrvatski </option> <option class="content-language-option" data-languagecode="id" value="id"> Bahasa Indonesia </option> <option class="content-language-option" data-languagecode="ja" value="ja"> 日本語 </option> <option class="content-language-option" data-languagecode="ko" value="ko"> 한국어 </option> <option class="content-language-option" data-languagecode="hu" value="hu"> Magyar </option> <option class="content-language-option" data-languagecode="ms" value="ms"> Bahasa Malaysia </option> <option class="content-language-option" data-languagecode="nl" value="nl"> Nederlands </option> <option class="content-language-option" data-languagecode="pl" value="pl"> Polski </option> <option class="content-language-option" data-languagecode="pt" value="pt"> Português </option> <option class="content-language-option" data-languagecode="ru" value="ru"> Русский </option> <option class="content-language-option" data-languagecode="ro" value="ro"> Română </option> <option class="content-language-option" data-languagecode="ta" value="ta"> தமிழ் </option> <option class="content-language-option" data-languagecode="th" value="th"> ภาษาไทย </option> <option class="content-language-option" data-languagecode="zh_HANT" value="zh_HANT"> 繁體中文 </option> <option class="content-language-option" data-languagecode="zh_HANS" value="zh_HANS"> 简体中文 </option> </select> </div> </td> </tr> <tr> <td colspan="1" style="height: 10px"></td> </tr> <tr class="row-box"> <td><i class="fa fa-globe icon-size"></i></td> <td> <div class="language-info"> <h3>Website language</h3> <p>Select your preferred language for the Cochrane Library website.</p> </div> </td> <td> <div class="language-dropdown"> <select id="portalLanguageSelector"> <option class="portal-language-selector" data-portallanguage="en" selected="" value="/en/cdsr/doi/10.1002/14651858.CD000204.pub2/full/en"> English </option> <option class="portal-language-selector" data-portallanguage="es" value="/es/cdsr/doi/10.1002/14651858.CD000204.pub2/full/es"> Español </option> </select> </div> </td> </tr> <tr> <td colspan="1" style="height: 10px"></td> </tr> </tbody> </table> </div> </div> <div style="text-align: right;"> <button class="btn primary btn-cancel" style="margin-left: 10px;" type="button">Cancel</button> <a class="btn secondary ok-btn" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage">Save</a> </div> </div> </div> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
<a class="auxiliary-menu-item signin last" href="https://www.cochranelibrary.com/c/portal/login?p_l_id=20757&amp;redirect=%2Fcdsr%2Fdoi%2F10.1002%2F14651858.CD000204.pub2%2Ffull" rel="nofollow">
<i class="icon fa fa-user"></i> Sign In
    </a>
<span class="auxiliary-container-extended"></span>
</div>
</div>
</div>
</header>
<div class="main-nav-wrapper">
<span class="main-nav-left-extended"></span>
<nav class="main container">
<ul>
<li class="nav-root-item parent">
<a href="#">Cochrane reviews<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_14" role="presentation">
<a aria-labelledby="layout_14" href="https://www.cochranelibrary.com/en/cdsr/reviews" role="menuitem">
            Search reviews (CDSR)
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_15" role="presentation">
<a aria-labelledby="layout_15" href="https://www.cochranelibrary.com/en/cdsr/reviews/topics" role="menuitem">
            Browse reviews
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_18" role="presentation">
<a aria-labelledby="layout_18" href="https://www.cochranelibrary.com/en/cdsr/table-of-contents" role="menuitem">
            Issues
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_17" role="presentation">
<a aria-labelledby="layout_17" href="https://www.cochranelibrary.com/en/cdsr/editorials" role="menuitem">
            Editorials
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_19" role="presentation">
<a aria-labelledby="layout_19" href="https://www.cochranelibrary.com/en/special-collections" role="menuitem">
            Special Collections
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_20" role="presentation">
<a aria-labelledby="layout_20" href="https://www.cochranelibrary.com/en/cdsr/supplements" role="menuitem">
            Supplements
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_121" role="presentation">
<a aria-labelledby="layout_121" href="https://www.cochranelibrary.com/en/about/about-cochrane-reviews" role="menuitem">
            About Cochrane reviews
        </a>
</li>
</ul>
</li>
<li class="nav-root-item parent">
<a href="#">Searching for trials<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_254" role="presentation">
<a aria-labelledby="layout_254" href="https://www.cochranelibrary.com/en/search/releases" role="menuitem">
            What's new (search and CENTRAL)
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_266" role="presentation">
<a aria-labelledby="layout_266" href="https://www.cochranelibrary.com/en/search-help" role="menuitem">
            Search help
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_252" role="presentation">
<a aria-labelledby="layout_252" href="https://www.cochranelibrary.com/en/search-help-quick-guides" role="menuitem">
            Search help quick guides
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_251" role="presentation">
<a aria-labelledby="layout_251" href="https://www.cochranelibrary.com/en/search-faqs" role="menuitem">
            Search FAQs
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_114" role="presentation">
<a aria-labelledby="layout_114" href="https://www.cochranelibrary.com/en/central/about-central" role="menuitem">
            About CENTRAL
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_115" role="presentation">
<a aria-labelledby="layout_115" href="https://www.cochranelibrary.com/en/central/central-creation" role="menuitem">
            How CENTRAL is created
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_241" role="presentation">
<a aria-labelledby="layout_241" href="https://www.cochranelibrary.com/en/retracted-trials" role="menuitem">
            Retracted publications in CENTRAL
        </a>
</li>
</ul>
</li>
<li class="nav-root-item parent">
<a href="#">Clinical Answers<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_29" role="presentation">
<a aria-labelledby="layout_29" href="https://www.cochranelibrary.com/en/cca" role="menuitem">
            Browse Clinical Answers
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_91" role="presentation">
<a aria-labelledby="layout_91" href="https://www.cochranelibrary.com/en/cca/about" role="menuitem">
            About Clinical Answers
        </a>
</li>
</ul>
</li>
<li class="nav-root-item parent">
<a href="#">About<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_116" role="presentation">
<a aria-labelledby="layout_116" href="https://www.cochranelibrary.com/en/about/about-cochrane-library" role="menuitem">
            About the Cochrane Library
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_13" role="presentation">
<a aria-labelledby="layout_13" href="https://www.cochranelibrary.com/en/cdsr/about-cdsr" role="menuitem">
            Cochrane Database of Systematic reviews
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_198" role="presentation">
<a aria-labelledby="layout_198" href="https://www.cochranelibrary.com/en/cdsr/editorial-policies" role="menuitem">
            Editorial policies
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_92" role="presentation">
<a aria-labelledby="layout_92" href="https://www.cochranelibrary.com/en/about/author-information" role="menuitem">
            Information for authors
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_212" role="presentation">
<a aria-labelledby="layout_212" href="https://www.cochranelibrary.com/en/about-pico" role="menuitem">
            About PICO
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_207" role="presentation">
<a aria-labelledby="layout_207" href="https://www.cochranelibrary.com/en/about/about-translations" role="menuitem">
            About translations
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_188" role="presentation">
<a aria-labelledby="layout_188" href="https://www.cochranelibrary.com/en/about/releases" role="menuitem">
            What's new
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_216" role="presentation">
<a aria-labelledby="layout_216" href="https://www.cochranelibrary.com/en/data" role="menuitem">
            Data reuse
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_235" role="presentation">
<a aria-labelledby="layout_235" href="https://www.cochranelibrary.com/en/about/about-cochrane-library/editorial-board" role="menuitem">
            Cochrane Library Editorial Board
        </a>
</li>
</ul>
</li>
<li class="nav-root-item parent">
<a href="#">Help<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_259" role="presentation">
<a aria-labelledby="layout_259" href="https://m.info.wiley.com/webApp/cochranenewsletter?id=0" role="menuitem">
            Newsletter
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_177" role="presentation">
<a aria-labelledby="layout_177" href="https://www.wiley.com/en-us/customer-success/cochrane-library-training-hub" role="menuitem">
            Cochrane Library Training
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_44" role="presentation">
<a aria-labelledby="layout_44" href="https://www.cochranelibrary.com/en/help/access" role="menuitem">
            Access
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_150" role="presentation">
<a aria-labelledby="layout_150" href="https://www.cochranelibrary.com/en/help/permissions" role="menuitem">
            Permissions and reprints
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_93" role="presentation">
<a aria-labelledby="layout_93" href="https://www.cochranelibrary.com/en/help/media" role="menuitem">
            Media information
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_97" role="presentation">
<a aria-labelledby="layout_97" href="https://www.cochranelibrary.com/en/help/contact-us" role="menuitem">
            Contact us
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_125" role="presentation">
<a aria-labelledby="layout_125" href="https://www.cochranelibrary.com/en/about/terms-and-conditions" role="menuitem">
            Terms and conditions
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_176" role="presentation">
<a aria-labelledby="layout_176" href="https://cochranesupport.wiley.com/s/article/cochrane-library-known-issues" role="menuitem">
            Known issues
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_270" role="presentation">
<a aria-labelledby="layout_270" href="https://www.cochranelibrary.com/search-help" role="menuitem">
            Search help
        </a>
</li>
</ul>
</li>
<li class="about-link"><a href="https://www.cochrane.org/about-us" target="_blank"><span>About Cochrane</span><i class="fa fa-caret-right"></i></a></li>
</ul>
</nav>
</div>
<div class="portlet-boundary portlet-boundary_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_ portlet-static portlet-static-end" id="p_p_id_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_">
<span id="p_scolariscontentlanguagebanner_WAR_scolarislanguageportlet"></span>
<section class="portlet" id="portlet_scolariscontentlanguagebanner_WAR_scolarislanguageportlet">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Content\x20Language\x20Banner\x20Portlet')">
<img alt="" id="etlj__null__null" src="/scolaris-language-portlet/icon.png"/> <span class="taglib-text hide-accessible">Scolaris Content Language Banner Portlet</span> </span> <span class="portlet-title-text">Scolaris Content Language Banner Portlet</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolariscontentlanguagebanner_WAR_scolarislanguageportlet" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
<div class="" id="content">
<div class="columns-1" id="main-content" role="main">
<div class="portlet-layout row-fluid">
<div class="portlet-column portlet-column-only span12" id="column-1">
<div class="portlet-dropzone portlet-column-content portlet-column-content-only" id="layout-column_column-1">
<div class="portlet-boundary portlet-boundary_scolariscontentdisplay_WAR_scolariscontentdisplay_ portlet-static portlet-static-end scolaris-content-display-portlet" id="p_p_id_scolariscontentdisplay_WAR_scolariscontentdisplay_">
<span id="p_scolariscontentdisplay_WAR_scolariscontentdisplay"></span>
<section class="portlet" id="portlet_scolariscontentdisplay_WAR_scolariscontentdisplay">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Content\x20Display')">
<img alt="" id="rjus__column1__0" src="/scolaris-content-display/icon.png"/> <span class="taglib-text hide-accessible">Scolaris Content Display</span> </span> <span class="portlet-title-text">Scolaris Content Display</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolariscontentdisplay_WAR_scolariscontentdisplay" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="publication cdsr container"> <div class="article-navigation-container" id="cdsr-nav"> <nav class="article-navigation"> <ul class="tools-row"> <li> <li class="tools pdf pulldown-menu readcube-menu closed en_US"> <a class="pulldown-menu-trigger" href="#0"> <span class="pdf-icon"> <i class="icon fa fa-file-pdf-o"></i> <span>Download PDF</span> </span> <i aria-hidden="true" class="fa fa-caret-down"></i> </a> <ul class="pulldown-menu-items"> <li class=""> <a class="download media pdf-link-full pdf-link" href="/cdsr/doi/10.1002/14651858.CD000204.pub2/pdf/full/en" title="Article in PDF format"> <span class="readcube-label"> Full </span> <span class="readcube-description"> All content </span> </a> <a class="download media pdf-link-full readcube-epdf-link" href="/cdsr/doi/10.1002/14651858.CD000204.pub2/epdf/full/en" title="Article in PDF format"> <span class="readcube-label"> Full </span> <span class="readcube-description"> All content </span> </a> </li> <li class=""> <a class="download media pdf-link-abstract pdf-link" href="/cdsr/doi/10.1002/14651858.CD000204.pub2/pdf/abstract/en" title="Article in PDF format"> <span class="readcube-label"> Summary </span> <span class="readcube-description"> Abstract and plain language summary only </span> </a> <a class="download media pdf-link-abstract readcube-epdf-link" href="/cdsr/doi/10.1002/14651858.CD000204.pub2/epdf/abstract/en" title="Article in PDF format"> <span class="readcube-label"> Summary </span> <span class="readcube-description"> Abstract and plain language summary only </span> </a> </li> </ul> </li> <li class="tools cite cite-article-link" data-article-id="CD000204.PUB2" data-modal-title="Cite this review"> <span><i aria-hidden="true" class="icon fa fa-share"></i></span> <span>Cite this review</span> </li> </li> </ul> <ul class="tools-row tools-secondary"> <li> <li class="tools print print-cdsr-link" data-content-language="en" data-indicator-tooltip="scolaris.print.modal.language.tooltip.en" data-print-options="[{&quot;param&quot;: &quot;abstract&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Abstract&quot;},{&quot;language&quot;:&quot;es&quot;,&quot;title&quot;:&quot;Resumen&quot;},{&quot;language&quot;:&quot;fa&quot;,&quot;title&quot;:&quot;چکیده&quot;},{&quot;language&quot;:&quot;zh_HANS&quot;,&quot;title&quot;:&quot;摘要&quot;}]},{&quot;param&quot;: &quot;pls&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Plain language summary&quot;},{&quot;language&quot;:&quot;de&quot;,&quot;title&quot;:&quot;Laienverständliche Zusammenfassung&quot;},{&quot;language&quot;:&quot;es&quot;,&quot;title&quot;:&quot;Resumen en términos sencillos&quot;},{&quot;language&quot;:&quot;fa&quot;,&quot;title&quot;:&quot;خلاصه به زبان ساده&quot;},{&quot;language&quot;:&quot;zh_HANS&quot;,&quot;title&quot;:&quot;简语概要&quot;}]},{&quot;param&quot;: &quot;conclusions&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Authors' conclusions&quot;}]},{&quot;param&quot;: &quot;summaryOfFindings&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Summary of findings&quot;}]},{&quot;param&quot;: &quot;background&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Background&quot;}]},{&quot;param&quot;: &quot;objectives&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Objectives&quot;}]},{&quot;param&quot;: &quot;methods&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Methods&quot;}]},{&quot;param&quot;: &quot;results&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Results&quot;}]},{&quot;param&quot;: &quot;discussion&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Discussion&quot;}]},{&quot;param&quot;: &quot;references&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;References&quot;}]},{&quot;param&quot;: &quot;appendices&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Appendices&quot;},{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Search strategies&quot;}]},{&quot;param&quot;: &quot;characteristics&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Characteristics of studies&quot;}]},{&quot;param&quot;: &quot;data&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Analyses&quot;}]},{&quot;param&quot;: &quot;information&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Information&quot;}]},{&quot;param&quot;: &quot;authors&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Authors&quot;}]},{&quot;param&quot;: &quot;history&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;History&quot;},{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;History&quot;}]},{&quot;param&quot;: &quot;comments&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Comments&quot;}]}]" data-print-urlbase="/cdsr/doi/10.1002/14651858.CD000204.pub2/print"> <span><i class="icon fa fa-print"></i></span> <span>Print</span> </li> <li class="js-old-version-modal-trigger tools comments comment-on-review" data-article-id="CD000204.PUB2" data-english-only-message="Please note, that commenting is available in English only. Apologies for any inconvenience." data-href="/cdsr/doi/10.1002/14651858.CD000204.pub2/read-comments" data-new-version="" id="comment-on-review"> <span class="comment-icon"><i class="icon fa fa-comment"></i></span> <span class="comments-count">0</span> <span>Comment</span> </li> <li class="tools share-cdsr-link" data-share-url="/cdsr/doi/10.1002/14651858.CD000204.pub2/full"> <span><i class="icon fa fa-share-alt"></i></span> <span>Share</span> </li> <li class="tools follow"> <span class="article-not-followed cochrane-link signin follow-wrapper"> <span> <i class="icon fa fa-plus"></i> </span> <span> Follow </span> </span> </li> </li> </ul> <div class="metrics-wrapper"> <div class="metrics-count"> <span>Full text views: </span> <span>7160 <i class="icon fa fa-info-circle custom-tooltip" style="padding-left: 2px;color: #962d91;" title="Usage represents full text views on Cochrane Library since January 2022 or 2023. For articles published after this date, the usage represents views since the article was first published on Cochrane Library."> </i> </span> </div> </div> <div class="metrics-wrapper nav-link-section"> <div class="altmetric-embed" data-badge-type="1" data-condensed="true" data-doi="10.1002/14651858.CD000204.pub2" data-link-target="_blank"></div> <div class="inline-status-wrapper guidelines-count" data-count-plural="Cited in $1 guidelines" data-count-single="Cited in 1 guideline"> <a href="related-content#guidelines_data" title="Guidelines"></a> </div> </div> <ul class="nav-section-header"> <li> <h3>Contents</h3> </li> </ul> <ul class="nav-long-form nav-link-section"> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD000204.pub2/full"> Abstract </a> </li> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD000204.pub2/full#pico"> PICOs </a> </li> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD000204.pub2/full#CD000204-abs-0003"> Plain language summary </a> </li> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD000204.pub2/full#CD000204-sec-0173"> Authors' conclusions </a> </li> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD000204.pub2/full#CD000204-sec-0022"> Summary of findings </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD000204.pub2/full#CD000204-sec-0023"> Background </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD000204.pub2/full#CD000204-sec-0028"> Objectives </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD000204.pub2/full#CD000204-sec-0029"> Methods </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD000204.pub2/full#CD000204-sec-0107"> Results </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD000204.pub2/full#CD000204-sec-0154"> Discussion </a> </li> <li class="cdsr-nav-link"> <a class="figures-and-tables-link" href="/cdsr/doi/10.1002/14651858.CD000204.pub2/#"> Figures and tables </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD000204.pub2/references"> References </a> </li> </ul> <div class="nav-section-header"> <h3>Supplementary materials</h3> </div> <ul class="nav-long-form nav-link-section"> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD000204.pub2/appendices#CD000204-sec-0187"> Search strategies </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD000204.pub2/references#characteristicStudies"> Characteristics of studies </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD000204.pub2/references#dataAndAnalyses"> Analyses </a> </li> <li class="cdsr-nav-link download-stats-data-link" data-download-href="/cdsr/doi/10.1002/14651858.CD000204.pub2/media/CDSR/CD000204/table_n/CD000204StatsDataOnly.rm5?content-disposition=attachment&amp;mime-type=application/octet-stream"> <a href="/cdsr/doi/10.1002/14651858.CD000204.pub2/media/CDSR/CD000204/table_n/CD000204StatsDataOnly.rm5?content-disposition=attachment&amp;mime-type=application/octet-stream"> Download data </a> </li> </ul> <ul class="tools-row"> <li> </li> </ul> <ul class="nav-section-header"> <li><h3>Related</h3></li> </ul> <ul class="linked-content linked-content-dropdown" id="linked-content-articles" tabindex="0"> <li class="linked-cca" data-type="cca"> <div class="linked-content-section"> <span class="linked-type">Cochrane Clinical Answers<span class="count"></span></span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="articles"></div> </li> <li class="linked-editorials" data-type="editorial"> <div class="linked-content-section"> <span class="linked-type">Editorials<span class="count"></span></span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="articles"></div> </li> <li class="linked-podcasts" data-type="podcast"> <div class="linked-content-section"> <span class="linked-type">Podcasts<span class="count"></span></span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="articles"></div> </li> <li class="linked-sc" data-type="sc"> <div class="linked-content-section"> <span class="linked-type">Special Collections<span class="count"></span></span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="articles"></div> </li> </ul> <div class="nav-section-header"> <h3>About this review</h3> </div> <ul class="nav-long-form nav-info nav-link-section"> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD000204.pub2/information"> <i> <svg viewbox="0 0 24 24"> <path d="M11,9H13V7H11M12,20C7.59,20 4,16.41 4,12C4,7.59 7.59,4 12,4C16.41,4 20,7.59 20,12C20,16.41 16.41,20 12,20M12,2A10,10 0 0,0 2,12A10,10 0 0,0 12,22A10,10 0 0,0 22,12A10,10 0 0,0 12,2M11,17H13V11H11V17Z"></path> </svg> </i> Information </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD000204.pub2/information#authors"> <i> <svg viewbox="0 0 24 24"> <path d="M12,5.5A3.5,3.5 0 0,1 15.5,9A3.5,3.5 0 0,1 12,12.5A3.5,3.5 0 0,1 8.5,9A3.5,3.5 0 0,1 12,5.5M5,8C5.56,8 6.08,8.15 6.53,8.42C6.38,9.85 6.8,11.27 7.66,12.38C7.16,13.34 6.16,14 5,14A3,3 0 0,1 2,11A3,3 0 0,1 5,8M19,8A3,3 0 0,1 22,11A3,3 0 0,1 19,14C17.84,14 16.84,13.34 16.34,12.38C17.2,11.27 17.62,9.85 17.47,8.42C17.92,8.15 18.44,8 19,8M5.5,18.25C5.5,16.18 8.41,14.5 12,14.5C15.59,14.5 18.5,16.18 18.5,18.25V20H5.5V18.25M0,20V18.5C0,17.11 1.89,15.94 4.45,15.6C3.86,16.28 3.5,17.22 3.5,18.25V20H0M24,20H20.5V18.25C20.5,17.22 20.14,16.28 19.55,15.6C22.11,15.94 24,17.11 24,18.5V20Z"></path> </svg> </i> Authors </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD000204.pub2/information#history"> <i> <svg viewbox="0 0 24 24"> <path d="M13.5,8H12V13L16.28,15.54L17,14.33L13.5,12.25V8M13,3A9,9 0 0,0 4,12H1L4.96,16.03L9,12H6A7,7 0 0,1 13,5A7,7 0 0,1 20,12A7,7 0 0,1 13,19C11.07,19 9.32,18.21 8.06,16.94L6.64,18.36C8.27,20 10.5,21 13,21A9,9 0 0,0 22,12A9,9 0 0,0 13,3"></path> </svg> </i> Version history </a> </li> <li class="cdsr-nav-link"> <a href="/cdsr/doi/10.1002/14651858.CD000204.pub2/information#keywords"> <i> <svg viewbox="0 0 24 24"> <path d="M11 3C10.18 3 9.44 3.5 9.14 4.27L3.64 18.27C3.12 19.58 4.09 21 5.5 21H7.75C8.59 21 9.33 20.5 9.62 19.7L10.26 18H13.74L14.38 19.7C14.67 20.5 15.42 21 16.25 21H18.5C19.91 21 20.88 19.58 20.36 18.27L14.86 4.27C14.56 3.5 13.82 3 13 3M11 5H13L18.5 19H16.25L15.12 16H8.87L7.75 19H5.5M12 7.67L9.62 14H14.37Z"></path> </svg> </i> Keywords (MeSH, PICOs) </a> </li> <li class="cdsr-nav-link"> <a href="/cdsr/doi/10.1002/14651858.CD000204.pub2/related-content"> <i class="icon fa fa-sitemap fa-rotate-270"></i> Related content </a> </li> <li class="cdsr-nav-link translation-notes-link"> <a href="/cdsr/doi/10.1002/14651858.CD000204.pub2/#"> <i> <svg viewbox="0 0 24 24"> <path d="M12.87,15.07L10.33,12.56L10.36,12.53C12.1,10.59 13.34,8.36 14.07,6H17V4H10V2H8V4H1V6H12.17C11.5,7.92 10.44,9.75 9,11.35C8.07,10.32 7.3,9.19 6.69,8H4.69C5.42,9.63 6.42,11.17 7.67,12.56L2.58,17.58L4,19L9,14L12.11,17.11L12.87,15.07M18.5,10H16.5L12,22H14L15.12,19H19.87L21,22H23L18.5,10M15.88,17L17.5,12.67L19.12,17H15.88Z"></path> </svg> </i> Translation notes </a> </li> <li class="cdsr-nav-link"> <a class="request-permissions" data-copyright="Copyright © 2018 The Cochrane Collaboration. Published by John Wiley &amp; Sons, Ltd." data-creative-commons="false" href="/cdsr/doi/10.1002/14651858.CD000204.pub2/#"> <span class="request-permissions-icon"></span> Request permissions </a> </li> <li class="cdsr-nav-link"> <a href="/data"> <i class="icon fa fa-database"></i> Request data reuse </a> </li> </ul> </nav> </div> <article> <div class="cdsr-header-top"> <div class="cdsr-header-left"> <a class="publish-database" href="/">Cochrane Database of Systematic reviews</a> <span class="publish-type">Review - Intervention</span> </div> <div class="cdsr-header-right"> <div class="inline-status-wrapper"> <ul class="cochrane-status"> <li aria-label="A new search for studies has been conducted." class="status-item up-to-date custom-tooltip" data-status="newsearch" title="A new search for studies has been conducted."> <a class="btn secondary" href="information#history">New search</a> </li> </ul> </div> </div> </div> <header class="publication-header"> <h1 class="publication-title" lang="en">Anticholinergic medication for antipsychotic‐induced tardive dyskinesia</h1> <div class="publication-metadata-block"> <div class="publication-authors"> <div class="publish-meta-wrapper"> <ul class="authors"> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD000204.pub2/information#CD000204-cr-0002"><i class="icon corresponding-author fa fa-envelope"></i>Hanna Bergman</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD000204.pub2/information#CD000204-cr-0003">Karla Soares‐Weiser</a></li> </ul> <span class="author declaration"> <a class="declarationsOfInterestLink" href="/cdsr/doi/10.1002/14651858.CD000204.pub2/information/en#CD000204-sec-0204">Authors' declarations of interest</a> </span> </div> </div> </div> <div class="publication-metadata-block"> <p> <span class="publish-date">Version published: 17 January 2018 </span> <a class="whatsNewLink" href="/cdsr/doi/10.1002/14651858.CD000204.pub2/information/en#versionTable">Version history</a> </p> <div class="doi-header"> <a href="https://doi.org/10.1002/14651858.CD000204.pub2">https://doi.org/10.1002/14651858.CD000204.pub2</a> </div> </div> </header> <div class="publication-control-bar"> <span class="publication-control-button publication-control-collapse"> Collapse all </span> <span class="publication-control-button publication-control-expand"> Expand all </span> </div> <section class="abstract"> <div class="section-header section-collapse-header" id="CD000204-abs-0001" lang="en"> <h2 class="title section-collapse-title"> Abstract <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> <div class="section-language-toggles"> <span class="section-languages-legend">available in</span> <nav class="section-languages"> <li class="section-language"> <a class="is-active" href="full/en#CD000204-abs-0001">English</a> </li> <li class="section-language"> <a class="" href="full/es#CD000204-abs-0002">Español</a> </li> <li class="section-language"> <a class="" href="full/fa#CD000204-abs-0006">فارسی</a> </li> <li class="section-language"> <a class="" href="full/zh_HANS#CD000204-abs-0008">简体中文</a> </li> </nav> </div> </div> <div class="abstract full_abstract" id="CD000204-abs-0001" lang="en"> <section id="CD000204-sec-0001"> <h3 class="title" id="CD000204-sec-0001">Background</h3> <p>Antipsychotic (neuroleptic) medication is used extensively to treat people with serious mental illnesses. However, it is associated with a wide range of adverse effects, including movement disorders. Because of this, many people treated with antipsychotic medication also receive anticholinergic drugs in order to reduce some of the associated movement side‐effects. However, there is also a suggestion from animal experiments that the chronic administration of anticholinergics could cause tardive dyskinesia. </p> </section> <section id="CD000204-sec-0002"> <h3 class="title" id="CD000204-sec-0002">Objectives</h3> <p>To determine whether the use or the withdrawal of anticholinergic drugs (benzhexol, benztropine, biperiden, orphenadrine, procyclidine, scopolamine, or trihexylphenidyl) are clinically effective for the treatment of people with both antipsychotic‐induced tardive dyskinesia and schizophrenia or other chronic mental illnesses. </p> </section> <section id="CD000204-sec-0003"> <h3 class="title" id="CD000204-sec-0003">Search methods</h3> <p>We retrieved 712 references from searching the Cochrane Schizophrenia Group's Study‐Based Register of Trials including the registries of clinical trials (16 July 2015 and 26 April 2017). We also inspected references of all identified studies for further trials and contacted authors of trials for additional information. </p> </section> <section id="CD000204-sec-0004"> <h3 class="title" id="CD000204-sec-0004">Selection criteria</h3> <p>We included reports identified in the search if they were controlled trials dealing with people with antipsychotic‐induced tardive dyskinesia and schizophrenia or other chronic mental illness who had been randomly allocated to (a) anticholinergic medication versus placebo (or no intervention), (b) anticholinergic medication versus any other intervention for the treatment of tardive dyskinesia, or (c) withdrawal of anticholinergic medication versus continuation of anticholinergic medication. </p> </section> <section id="CD000204-sec-0005"> <h3 class="title" id="CD000204-sec-0005">Data collection and analysis</h3> <p>We independently extracted data from included trials and we estimated risk ratios (RR) with 95% confidence intervals (CIs). We assumed that people who left early had no improvement. We assessed risk of bias and created a 'Summary of findings' table using GRADE. </p> </section> <section id="CD000204-sec-0006"> <h3 class="title" id="CD000204-sec-0006">Main results</h3> <p>The previous version of this review included no trials. We identified two trials that could be included from the 2015 and 2017 searches. They randomised 30 in‐ and outpatients with schizophrenia in the USA and Germany. Overall, the risk of bias was unclear, mainly due to poor reporting: allocation concealment was not described; generation of the sequence was not explicit; studies were not clearly blinded; and outcome data were not fully reported. </p> <p>Findings were sparse. One study reported on the primary outcomes and found that significantly more participants allocated to procyclidine (anticholinergic) had not improved to a clinically important extent compared with those allocated to isocarboxazid (MAO‐inhibitor) after 40 weeks' treatment (1 RCT, n = 20; RR 4.20, 95% CI 1.40 to 12.58; <i>very low quality evidence</i> ); that there was no evidence of a difference in the incidence of any adverse effects (1 RCT, n = 20; RR 0.33, 95% CI 0.02 to 7.32; <i>very low quality evidence</i> ); or acceptability of treatment (measured by participants leaving the study early) (1 RCT, n = 20; RR 0.33, 95% CI 0.02 to 7.32; <i>very low quality evidence</i> ). The other trial compared anticholinergic withdrawal with anticholinergic continuation and found no evidence of a difference in the incidence of acceptability of treatment (measured by participants leaving the study early) (1 RCT, n = 10; RR 2.14, 95% CI 0.11 to 42.52; <i>very low quality evidence</i>). </p> <p>No trials reported on social confidence, social inclusion, social networks, or personalised quality of life — outcomes designated important to patients. No studies comparing either i. anticholinergics with placebo or no treatment, or ii. studies of anticholinergic withdrawal, were found that reported on the primary outcome 'no clinically important improvement in TD symptoms and adverse events'. </p> </section> <section id="CD000204-sec-0007"> <h3 class="title" id="CD000204-sec-0007">Authors' conclusions</h3> <p>Based on currently available evidence, no confident statement can be made about the effectiveness of anticholinergics to treat people with antipsychotic‐induced tardive dyskinesia. The same applies for the withdrawal of such medications. Whether the withdrawal of anticholinergics may benefit people with antipsychotic‐induced TD should be evaluated in a parallel‐group, placebo‐controlled randomised trial, with adequate sample size and at least 6 weeks of follow‐up. </p> </section> </div> </section> <section class="pico-section" id="pico"> <h2 class="title section-collapse-title">PICOs <i class="icon fa fa-info-circle" title="The PICO model is widely used and taught in evidence-based health care as a strategy for formulating questions and search strategies and for characterizing clinical studies or meta-analyses. PICO stands for four different potential components of a clinical question: Patient, Population or Problem; Intervention; Comparison; Outcome."></i> <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> <div class="section-content" style="display: block;"> <h3 class="keyword-heading">PICOs</h3> <div class="pico-table"> <div class="pico-column Population"> <h6>Population<span class="pico-count"></span></h6> <ul class="pico-terms"> </ul> </div> <div class="pico-column Intervention"> <h6>Intervention<span class="pico-count"></span></h6> <ul class="pico-terms"> </ul> </div> <div class="pico-column Comparison"> <h6>Comparison<span class="pico-count"></span></h6> <ul class="pico-terms"> </ul> </div> <div class="pico-column Outcome"> <h6>Outcome<span class="pico-count"></span></h6> <ul class="pico-terms"> </ul> </div> </div> <div class="pico-information"> <p><i class="icon fa fa-info-circle"></i> The PICO model is widely used and taught in evidence-based health care as a strategy for formulating questions and search strategies and for characterizing clinical studies or meta-analyses. PICO stands for four different potential components of a clinical question: Patient, Population or Problem; Intervention; Comparison; Outcome.</p> <p>See more on using PICO in the <a href="https://training.cochrane.org/handbook/current/chapter-02#section-2-3">Cochrane Handbook</a>.</p> </div> </div> </section> <section class="pls"> <div class="section-header section-collapse-header" id="CD000204-abs-0003" lang="en"> <h2 class="title section-collapse-title"> Plain language summary <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> <div class="section-language-toggles"> <span class="section-languages-legend">available in</span> <nav class="section-languages"> <li class="section-language"> <a class="is-active" href="full/en#CD000204-abs-0003">English</a> </li> <li class="section-language"> <a class="" href="full/de#CD000204-abs-0004">Deutsch</a> </li> <li class="section-language"> <a class="" href="full/es#CD000204-abs-0005">Español</a> </li> <li class="section-language"> <a class="" href="full/fa#CD000204-abs-0007">فارسی</a> </li> <li class="section-language"> <a class="" href="full/zh_HANS#CD000204-abs-0009">简体中文</a> </li> </nav> </div> </div> <div class="abstract abstract_plainLanguageSummary" id="CD000204-abs-0003" lang="en"> <h3>Anticholinergic medication for people who have tardive dyskinesia after taking antipsychotic medication </h3> <p><b>Review question</b>. </p> <p>Are anticholinergic drugs or withdrawal of anticholinergic drugs effective in the treatment of tardive dyskinesia in people with schizophrenia or other similar mental health problems. </p> <p><b>Background</b>. </p> <p>People with schizophrenia often hear voices and see things (hallucinations) and have beliefs which are at odds with those held by people without schizophrenia (delusions). The main treatment of these symptoms are antipsychotic drugs. However, these drugs can have debilitating side‐effects. Tardive dyskinesia is an involuntary movement that causes the face, mouth, tongue and jaw to convulse, spasm and grimace. It is caused by long‐term use, or high doses, of antipsychotic drugs, is difficult to treat and can be incurable. Many people being treated with antipsychotic medication also receive anticholinergic drugs to try to reduce some of these movement side‐effects. There is, however, evidence from animal experiments that anticholinergic drugs could cause tardive dyskinesia. </p> <p><b>Study characteristics</b>. </p> <p>The review includes two small randomised studies with a total of 30 people with schizophrenia who had also developed antipsychotic‐induced tardive dyskinesia. Participants in one study received either the anticholinergic drug procyclidine or isocarboxacid, an antidepressant drug. One participant group in the other study was withdrawn from the anticholinergic drug biperiden whereas the other group of participants continued taking biperiden. </p> <p><b>Key results</b>. </p> <p>There were sparse findings from two small and poorly reported trials. It is uncertain whether giving anticholinergic drugs is helpful in the treatment of tardive dyskinesia for people who are taking antipsychotic medication. It is also uncertain whether the withdrawal of anticholinergic medication improves the symptoms of tardive dyskinesia. </p> <p><b>Quality of the evidence</b>. </p> <p>Available evidence is very low or low quality, limited, and small scale. It is not possible to recommend these drugs or the withdrawal of these drugs as a treatment for tardive dyskinesia. To fully investigate whether the withdrawal of anticholinergic drugs has any positive effects for people with tardive dyskinesia, we need more high quality research data. </p> <p>This plain language summary was adapted by the review authors from a summary originally written by Ben Gray, Senior Peer Researcher, McPin Foundation (<a href="http://mcpin.org/" target="_blank">mcpin.org</a>). </p> </div> </section> <section id="vls" style="display: none"> <div class="section-header section-collapse-header"> <h2 class="title section-collapse-title">Visual summary<i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i></h2> </div> <a href="" target="_blank"><img alt="visual summary" src=""/></a> </section> <section class="conclusions"> <div class="section-header section-collapse-header" id="CD000204-sec-0173" lang="en"> <h2 class="title section-collapse-title"> Authors' conclusions <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="authorsConclusions" lang="en"> <div class="section-header" id="CD000204-sec-0173"></div> <h3 class="title" id="CD000204-sec-0174">Implications for practice</h3> <section id="CD000204-sec-0174"> <section id="CD000204-sec-0175"> <h5 class="title">1. For people with TD</h5> <p>Based on the currently available data, this systematic review can provide no useful information for service‐users about the use of anticholinergics (benzhexol, benztropine, biperiden, orphenadrine, procyclidine, scopolamine or trihexylphenidyl) for the treatment of antipsychotic‐induced TD. In addition, there is no evidence to support the suggestion that the withdrawal of these medications may benefit people with TD. People with TD could consider these as other experimental treatments for which very little supportive data exist. Few data exist for any treatment for TD. </p> </section> <section id="CD000204-sec-0176"> <h5 class="title">2. For clinicians</h5> <p>Anticholinergics have been widely used in modern psychiatry for the treatment of extrapyramidal side effects (EPS). There is some suggestion that they may exacerbate TD symptoms; however, the link between the use of anticholinergics and the emergence of TD may be only an epiphenomenon, since people who develop EPS are thought to be more likely to receive anticholinergics and also to develop TD (<a href="./references#CD000204-bbs2-0029" title="American Psychiatric Association. Tardive dyskinesia: a task force report of the American Psychiatric Association. Washington DC: American Psychiatric Association, 1992. ">APA 1992</a>). Nevertheless, based on this systematic review there is no solid evidence to support or discourage the use or withdrawal of these medications as a treatment for TD. There is a real place for clinician‐driven research, with prescription within the context of a randomised trial and routine data collection on outcomes of relevance to people with TD and their clinicians. </p> </section> <section id="CD000204-sec-0177"> <h5 class="title">3. Policy makers or managers</h5> <p>This is one of the reviews in the series of Cochrane Reviews on treatments for antipsychotic‐induced TD (see <a href="#CD000204-tbl-0004">Table 1</a>). No evidence is convincing that addition or withdrawal of another drug helps with the symptoms of TD. There are, however, many unanswered questions in this area. This unattractive adverse effect is caused, to a greater or lesser extent, by antipsychotic drugs. Clinicians and researchers should feel responsible enough to continue to try to help it. Those compiling guidance could encourage supportive activity and more research into this neglected area. </p> </section> </section> <h3 class="title" id="CD000204-sec-0178">Implications for research</h3> <section id="CD000204-sec-0178"> <section id="CD000204-sec-0179"> <h5 class="title">1. General</h5> <p>The power of this review would have been greatly enhanced by better reporting of data. For example, none of the trials made explicit how randomisation was undertaken. We realise that the work for these trials predates <a href="http://www.consort-statement.org/" target="_blank">CONSORT</a>, which was first published in 1996 (<a href="./references#CD000204-bbs2-0032" title="BeggC , ChoM , EastwoodS , HortonR , MoherD , OlkinI , et al. Improving the quality of reporting of randomized controlled trials: the CONSORT statement. JAMA1996;276(8):637‐9. ">Begg 1996</a>), and that it is only too easy to judge studies of the past by standards of today. Future studies, however, should report to a much higher standard. </p> </section> <section id="CD000204-sec-0180"> <h5 class="title">2. Specific</h5> <p>From the theoretical background, there is some evidence to suggest that withdrawal of anticholinergics may benefit people with antipsychotic‐induced TD. Well‐designed randomised controlled trials, involving a large number of participants over protracted periods of time, are needed if we are to see if anticholinergics or anticholinergic withdrawal could have a role in prevention and treatment of TD. Such studies are of importance to people with the problem and have long been ignored (<a href="#CD000204-fig-0001">Figure 1</a>). </p> <section id="CD000204-sec-0181"> <h6 class="title">2.1 Use of cross‐over design</h6> <p>Trialists find it difficult to identify people with both TD and schizophrenia to participate in trials. Randomised cross‐over design is used in the hope of improving the power of the study to find outcomes of interest. This design initially asks participants to be randomised to one of the experimental interventions, and then, at a pre‐specified time, to be crossed over to the treatment that they did not at first receive. Conditions with a more stable time course than TD are better suited for cross‐over studies (<a href="./references#CD000204-bbs2-0051" title="FleissJL . The crossover study. The Design and Analysis of Clinical Experiments. Chichester: John Wiley &amp; Sons, 1984. ">Fleiss 1984</a>). Further difficulties are the carry‐over effect and a related neuroreceptor issue. Unless cross‐over studies include a mid‐study washout period (where the person is free of treatment before starting the next arm of the study), any effect of anticholinergic drugs may continue into the second half placebo arm of the trial — the 'carry‐over effect'. Also, carry‐over may involve the re‐growth or retreat of neuroreceptors. This slow re‐balancing, if started, could continue long after all traces of intervention drugs are gone, so physiological half life of the experimental treatment may not be the only variable to consider when thinking though the issues of carry‐over. TD is also an unstable condition and people with TD may not remain compliant with medication. All these factors make the arguments for not using cross‐over methodology strong, despite the initial attraction (<a href="./references#CD000204-bbs2-0030" title="ArmitageP . Should we cross off the crossover?. Journal of Clinical Pharmacology1991;32(1):1‐2. ">Armitage 1991</a>; <a href="./references#CD000204-bbs2-0051" title="FleissJL . The crossover study. The Design and Analysis of Clinical Experiments. Chichester: John Wiley &amp; Sons, 1984. ">Fleiss 1984</a>; <a href="./references#CD000204-bbs2-0069" title="PocockSJ . Crossover trials. Clinical trials. A practical approach. Chichester: John Wiley &amp; Sons, 1983. ">Pocock 1983</a>). </p> </section> <section id="CD000204-sec-0182"> <h6 class="title">2.2 Sample size calculation</h6> <p>None of the trials explained how they calculated their sample size. However, the results suggest that larger sample size should be used to provide more precise estimates of effect. </p> </section> <section id="CD000204-sec-0183"> <h6 class="title">2.3 Length of study</h6> <p>One of the studies included in this review used the intervention for 40 weeks (<a href="./references#CD000204-bbs2-0001" title="BucciL . The dyskinesias: a new therapeutic approach. Diseases of the Nervous System1971;32(5):324‐7. ">Bucci 1971</a>). TD is a chronic condition of insidious onset, the severity of which fluctuates spontaneously (<a href="./references#CD000204-bbs2-0029" title="American Psychiatric Association. Tardive dyskinesia: a task force report of the American Psychiatric Association. Washington DC: American Psychiatric Association, 1992. ">APA 1992</a>). Even if anticholinergics or anticholinergic withdrawal has a swift effect, which is unlikely, it is the long‐term outcomes that must be considered of most clinical value. </p> </section> <section id="CD000204-sec-0184"> <h6 class="title">2.4 Outcomes</h6> <p>Many of the outcomes we initially desired when we started this review have not been investigated. In addition, a service user consultation also informed the addition of outcomes of special importance to patients. We have reconsidered all these outcomes in case they were too ambitious and tried to tailor them to a real‐world pragmatic trial design (see <a href="#CD000204-tbl-0005">Table 2</a>). </p> <div class="table" id="CD000204-tbl-0005"> <table><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Table 2.</span> <span class="table-title">Suggestions for design of future study</span></div> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Methods</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Allocation: randomised, with sequence generation and concealment of allocation clearly described.<br/> Blindness: double, tested.<br/> Duration: 12 months beyond end of intervention at least.<br/> Raters: independent. </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Participants</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>People with antipsychotic‐induced tardive dyskinesia.*<br/> Age: any.<br/> Sex: both.<br/> History: any.<br/> N = 300.** </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Interventions</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1. Anticholinergic withdrawal (N = 150) versus anticholinergic continuation (N = 150).</p> <p>OR</p> <p>2. Specific anticholinergic (N = 150) versus placebo (N = 150).</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Outcomes</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Tardive dyskinesia: any clinically important improvement in TD, any improvement, deterioration.***<br/> Adverse effects: no clinically significant extrapyramidal adverse effects ‒ any time period***, use of any antiparkinsonism drugs, other important adverse events.<br/> Leaving the study early.<br/> Service outcomes: admitted, number of admissions, length of hospitalisation, contacts with psychiatric services.<br/> Compliance with drugs.<br/> Economic evaluations: cost‐effectiveness, cost‐benefit.<br/> General state: relapse, frequency and intensity of minor and major exacerbations.<br/> Social confidence, social inclusion, social networks, or personalised quality of life: binary measure<br/> Distress among relatives: binary measure.<br/> Burden on family: binary measure. </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Notes</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>* This could be diagnosed by clinical decision. If funds were permitting, all participants could be screened using operational criteria; otherwise a random sample should suffice. </p> <p>** Size of study with sufficient power to highlight about a 10% difference between groups for primary outcome.<br/> *** Primary outcome. The same applies to the measure of primary outcome as for diagnosis. Not everyone may need to have operational criteria applied if clinical impression is proved to be accurate. </p> </td> </tr> </tbody> </table> </div> </section> </section> </section> </section> </section> <section class="summaryOfFindings"> <div class="section-header section-collapse-header" id="CD000204-sec-0022" lang="en"> <h2 class="title section-collapse-title"> Summary of findings <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="summaryOfFindings" lang="en"> <div class="section-header" id="CD000204-sec-0022"></div> <div class="table" id="CD000204-tbl-0001"> <table class="summary-of-findings framed"><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Summary of findings for the main comparison.</span> <span class="table-title">Anticholinergic medication compared with placebo for antipsychotic‐induced tardive dyskinesia</span></div> <tbody> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>Anticholinergic medication compared with other treatments for antipsychotic‐induced tardive dyskinesia</b> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>Patient or population:</b> patients with antipsychotic‐induced tardive dyskinesia </p> <p><b>Settings:</b> anywhere. </p> <p><b>Intervention:</b> any anticholinergic </p> <p><b>Comparison:</b> placebo </p> </td> </tr> <tr class="table-header separated"> <td align="" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Outcomes</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p><b>Illustrative comparative risks* (CI)</b> </p> </td> <td align="" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Relative effect<br/> (CI)</b> </p> </td> <td align="" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>No of Participants<br/> (studies)</b> </p> </td> <td align="" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Quality of the evidence<br/> (GRADE)</b> </p> </td> <td align="" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Comments</b> </p> </td> </tr> <tr class="table-header separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Assumed risk</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Corresponding risk</b> </p> </td> </tr> <tr class="table-header separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>risk with placebo</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>risk with anticholinergic drugs</b> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Tardive dyskinesia: not improved to a clinically important extent</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>see comment</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>see comment</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>not estimable</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>(0 studies)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>None of the included studies reported on this outcome.</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Tardive dyskinesia: deterioration of symptoms</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>see comment</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>see comment</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>not estimable</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>(0 studies)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>None of the included studies reported on this outcome.</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Mental state</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>see comment</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>see comment</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>not estimable</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>(0 studies)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>None of the included studies reported on this outcome.</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Adverse effect: any adverse effects</b><br/> follow‐up: 40 weeks </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>see comment</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>see comment</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>not estimable</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>(0 studies)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>None of the included studies reported on this outcome.</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Acceptability of the treatment: leaving the study early</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>see comment</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>see comment</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>not estimable</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>(0 studies)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>None of the included studies reported on this outcome.</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Social confidence, social inclusion, social networks, or personalised quality of life</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>see comment</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>see comment</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>not estimable</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>(0 studies)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>None of the included studies reported on this outcome.</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>*The basis for the <b>assumed risk</b> (e.g. the median control group risk across studies) is provided in footnotes. The <b>corresponding risk</b> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its CI).<br/> <b>CI:</b> Confidence interval; <b>MAO</b> : monoamine oxidase; <b>RR:</b> Risk Ratio </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>GRADE Working Group grades of evidence<br/> <b>High quality:</b> Further research is very unlikely to change our confidence in the estimate of effect.<br/> <b>Moderate quality:</b> Further research is likely to have an important impact on our confidence in the estimate of effect and may change the estimate.<br/> <b>Low quality:</b> Further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to change the estimate.<br/> <b>Very low quality:</b> We are very uncertain about the estimate. </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="7"> <div class="table-footnote"> <p><sup>1</sup> Downgraded one level for risk of bias: the included study did not adequately describe randomisation procedure or allocation concealment, and there was no mention of the study being blinded. </p> <p><sup>2</sup> Downgraded two levels for imprecision: very small sample size (n = 20). </p> <p><sup>3</sup> Downgraded two levels for imprecision: very wide CI that includes appreciable benefit for both groups; very small sample size (n = 20). </p> <p><sup>4</sup> Downgraded one level for indirectness: leaving the study early can give an indication, but is not a direct measurement, of treatment acceptability. </p> </div> </td> </tr> </tfoot> </table> </div> <div class="table" id="CD000204-tbl-0002"> <table class="summary-of-findings framed"><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Summary of findings 2.</span> <span class="table-title">Anticholinergic medication compared with other treatments for antipsychotic‐induced tardive dyskinesia</span></div> <tbody> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>Anticholinergic medication compared with other treatments for antipsychotic‐induced tardive dyskiesia</b> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>Patient or population:</b> chronic schizophrenia patients with antipsychotic‐induced tardive dyskinesia </p> <p><b>Settings:</b> outpatients in the USA. </p> <p><b>Intervention:</b> procyclidine (anticholinergic), 5 mg twice/day </p> <p><b>Comparison:</b> isocarboxazid (MAO‐inhibitor), 10 mg twice/day </p> </td> </tr> <tr class="table-header separated"> <td align="" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Outcomes</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p><b>Illustrative comparative risks* (CI)</b> </p> </td> <td align="" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Relative effect<br/> (CI)</b> </p> </td> <td align="" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>No of Participants<br/> (studies)</b> </p> </td> <td align="" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Quality of the evidence<br/> (GRADE)</b> </p> </td> <td align="" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Comments</b> </p> </td> </tr> <tr class="table-header separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Assumed risk</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Corresponding risk</b> </p> </td> </tr> <tr class="table-header separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>risk with MAO‐inhibitor</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>risk with anticholinergic drugs</b> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Tardive dyskinesia: Not improved to a clinically important extent</b><br/> follow‐up: 40 weeks </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>200 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>840 per 1000</b><br/> (280 to 1000) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>RR 4.20</b> (1.40 to 12.58) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>20<br/> (1 study) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝<br/> <b>very low</b><sup>1 2</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Tardive dyskinesia: deterioration of symptoms</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>see comment</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>see comment</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>not estimable</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>(0 studies)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>None of the included studies reported on this outcome.</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Mental state</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>see comment</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>see comment</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>not estimable</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>(0 studies)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>None of the included studies reported on this outcome.</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Adverse effect: any adverse effects</b><br/> follow‐up: 40 weeks </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>100 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>33 per 1000</b><br/> (2 to 732) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>RR 0.33</b> (0.02 to 7.32) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>20<br/> (1 study) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝<br/> <b>very low</b><sup>1 3</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Acceptability of the treatment: leaving the study early</b><br/> follow‐up: 40 weeks </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>100 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>33 per 1000</b><br/> (2 to 732) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>RR 0.33</b> (0.02 to 7.32) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>20<br/> (1 study) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝<br/> <b>very low</b><sup>1 3 4</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Social confidence, social inclusion, social networks, or personalised quality of life</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>see comment</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>see comment</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>not estimable</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>(0 studies)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>None of the included studies reported on this outcome.</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>*The basis for the <b>assumed risk</b> (e.g. the median control group risk across studies) is provided in footnotes. The <b>corresponding risk</b> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its CI).<br/> <b>CI:</b> Confidence interval; <b>MAO</b> : monoamine oxidase; <b>RR:</b> Risk Ratio </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>GRADE Working Group grades of evidence<br/> <b>High quality:</b> Further research is very unlikely to change our confidence in the estimate of effect.<br/> <b>Moderate quality:</b> Further research is likely to have an important impact on our confidence in the estimate of effect and may change the estimate.<br/> <b>Low quality:</b> Further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to change the estimate.<br/> <b>Very low quality:</b> We are very uncertain about the estimate. </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="7"> <div class="table-footnote"> <p><sup>1</sup> Downgraded one level for risk of bias: the included study did not adequately describe randomisation procedure or allocation concealment, and there was no mention of the study being blinded. </p> <p><sup>2</sup> Downgraded two levels for imprecision: very small sample size (n = 20). </p> <p><sup>3</sup> Downgraded two levels for imprecision: very wide CI that includes appreciable benefit for both groups; very small sample size (n = 20). </p> <p><sup>4</sup> Downgraded one level for indirectness: leaving the study early can give an indication, but is not a direct measurement, of treatment acceptability. </p> </div> </td> </tr> </tfoot> </table> </div> <div class="table" id="CD000204-tbl-0003"> <table class="summary-of-findings framed"><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Summary of findings 3.</span> <span class="table-title">Withdrawal of anticholinergic medication compared to continuing anticholinergic medication for antipsychotic‐induced tardive dyskinesia</span></div> <tbody> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p><b>Withdrawal of anticholinergic medication compared to continuing anticholigergic medication for antipsychotic‐induced tardive dyskinesia</b> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p><b>Patient or population:</b> chronic schizophrenia patients with antipsychotic‐induced tardive dyskinesia<br/> <b>Setting:</b> Germany (1 study)<br/> <b>Intervention:</b> withdrawal of biperiden (stopping after 1 week)<br/> <b>Comparison:</b> continuing biperiden (stopping after 4 weeks) </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Outcomes</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p><b>Anticipated absolute effects<sup>*</sup> (CI)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Relative effect<br/> (CI)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>№ of participants<br/> (studies)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Quality of the evidence<br/> (GRADE)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Comments</b> </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Risk with continuation of anticholinergic drugs</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Risk with withdrawal of anticholinergic drugs</b> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Tardive dyskinesia: not improved to a clinically important extent</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>see comment</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>see comment</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>not estimable</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0</p> <p>(0 studies)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>None of the included studies reported on this outcome.</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Tardive dyskinesia: deterioration of symptoms</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>see comment</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>see comment</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>not estimable</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0</p> <p>(0 studies)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>None of the included studies reported on this outcome.</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Mental state</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>see comment</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>see comment</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>not estimable</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0</p> <p>(0 studies)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>None of the included studies reported on this outcome.</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Adverse effects</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>see comment</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>see comment</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>not estimable</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0</p> <p>(0 studies)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>None of the included studies reported on this outcome.</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Acceptability of the treatment: leaving the study early</b><br/> follow‐up: 7 weeks </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>0 per 1,000</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>0 per 1,000</b><br/> (0 to 0) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>RR 2.14<br/> (0.11 to 42.52) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>10<br/> (1 RCT) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝<br/> <b>very low</b><sup>1 2 3</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Social confidence, social inclusion, social networks, or personalised quality of life</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>see comment</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>see comment</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>not estimable</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0</p> <p>(0 studies)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>None of the included studies reported on this outcome.</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>*<b>The risk in the intervention group</b> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its CI).<br/> <br/> <b>CI:</b> Confidence interval; <b>RR:</b> Risk ratio </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>GRADE Working Group grades of evidence</b> <br/> <b>High quality:</b> We are very confident that the true effect lies close to that of the estimate of the effect<br/> <b>Moderate quality:</b> We are moderately confident in the effect estimate: The true effect is likely to be close to the estimate of the effect, but there is a possibility that it is substantially different<br/> <b>Low quality:</b> Our confidence in the effect estimate is limited: The true effect may be substantially different from the estimate of the effect<br/> <b>Very low quality:</b> We have very little confidence in the effect estimate: The true effect is likely to be substantially different from the estimate of effect </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="7"> <div class="table-footnote"> <p><sup>1</sup> Downgraded one level for risk of bias: the included study did not adequately describe randomisation procedure or allocation concealment. </p> <p><sup>2</sup> Downgraded one level for indirectness: leaving the study early can give an indication, but is not a direct measurement, of treatment acceptability. In addition, the continuation of anticholinergic medication group stopped biperiden after 4 weeks but the results were measured after 7 weeks. </p> <p><sup>3</sup> Downgraded two levels for imprecision: very wide CI that includes appreciable benefit for both groups; very small sample size (n = 10). </p> </div> </td> </tr> </tfoot> </table> </div> </section> </section> <section class="background"> <div class="section-header section-collapse-header" id="CD000204-sec-0023" lang="en"> <h2 class="title section-collapse-title"> Background <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="background" lang="en"> <div class="section-header" id="CD000204-sec-0023"></div> <section id="CD000204-sec-0024"> <h3 class="title" id="CD000204-sec-0024">Description of the condition</h3> <p>Since the 1950s antipsychotic (neuroleptic) medication has been used extensively to treat people with chronic mental illnesses, such as schizophrenia. These drugs can effectively control symptoms such as abnormal perceptions (hallucinations), disordered thinking and fixed false beliefs (delusions). In addition, maintenance therapy with antipsychotics is associated with a reduced risk of relapses (<a href="./references#CD000204-bbs2-0070" title="SchoolerNR , KeithSJ . The clinical research base for the treatment of schizophrenia. Psychopharmacology Bulletin1993;29(4):431‐46. ">Schooler 1993</a>). However, antipsychotic medication has also been associated with a wide range of adverse effects, including movement disorders. The appearance of these disorders can be extremely disfiguring, compounds stigma, and is associated with poor compliance to antipsychotic treatment (<a href="./references#CD000204-bbs2-0031" title="BarnesTRE , EdwardsJG . The side‐effects of antipsychotic drugs. I. CNS and neuromuscular effects. In: BarnesTRE editor(s). Antipsychotic drugs and their side‐effects. London: Harcourt Brace &amp; Company, 1993. ">Barnes 1993</a>; <a href="./references#CD000204-bbs2-0078" title="TarsyD , LunguC , BaldessariniRJ . Epidemiology of tardive dyskinesia before and during the era of modern antipsychotic drugs. Handbook of Clinical Neurology / Edited by P.J. Vinken and G.W. Bruyn2011;100:601‐16. ">Tarsy 2011</a>). </p> <p>Tardive dyskinesia (TD) is one such movement disorder and is characterised by abnormal, repetitive and involuntary movements. TD is a chronic condition of insidious onset, the severity of which spontaneously fluctuates (<a href="./references#CD000204-bbs2-0029" title="American Psychiatric Association. Tardive dyskinesia: a task force report of the American Psychiatric Association. Washington DC: American Psychiatric Association, 1992. ">APA 1992</a>). The clinical features include tongue protrusion, side‐to‐side or rotatory movement of the jaw, lip smacking, puckering and pursing, and rapid eye blinking (<a href="./references#CD000204-bbs2-0037" title="CaseyDE . Tardive dyskinesia: pathophysiology. In: BloomFE , KupferDJ editor(s). Psychopharmacology. The Fourth Generation of Progress. New York: Raven Press, 1994. ">Casey 1994</a>). In some people rapid movements of the arms, legs, and trunk may also occur. Studies on the natural history of TD have reported widely variable remission rates (1% to 62%) depending on patient age, psychiatric diagnosis, course of the psychiatric disorder, and duration of therapy (<a href="./references#CD000204-bbs2-0033" title="BergenJA , EylandEA , CampbellJA . The course of tardive dyskinesia in patients on long‐term neuroleptics. British Journal of Psychiatry1989;154:523‐8. ">Bergen 1989</a>; <a href="./references#CD000204-bbs2-0050" title="FernandezHH , KruppB , FriedmanJH . The course of tardive dyskinesia and parkinsonism in psychiatric inpatients: 14‐year follow‐up. Neurology2001;56:805‐7. ">Fernandez 2001</a>; <a href="./references#CD000204-bbs2-0053" title="GlazerWM , MorgensternH , SchoolerN , BerkmanCS , MooreDC . Predictors of improvement in tardive dyskinesia following discontinuation of neuroleptic medication. British Journal of Psychiatry1990;157:585‐92. ">Glazer 1990</a>). It occurs in more than 20% of those using antipsychotic medication continually for longer than three months. Every year 4% to 5% of adults and 25% to 30% of elderly persons who continually use these drugs begin to show signs of TD (<a href="./references#CD000204-bbs2-0029" title="American Psychiatric Association. Tardive dyskinesia: a task force report of the American Psychiatric Association. Washington DC: American Psychiatric Association, 1992. ">APA 1992</a>; <a href="./references#CD000204-bbs2-0041" title="CorrellCU , LeuchtS , KaneJM . Lower Risk for Tardive Dyskinesia Associated With Second‐Generation Antipsychotics: A Systematic Review of 1‐Year Studies. American Journal of Psychiatry2004;161(3):414‐25. ">Correll 2004</a>). This disorder can result in considerable social and physical disability (<a href="./references#CD000204-bbs2-0031" title="BarnesTRE , EdwardsJG . The side‐effects of antipsychotic drugs. I. CNS and neuromuscular effects. In: BarnesTRE editor(s). Antipsychotic drugs and their side‐effects. London: Harcourt Brace &amp; Company, 1993. ">Barnes 1993</a>). </p> <p>The prevalence of TD is often thought to be decreasing based on the use of second generation antipsychotics (SGA) in place of first generation antipsychotics (FGA) (<a href="./references#CD000204-bbs2-0040" title="CloudLJ , ZutshiD , FactorSA . Tardive dyskinesia: therapeutic options for an increasingly common disorder. Neurotherapeutics2014;11(1):166‐76. ">Cloud 2014</a>). A systematic review found that the incidence of TD associated with SGAs (2% to 4%) was significantly lower than that for FGAs (5% to 8%) (<a href="./references#CD000204-bbs2-0042" title="CorrellCU , SchenkaEM . Tardive dyskinesia and new antipsychotics. Current Opinion in Psychiatry2008;21(2):151‐6. ">Correll 2008</a>). Despite this, widespread use of SGAs in clinical settings may still result in an overall increase in the number of cases of TD (<a href="./references#CD000204-bbs2-0054" title="GlazerWM . Review of incidence studies of tardive dyskinesia associated with typical antipsychotics. Journal of Clinical Psychiatry2000;61(suppl 4):15‐20. ">Glazer 2000</a>). </p> <p>Although the most frequent cause of TD is the use of antipsychotic medication it is striking that dose reduction can lead to a temporary exacerbation in symptoms. Conversely, increasing the dose is often associated with a temporary remission (<a href="./references#CD000204-bbs2-0038" title="CavallaroR , RegazzettiMG , MundoE , BrancatoV , SmeraldiE . Tardive Dyskinesia Outcomes: Clinical and Pharmacologic Correlates of Remission and persistence. Neuropsychopharmacology1993;8(3):233‐9. ">Cavallaro 1993</a>; <a href="./references#CD000204-bbs2-0073" title="SmithJM , BalessariniRJ . Changes in prevalence, severity and recovery in tardive dyskinesia with age. Archives of General Psychiatry1980;37(12):1368‐73. ">Smith 1980</a>). Antipsychotic drugs block certain chemical receptor sites in the brain — one of these is specific for dopamine (<a href="./references#CD000204-bbs2-0037" title="CaseyDE . Tardive dyskinesia: pathophysiology. In: BloomFE , KupferDJ editor(s). Psychopharmacology. The Fourth Generation of Progress. New York: Raven Press, 1994. ">Casey 1994</a>). One hypothesis explaining the cause of antipsychotic‐induced TD is that chronic blockade of dopamine receptors in specific cells of the brain (neurones from the nigrostriatum) causes an overgrowth of these receptors (<a href="./references#CD000204-bbs2-0037" title="CaseyDE . Tardive dyskinesia: pathophysiology. In: BloomFE , KupferDJ editor(s). Psychopharmacology. The Fourth Generation of Progress. New York: Raven Press, 1994. ">Casey 1994</a>). Consequently, interactions between antipsychotic drugs and dopamine receptors in the brain have been proposed as both the mechanisms for their beneficial effects in psychoses as well as the cause of the movement disorder side effects, including TD (<a href="./references#CD000204-bbs2-0058" title="JesteDV , WyattRJ . Understanding and treating tardive dyskinesia. New York: The Guilford Press, 1982. ">Jeste 1982</a>). In addition, there is evidence to suggest that an imbalance between cells that use dopamine and cells that use acetylcholine may be a cause of TD (<a href="./references#CD000204-bbs2-0027" title="AlphsLD , DavisJM . Cholinergic treatments for tardive dyskinesia. Modern Problems in Pharmacopsychiatry1983;21:168‐86. ">Alphs 1983</a>, <a href="./references#CD000204-bbs2-0037" title="CaseyDE . Tardive dyskinesia: pathophysiology. In: BloomFE , KupferDJ editor(s). Psychopharmacology. The Fourth Generation of Progress. New York: Raven Press, 1994. ">Casey 1994</a>). </p> </section> <section id="CD000204-sec-0025"> <h3 class="title" id="CD000204-sec-0025">Description of the intervention</h3> <p>Drugs that reduce the activity of the cholinergic cells (anticholinergic drugs) are widely used to help treat other antipsychotic‐induced movement disorders such as parkinsonism and dystonia (<a href="./references#CD000204-bbs2-0029" title="American Psychiatric Association. Tardive dyskinesia: a task force report of the American Psychiatric Association. Washington DC: American Psychiatric Association, 1992. ">APA 1992</a>). Many acutely psychotic patients who receive antipsychotic medication also receive anticholinergic drugs in order to reduce some of the movement side effects associated with antipsychotic medication. However, anticholinergic drugs can cause many undesirable side effects, such as dryness of mouth, constipation, blurring of vision, and confusion (<a href="./references#CD000204-bbs2-0029" title="American Psychiatric Association. Tardive dyskinesia: a task force report of the American Psychiatric Association. Washington DC: American Psychiatric Association, 1992. ">APA 1992</a>). </p> </section> <section id="CD000204-sec-0026"> <h3 class="title" id="CD000204-sec-0026">How the intervention might work</h3> <p>The rationale for the use of anticholinergic drugs in TD is less clear, as there is a suggestion from animal experiments that the chronic administration of anticholinergics could increase the supersensitivity of dopamine receptors and consequently cause TD (<a href="./references#CD000204-bbs2-0059" title="KaneJM . Tardive dyskinesia: epidemiological and clinical presentation. In: BloomFE , KupferDJ editor(s). Psychopharmacology. The Fourth Generation of Progress. New York: Raven Press, 1994. ">Kane 1994</a>). As a result these drugs have not been widely used for the treatment of antipsychotic‐induced TD. </p> </section> <section id="CD000204-sec-0027"> <h3 class="title" id="CD000204-sec-0027">Why it is important to do this review</h3> <p>Several SGAs have been produced in the last decades that are claimed to cause less or no TD (<a href="./references#CD000204-bbs2-0064" title="LiebermanJA , FleishhackerW . Introduction. British Journal of Psychiatry1996;168(Supplement 29):7‐8. ">Lieberman 1996</a>). These claims may or may not be true: certainly evidence does indicate that thoughtful use of older generation drugs is not associated with more TD than occurs with newer treatments (<a href="./references#CD000204-bbs2-0039" title="ChouinardG , ChouinardVA . Atypical antipsychotics: CATIE study, drug‐induced movement disorder and resulting iatrogenic psychiatric‐like symptoms, supersensitivity rebound psychosis and withdrawal discontinuation syndromes. Psychotherapy and Psychosomatics2008;77(2):69‐77. ">Chouinard 2008</a>). Furthermore it is likely that the less expensive and more familiar drugs — such as chlorpromazine or haloperidol — will continue to be the mainstay of treatment of people with schizophrenia in a global context (<a href="http://www.who.int/medicines/publications/essentialmedicines/Updated_sixteenth_adult_list_en.pdf" target="_blank">WHO Essential List 2010</a>). Use of drugs such as these is associated with emergence of TD and therefore this condition will remain a problem for years to come. </p> <p>Given the high incidence and prevalence of TD among people taking antipsychotic medication, the need for prevention or treatment is clear. Unfortunately, there has been sparse evidence to guide clinicians (<a href="./references#CD000204-bbs2-0067" title="NICE . Psychosis and schizophrenia in adults: treatment and management. NICE clinical guideline 178 (guidance.nice.org.uk/cg178)2014. ">NICE 2014</a>; <a href="./references#CD000204-bbs2-0079" title="TaylorD , PatonC , KapurS . The Maudsley Prescribing Guidelines (10th Edition). London: Informa Healthcare, 2009. ">Taylor 2009</a>). Although many treatments have been tested, no one intervention has been shown clearly to be effective. Cessation or reduction of the dose of antipsychotic medication is the ideal management for TD. In clinical practice this is not always possible, not least because in many individuals such a reduction would lead to relapse. This review focuses on whether the addition or withdrawal of anticholinergic drugs to those already receiving antipsychotic medication is likely to help TD. </p> <p>This review is one in a series of Cochrane Reviews (see <a href="#CD000204-tbl-0004">Table 1</a>) evaluating treatments for antipsychotic‐induced TD, and is an update of a Cochrane Review first published in 1997 (<a href="./references#CD000204-bbs2-0082" title="Soares‐WeiserK , MobsyC , HollidayE . Anticholinergic medication for neuroleptic‐induced tardive dyskinesia. Cochrane Database of Systematic Reviews1997, Issue 2. [DOI: 10.1002/14651858.CD000204] ">Soares‐Weiser 1997</a>). </p> <div class="table" id="CD000204-tbl-0004"> <table><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Table 1.</span> <span class="table-title">Other reviews in the series</span></div> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Interventions</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Reference</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Anticholinergic medication</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>This review</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Benzodiazepines</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD000204-bbs2-0034" title="BhoopathiPS , Soares‐WeiserK . Benzodiazepines for neuroleptic‐induced tardive dyskinesia. Cochrane Database of Systematic Reviews2006, Issue 3. [DOI: 10.1002/14651858.CD000205.pub2] ">Bhoopathi 2006</a>; update to be published </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Calcium channel blockers</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD000204-bbs2-0049" title="EssaliA , DeirawanH , Soares‐WeiserK , AdamsCE . Calcium channel blockers for neuroleptic‐induced tardive dyskinesia. Cochrane Database of Systematic Reviews2011, Issue 11. [DOI: 10.1002/14651858.CD000206.pub3] ">Essali 2011</a>; update to be published </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Cholinergic medication</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD000204-bbs2-0077" title="TammenmaaI , McGrathJ , SailasE , Soares‐WeiserK . Cholinergic medication for neuroleptic‐induced tardive dyskinesia. Cochrane Database of Systematic Reviews2002, Issue 3. [DOI: 10.1002/14651858.CD000207; MEDLINE: 22133093] ">Tammenmaa 2002</a>; update to be published </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Gamma‐aminobutyric acid agonists</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD000204-bbs2-0026" title="AlabedS , LatifehY , MohammadHA , RifaiA . Gamma‐aminobutyric acid agonists for neuroleptic‐induced tardive dyskinesia. Cochrane Database of Systematic Reviews2011, Issue 4. [DOI: 10.1002/14651858.CD000203.pub3] ">Alabed 2011</a>; update to be published </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Miscellaneous treatments</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD000204-bbs2-0074" title="Soares‐WeiserK , JoyC . Miscellaneous treatments for neuroleptic‐induced tardive dyskinesia. Cochrane Database of Systematic Reviews2003, Issue 2. [DOI: 10.1002/14651858.CD000208] ">Soares‐Weiser 2003</a>; update to be published </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Neuroleptic reduction and/or cessation and neuroleptics</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD000204-bbs2-0075" title="Soares‐WeiserK , RathboneJ . Neuroleptic reduction and/or cessation and neuroleptics as specific treatments for tardive dyskinesia. Cochrane Database of Systematic Reviews2006, Issue 1. [DOI: 10.1002/14651858.CD000459.pub2] ">Soares‐Weiser 2006</a>; update to be published </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Non‐neuroleptic catecholaminergic drugs</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD000204-bbs2-0047" title="El‐SayehHG , Lyra da SilvaJP , RathboneJ , Soares‐WeiserK . Non‐neuroleptic catecholaminergic drugs for neuroleptic‐induced tardive dyskinesia. Cochrane Database of Systematic Reviews2006, Issue 1. [DOI: 10.1002/14651858.CD000458.pub2] ">El‐Sayeh 2006</a>; update to be published </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Vitamin E</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD000204-bbs2-0076" title="Soares‐WeiserK , MaayanN , McGrathJ . Vitamin E for neuroleptic‐induced tardive dyskinesia. Cochrane Database of Systematic Reviews2011, Issue 2. [DOI: 10.1002/14651858.CD000209.pub2] ">Soares‐Weiser 2011</a>; update to be published </p> </td> </tr> </tbody> </table> </div> </section> </section> </section> <section class="objectives"> <div class="section-header section-collapse-header" id="CD000204-sec-0028" lang="en"> <h2 class="title section-collapse-title"> Objectives <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="objectives" lang="en"> <div class="section-header" id="CD000204-sec-0028"></div> <p>To determine whether the use or the withdrawal of anticholinergic drugs (benzhexol, benztropine, biperiden, orphenadrine, procyclidine, scopolamine, or trihexyphenidyl) are clinically effective for the treatment of people with both antipsychotic‐induced tardive dyskinesia and schizophrenia or other chronic mental illnesses. </p> </section> </section> <section class="methods"> <div class="section-header section-collapse-header" id="CD000204-sec-0029" lang="en"> <h2 class="title section-collapse-title"> Methods <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="methods" lang="en"> <div class="section-header" id="CD000204-sec-0029"></div> <section id="CD000204-sec-0030"> <h3 class="title">Criteria for considering studies for this review</h3> <section id="CD000204-sec-0031"> <h4 class="title">Types of studies</h4> <p>All relevant randomised controlled trials. Where a trial was described as 'double‐blind' but it implied that the study was randomised and the demographic details of each group were similar, we included it. We had planned to exclude quasi‐randomised studies, such as those allocated by using alternate days of the week (see <a href="#CD000204-sec-0208">Differences between protocol and review</a>). </p> </section> <section id="CD000204-sec-0032"> <h4 class="title">Types of participants</h4> <p>Adults, however defined, with schizophrenia or related disorders, including schizophreniform disorder, schizoaffective disorder and delusional disorder, by any means of diagnosis. We are interested in making sure that information is as relevant as possible to the current care of people with schizophrenia, so if information was available we highlighted the current clinical state of participants (acute, early post‐acute, partial remission, remission), the stage (prodromal, first episode, early illness, persistent) and whether the studies primarily focused on people with particular problems (for example negative symptoms, treatment‐resistant illnesses). </p> </section> <section id="CD000204-sec-0033"> <h4 class="title">Types of interventions</h4> <p>i. Anticholinergic drugs (benzhexol, benztropine, biperiden, dexetimide, orphenadrine, procyclidine, scopolamine, trihexyphenidyl) compared to placebo, or no intervention;<br/> ii. anticholinergic drugs (as above) compared to any other intervention to treat TD; or<br/> iii. the withdrawal of the above anticholinergic drugs compared with the continuation of the treatment. </p> </section> <section id="CD000204-sec-0034"> <h4 class="title">Types of outcome measures</h4> <p>We have defined clinical efficacy as an improvement in the symptoms of TD of more than 50%, on any scale. We grouped outcomes into short term (less than 6 weeks), medium term (between 6 weeks and six months) and long term (more than six months). </p> <section id="CD000204-sec-0035"> <h5 class="title">Primary outcomes</h5> <section id="CD000204-sec-0036"> <h6 class="title">1. Tardive dyskinesia</h6> <p>No clinically important improvement in the symptoms of individuals, defined as more than 50% improvement on any TD scale ‒ any time period. </p> </section> <section id="CD000204-sec-0037"> <h6 class="title">2. Adverse effects</h6> <p>No clinically significant extrapyramidal adverse effects ‒ any time period.</p> </section> </section> <section id="CD000204-sec-0038"> <h5 class="title">Secondary outcomes</h5> <section id="CD000204-sec-0039"> <h6 class="title">1. Tardive dyskinesia (TD)</h6> <p>1.1 Any improvement in the symptoms of individuals on any TD scale, as opposed to no improvement.<br/> 1.2 Deterioration in the symptoms of individuals, defined as any deleterious change on any TD scale.<br/> 1.3 Average change in severity of TD during the trial period.<br/> 1.4 Average difference in severity of TD at the end of the trial. </p> </section> <section id="CD000204-sec-0040"> <h6 class="title">2. General mental state changes</h6> <p>2.1 Deterioration in general psychiatric symptoms (such as delusions and hallucinations) defined as any deleterious change on any scale.<br/> 2.2 Average difference in severity of psychiatric symptoms at the end of the trial. </p> </section> <section id="CD000204-sec-0041"> <h6 class="title">3. Acceptability of the treatment</h6> <p>3.1 Acceptability of the intervention to the participant group as measured by numbers of people dropping out during the trial. </p> </section> <section id="CD000204-sec-0042"> <h6 class="title">4. Adverse effects</h6> <p>4.1 Use of any anti‐parkinsonism drugs.<br/> 4.2 Average score/change in extrapyramidal adverse effects.<br/> 4.3 Acute dystonia. </p> </section> <section id="CD000204-sec-0043"> <h6 class="title">5. Other adverse effects, general and specific</h6> </section> <section id="CD000204-sec-0044"> <h6 class="title">6. Hospital and service utilisation outcomes</h6> <p>6.1 Hospital admission.<br/> 6.2 Average change in days in hospital.<br/> 6.3 Improvement in hospital status (for example: change from formal to informal admission status, use of seclusion, level of observation). </p> </section> <section id="CD000204-sec-0045"> <h6 class="title">7. Economic outcomes</h6> <p>7.1 Average change in total cost of medical and mental health care.<br/> 7.2 Total indirect and direct costs. </p> </section> <section id="CD000204-sec-0046"> <h6 class="title">8. Social confidence, social inclusion, social networks, or personalised quality of life measures </h6> <p>8.1. No significant change in social confidence, social inclusion, social networks, or personalised quality of life measures.<br/> 8.2 Average score/change in social confidence, social inclusion, social networks, or personalised quality of life measures. </p> </section> <section id="CD000204-sec-0047"> <h6 class="title">9. Behaviour</h6> <p>9.1 Clinically significant agitation.<br/> 9.2 Use of adjunctive medication for sedation.<br/> 9.3 Aggression to self or others. </p> </section> <section id="CD000204-sec-0048"> <h6 class="title">10. Cognitive state</h6> <p>10.1 No clinically important change.<br/> 10.2 No change, general and specific. </p> </section> <section id="CD000204-sec-0049"> <h6 class="title">'Summary of findings' table</h6> <p>We used the GRADE approach to interpret findings (<a href="./references#CD000204-bbs2-0071" title="SchünemannHJ , OxmanAD , VistGE , HigginsJPT , DeeksJJ , GlasziouP , et al. Chapter 12: Interpreting results and drawing conclusions. In: Higgins JPT, Green S (editors), Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 (updated March 2011). The Cochrane Collaboration, 2011. Available from handbook.cochrane.org. ">Schünemann 2008</a>); and <a href="http://www.tech.cochrane.org/gradepro" target="_blank">GRADEPRO</a> to import data from <a href="http://www.tech.cochrane.org/revman" target="_blank">Review Manager</a> to create 'Summary of findings' tables. These tables provide outcome‐specific information concerning the overall quality of evidence from each included study in the comparison, the magnitude of effect of the interventions examined, and the sum of the available data on all outcomes we rated as important to patient care and decision making. This summary was used to guide our conclusions and recommendations. We selected the following main outcomes for inclusion in the 'Summary of findings' table. </p> <section id="CD000204-sec-0050"> <p><b>1. Tardive dyskinesia</b></p> <p>1.1 Improved to a clinically important extent.<br/> 1.2 Deteriorated. </p> </section> <section id="CD000204-sec-0051"> <p><b>2. Mental state</b></p> <p>2.1 Deterioration.</p> </section> <section id="CD000204-sec-0052"> <p><b>3. Adverse effects</b></p> <p>3.1 Any adverse event.<br/> 3.2 Adverse effects: no clinically significant extrapyramidal adverse effects. </p> </section> <section id="CD000204-sec-0053"> <p><b>4. Acceptability of treatment</b></p> <p>4.1 Leaving the study early.</p> </section> <section id="CD000204-sec-0054"> <p><b>5. Social confidence, social inclusion, social networks, or personalised quality‐of‐life measures*</b></p> <p>5.1 No significant change in social confidence, social inclusion, social networks, or personalised quality of life measures for either recipients of care or caregivers. </p> <p>* Outcome designated important to patients. We wished to add perspectives from people’s personal experience with TD to the research agenda. A consultation with service users was planned where a previously published version of a review in the Cochrane TD series and a lay overview of that review gave the foundation for the discussions (<a href="./references#CD000204-bbs2-0076" title="Soares‐WeiserK , MaayanN , McGrathJ . Vitamin E for neuroleptic‐induced tardive dyskinesia. Cochrane Database of Systematic Reviews2011, Issue 2. [DOI: 10.1002/14651858.CD000209.pub2] ">Soares‐Weiser 2011</a>; <a href="#CD000204-tbl-0004">Table 1</a>). The session was planned to provide time to reflect on current research on TD and consider gaps in knowledge. The report is not completed but we will add a link to it within this review. In the meantime we have added one figure showing a service user's feelings concerning this neglected area of research (<a href="#CD000204-fig-0001">Figure 1</a>). Informed by the results of the consultation, for this review we included outcomes important to service users to the 'Summary of findings' table. </p> <div class="figure" id="CD000204-fig-0001"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 1</div> </div> <hr class="top"/><img alt="Message from one of the participants of the Public and patient involvement consultation of service user perspectives on tardive dyskinesia research." data-id="CD000204-fig-0001" src="/cdsr/doi/10.1002/14651858.CD000204.pub2/media/CDSR/CD000204/image_n/nCD000204-AFig-FIG01.png"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Message from one of the participants of the Public and patient involvement consultation of service user perspectives on tardive dyskinesia research. </p> </div> </div> </div> </section> </section> </section> </section> </section> <section id="CD000204-sec-0055"> <h3 class="title">Search methods for identification of studies</h3> <section id="CD000204-sec-0056"> <h4 class="title">Electronic searches</h4> <p>The 2017 review update was carried out in parallel with updating eight other TD reviews: see <a href="#CD000204-tbl-0004">Table 1</a> for details. The search covered all nine TD reviews. </p> <section id="CD000204-sec-0057"> <h5 class="title">Cochrane Schizophrenia Group's Study‐Based Register of Trials</h5> <p>On 16 July 2015 and 26 April 2017, the Information Specialist searched the register using the following search strategy: </p> <p>*Tardive Dyskinesia* in Health Care Condition Field of STUDY</p> <p>In such study‐based registers, searching the major concept retrieves all the synonyms and relevant studies because all the studies have already been organised based on their interventions and linked to the relevant topics (<a href="./references#CD000204-bbs2-0072" title="ShokranehF , AdamsCE . Study‐based registers of randomized controlled trials: Starting a systematic review with data extraction or meta‐analysis. BioImpacts2017;7(4):209‐17. ">Shokraneh 2017</a>). </p> <p>This register is compiled by systematic searches of major resources (AMED, BIOSIS, CINAHL, ClinicalTrials.gov, Embase, MEDLINE, PsycINFO, PubMed, WHO ICTRP) and their monthly updates; ProQuest Dissertations and Theses A&amp;I and its quarterly update; Chinese databases (CBM, CNKI, and Wanfang) and their annual updates; handsearches; grey literature; and conference proceedings (see <a href="http://onlinelibrary.wiley.com/o/cochrane/clabout/articles/SCHIZ/frame.html" target="_blank">Group's Module</a>). There are no language, date, document type, or publication status limitations for inclusion of records into the register. </p> <p>For previous searches, please see <a href="./appendices#CD000204-sec-0188">Appendix 1</a>. </p> </section> </section> <section id="CD000204-sec-0058"> <h4 class="title">Searching other resources</h4> <section id="CD000204-sec-0059"> <h5 class="title">1. Reference searching</h5> <p>We inspected references of all included studies for further relevant studies.</p> </section> <section id="CD000204-sec-0060"> <h5 class="title">2. Personal contact</h5> <p>Where necessary, we contacted the first author of each included study for information regarding unpublished trials. We noted the outcome of this contact in the <a href="./references#CD000204-bbs1-0001" title="">Included studies</a> or <a href="./references#CD000204-bbs1-0003" title="">Studies awaiting classification</a> tables. </p> </section> </section> </section> <section id="CD000204-sec-0061"> <h3 class="title" id="CD000204-sec-0061">Data collection and analysis</h3> <section id="CD000204-sec-0062"> <h4 class="title">Selection of studies</h4> <p>For the 2017 update, reviewers RA and AG (see <a href="#CD000204-sec-0185">Acknowledgements</a>) inspected all abstracts of studies identified as above for potentially relevant reports. We resolved disagreement by discussion; or, where there was still doubt, we acquired the full article for further inspection. We acquired the full articles of relevant reports/abstracts meeting initial criteria for reassessment and carefully inspected for a final decision on inclusion (see <a href="#CD000204-sec-0030">Criteria for considering studies for this review</a>). RA and AG were not blinded to the names of the authors, institutions or journal of publication. Where difficulties or disputes arose, we asked author HB for help; and where it was impossible to decide or if adequate information was not available to make a decision, we added these studies to <a href="./references#CD000204-bbs1-0003" title="">Studies awaiting classification</a> and contacted the authors of the papers for clarification. </p> </section> <section id="CD000204-sec-0063"> <h4 class="title">Data extraction and management</h4> <section id="CD000204-sec-0064"> <h5 class="title">1. Extraction</h5> <p>For the 2017 update, reviewers RA and HB independently extracted data from all included studies. Again, we discussed any disagreement and documented decisions. KSW helped clarify issues with any remaining problems and we documented these final decisions. We extracted data presented only in graphs and figures whenever possible, but included them only if two reviewers independently had the same result. We attempted to contact authors through an open‐ended request in order to obtain missing information or for clarification whenever necessary. If studies were multi‐centre, where possible we extracted data relevant to each component centre separately. </p> </section> <section id="CD000204-sec-0065"> <h5 class="title">2. Management</h5> <section id="CD000204-sec-0066"> <h6 class="title">2.1 Forms</h6> <p>For the 2017 update we extracted data to simple forms. Extracted data are available <a href="https://www.researchgate.net/publication/308698005_Appendix_Traceable_Extracted_Data_from_Included_Studies_of_Tardive_Dyskinesia_Reviews?channel=doi%26linkId=57ebe1c508ae92a5dbd051c1%26showFulltext=true" target="_blank">here</a> with a link to the original source PDF for each item. </p> </section> <section id="CD000204-sec-0067"> <h6 class="title">2.2 Scale‐derived data</h6> <p>We included continuous data from rating scales only if:</p> <p>a) the psychometric properties of the measuring instrument have been described in a peer‐reviewed journal (<a href="./references#CD000204-bbs2-0065" title="MarshallM , LockwoodA , BradleyC , AdamsC , JoyC , FentonM . Unpublished rating scales: a major source of bias in randomised controlled trials of treatments for schizophrenia. British Journal of Psychiatry2000;176:249‐52. ">Marshall 2000</a>);<br/> b) the measuring instrument has not been written or modified by one of the trialists for that particular trial; and<br/> c) the instrument should be a global assessment of an area of functioning and not sub‐scores which are not, in themselves, validated or shown to be reliable. However there are exceptions, we included sub‐scores from mental state scales measuring positive and negative symptoms of schizophrenia.<br/> <br/> Ideally the measuring instrument should either be i. a self‐report or ii. completed by an independent rater or relative (not the therapist). We realise that this is not often reported clearly; we noted in <a href="#CD000204-sec-0108">Description of studies</a> if this was the case or not. </p> </section> <section id="CD000204-sec-0068"> <h6 class="title">2.3 Endpoint versus change data</h6> <p>There are advantages of both endpoint and change data. Change data can remove a component of between‐person variability from the analysis. On the other hand calculation of change needs two assessments (baseline and endpoint) which can be difficult in unstable and difficult‐to‐measure conditions such as schizophrenia. We decided to primarily use endpoint data, and only use change data if the former were not available. We combined endpoint and change data in the analysis as we preferred to use mean differences (MD) rather than standardised mean differences throughout (<a href="./references#CD000204-bbs2-0057" title="HigginsJPT , GreenS (editors) . Cochrane Handbook for Systematic Reviews of Interventions Version 5.0.2 (updated September 2011). The Cochrane Collaboration, 2011. Available from handbook.cochrane.org. ">Higgins 2011</a>). </p> </section> <section id="CD000204-sec-0069"> <h6 class="title">2.4 Skewed data</h6> <p>Continuous data on clinical and social outcomes are often not normally distributed. To avoid the pitfall of applying parametric tests to non‐parametric data, we applied the following standards to relevant data before inclusion; see (a) and (b) below. </p> <p>Please note: we would have entered data from studies of at least 200 participants in the analysis, because skewed data pose less of a problem in large studies. We also would have entered all relevant change data as when continuous data are presented on a scale that includes a possibility of negative values (such as change data), it is difficult to tell whether data are skewed or not. </p> <p>For endpoint data from studies of fewer than 200 participants:</p> <p>(a) when a scale starts from the ﬁnite number zero, we planned to subtract the lowest possible value from the mean, and divide this by the standard deviation. If this value was lower than 1, it strongly suggests a skew and we would have excluded these data. If this ratio was higher than 1 but below 2, there is suggestion of skew. We would have entered these data and tested whether its inclusion or exclusion changed the results substantially. Finally, if the ratio was larger than 2 we would have included these data, because skew is less likely (<a href="./references#CD000204-bbs2-0028" title="AltmanDG , BlandJM . Detecting skewness from summary information. BMJ1996;313(7066):1200. ">Altman 1996</a>; <a href="./references#CD000204-bbs2-0057" title="HigginsJPT , GreenS (editors) . Cochrane Handbook for Systematic Reviews of Interventions Version 5.0.2 (updated September 2011). The Cochrane Collaboration, 2011. Available from handbook.cochrane.org. ">Higgins 2011</a>). </p> <p>(b) if a scale starts from a positive value (such as the Positive and Negative Syndrome Scale (PANSS), (<a href="./references#CD000204-bbs2-0060" title="KaySR , OplerLA , FiszbeinA . Positive and Negative Syndrome Scale (PANSS) Manual. North Tonawanda, NY: Multi‐Health Systems, 1986. ">Kay 1986</a>)) which can have values from 30 to 210), we would have modified the calculation described above to take the scale starting point into account. In these cases skew is present if 2 SD &gt; (S − S min), where S is the mean score and 'S min' is the minimum score. </p> </section> <section id="CD000204-sec-0070"> <h6 class="title">2.5 Common measure</h6> <p>Where relevant, to facilitate comparison between trials we would have converted variables that can be reported in different metrics, such as days in hospital (mean days per year, per week or per month) to a common metric (e.g. mean days per month). </p> </section> <section id="CD000204-sec-0071"> <h6 class="title">2.6 Conversion of continuous to binary</h6> <p>Where possible, we converted continuous outcome measures to dichotomous data. This can be done by identifying cut‐off points on rating scales and dividing participants accordingly into 'clinically improved' or 'not clinically improved'. It is generally assumed that if there is a 50% reduction in a scale‐derived score such as the Brief Psychiatric Rating Scale (BPRS, <a href="./references#CD000204-bbs2-0068" title="OverallJE , GorhamDR . The brief psychiatric rating scale. Psychological Reports1962;10:799‐812. ">Overall 1962</a>) or the Positive and Negative Syndrome Scale (PANSS, <a href="./references#CD000204-bbs2-0060" title="KaySR , OplerLA , FiszbeinA . Positive and Negative Syndrome Scale (PANSS) Manual. North Tonawanda, NY: Multi‐Health Systems, 1986. ">Kay 1986</a>), this can be considered as a clinically significant response (<a href="./references#CD000204-bbs2-0062" title="LeuchtS , KaneJM , KisslingW , HamannJ , EtschelE , EngelRR . What does the PANSS mean?. Schizophrenia Research2005;79(2‐3):231‐8. [PUBMED: 15982856] ">Leucht 2005a</a>, <a href="./references#CD000204-bbs2-0063" title="LeuchtS , KaneJM , KisslingW , HamannJ , EtschelE , EngelR . Clinical implications of brief psychiatric rating scale scores. British Journal of Psychiatry2005;187:366‐71. [PUBMED: 16199797] ">Leucht 2005b</a>). If data based on these thresholds were not available, we used the primary cut‐off presented by the original authors. </p> </section> <section id="CD000204-sec-0072"> <h6 class="title">2.7 Direction of graphs</h6> <p>Where possible, we entered data in such a way that the area to the left of the line of no effect indicated a favourable outcome for anticholinergic medication. Where keeping to this made it impossible to avoid outcome titles with clumsy double‐negatives (e.g. 'Not un‐improved') we presented data where the left of the line indicates an unfavourable outcome and noted this in the relevant graphs. </p> </section> </section> </section> <section id="CD000204-sec-0073"> <h4 class="title">Assessment of risk of bias in included studies</h4> <p>Reviewers RA and HB independently assessed risk of bias within the included studies by using criteria described in the <i>Cochrane Handbook for Systematic Reviews of Interventions</i> to assess trial quality (<a href="./references#CD000204-bbs2-0057" title="HigginsJPT , GreenS (editors) . Cochrane Handbook for Systematic Reviews of Interventions Version 5.0.2 (updated September 2011). The Cochrane Collaboration, 2011. Available from handbook.cochrane.org. ">Higgins 2011</a>). This set of criteria is based on evidence of associations between overestimate of effect and high risk of bias of the article such as sequence generation, allocation concealment, blinding, incomplete outcome data and selective reporting. </p> <p>If the raters disagreed, we made the final rating by consensus, with the involvement of another member of the review group. Where inadequate details of randomisation and other characteristics of trials were provided, we contacted authors of the studies in order to obtain further information. If non‐concurrence occurred, we reported this. </p> <p>We noted the level of risk of bias in the text of the review and in <a href="#CD000204-fig-0002">Figure 2</a>, <a href="#CD000204-fig-0003">Figure 3</a>, <a href="./full#CD000204-tbl-0003">summary of findings Table 3</a> and <a href="./full#CD000204-tbl-0002">summary of findings Table 2</a>. </p> <div class="figure" id="CD000204-fig-0002"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 2</div> </div> <hr class="top"/><img alt="Risk of bias graph: review authors' judgements about each risk of bias item presented as percentages across all included studies." data-id="CD000204-fig-0002" src="/cdsr/doi/10.1002/14651858.CD000204.pub2/media/CDSR/CD000204/image_n/nCD000204-AFig-FIG02.png"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Risk of bias graph: review authors' judgements about each risk of bias item presented as percentages across all included studies. </p> </div> </div> </div> <div class="figure" id="CD000204-fig-0003"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 3</div> </div> <hr class="top"/><img alt="Risk of bias summary: review authors' judgements about each risk of bias item for each included study." data-id="CD000204-fig-0003" src="/cdsr/doi/10.1002/14651858.CD000204.pub2/media/CDSR/CD000204/image_n/nCD000204-AFig-FIG03.png"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Risk of bias summary: review authors' judgements about each risk of bias item for each included study. </p> </div> </div> </div> </section> <section id="CD000204-sec-0074"> <h4 class="title">Measures of treatment effect</h4> <section id="CD000204-sec-0075"> <h5 class="title">1. Binary data</h5> <p>For binary outcomes we calculated a standard estimation of the risk ratio (RR) and its 95% confidence interval (CI). It has been shown that RR is more intuitive than odds ratios (<a href="./references#CD000204-bbs2-0036" title="BoisselJP , CucheratM , LiW , ChatellierG , GueyffierF , BuyseM , et al. The problem of therapeutic efficacy indices. 3. Comparison of the indices and their use [Apercu sur la problematique des indices d'efficacite therapeutique, 3: comparaison des indices et utilisation. Groupe d'Etude des Indices D'efficacite]. Therapie1999;54(4):405‐11. [PUBMED: 10667106] ">Boissel 1999</a>), as odds ratios tend to be interpreted as RR by clinicians (<a href="./references#CD000204-bbs2-0043" title="DeeksJ . Issues in the selection for meta‐analyses of binary data. Proceedings of the 8th International Cochrane Colloquium; 2000 Oct 25‐28; Cape Town. Cape Town: The Cochrane Collaboration, 2000. ">Deeks 2000</a>). </p> </section> <section id="CD000204-sec-0076"> <h5 class="title">2. Continuous data</h5> <p>For continuous outcomes we estimated mean difference (MD) between groups. We preferred not to calculate effect size measures (standardised mean difference (SMD)). However, if scales of very considerable similarity were used, we presumed there is a small difference in measurement, and calculated effect size and transformed the effect back to the units of one or more of the specific instruments. </p> </section> </section> <section id="CD000204-sec-0077"> <h4 class="title">Unit of analysis issues</h4> <section id="CD000204-sec-0078"> <h5 class="title">1. Cluster trials</h5> <p>Studies increasingly employ 'cluster randomisation' (such as randomisation by clinician or practice) but analysis and pooling of clustered data can be a problem. Authors often fail to account for intra‐class correlation in clustered studies, leading to a 'unit of analysis' error (<a href="./references#CD000204-bbs2-0044" title="DivineGW , BrownJT , FrazierLM . The unit of analysis error in studies about physicians' patient care behavior. Journal of General Internal Medicine1992;7(6):623‐9. ">Divine 1992</a>), whereby P values are spuriously low, confidence intervals unduly narrow and statistical significance overestimated. This causes type I errors (<a href="./references#CD000204-bbs2-0035" title="BlandJM , KerrySM . Statistics notes. Trials randomised in clusters. BMJ1997;315(7108):600. ">Bland 1997</a>; <a href="./references#CD000204-bbs2-0055" title="GullifordMC . Components of variance and intraclass correlations for the design of community‐based surveys and intervention studies: data from the Health Survey for England 1994. American Journal of Epidemiology1999;149(9):876‐83. ">Gulliford 1999</a>). </p> <p>If any of the included trials had randomised participants by clusters, and where clustering is not accounted for in primary studies, we would have presented such data in a table, with a (*) symbol to indicate the presence of a probable 'unit of analysis' error. In subsequent versions of this review we will seek to contact first authors of studies to obtain intra‐class correlation coefficients for their clustered data and to adjust for this by using accepted methods (<a href="./references#CD000204-bbs2-0055" title="GullifordMC . Components of variance and intraclass correlations for the design of community‐based surveys and intervention studies: data from the Health Survey for England 1994. American Journal of Epidemiology1999;149(9):876‐83. ">Gulliford 1999</a>). Where clustering has been incorporated into the analysis of primary studies, we will present these data as if from a non‐cluster randomised study, but adjust for the clustering effect. </p> <p>We have sought statistical advice and have been advised that the binary data as presented in a report should be divided by a 'design effect'. This is calculated using the mean number of participants per cluster (m) and the intra‐class correlation coefficient (ICC) (Design effect = 1 + (m − 1) * ICC) (<a href="./references#CD000204-bbs2-0045" title="DonnerA , KlarN . Issues in the meta‐analysis of cluster randomized trials. Statistics in Medicine2002;21(19):2971‐80. ">Donner 2002</a>). If the ICC is not reported it will be assumed to be 0.1 (<a href="./references#CD000204-bbs2-0080" title="UkoumunneOC , GullifordMC , ChinnS , SterneJAC , BurneyPGJ . Methods for evaluating area‐wide and organistation‐based intervention in health and health care: a systematic review. Health Technology Assessment1999;3(5):1‐75. ">Ukoumunne 1999</a>). </p> <p>If cluster studies have been appropriately analysed taking into account intra‐class correlation coefficients and relevant data documented in the report, synthesis with other studies would be possible using the generic inverse variance technique. </p> </section> <section id="CD000204-sec-0079"> <h5 class="title">2. Cross‐over trials</h5> <p>A major concern of cross‐over trials is the carry‐over effect. It occurs if an effect (pharmacological, physiological or psychological) of the treatment in the first phase is carried over to the second phase. As a consequence on entry to the second phase the participants can differ systemically from their initial state despite a wash‐out phase. For the same reason cross‐over trials are not appropriate if the condition of interest is unstable (<a href="./references#CD000204-bbs2-0048" title="ElbourneD , AltmanDG , HigginsJPT , CurtinaF , WorthingtondHV , VaileA . Meta‐analyses involving cross‐over trials: methodological issues. International Journal of Epidemiology2002;31(1):140‐9. ">Elbourne 2002</a>). As both effects are very likely in severe mental illness, we only used data of the first phase of cross‐over studies. </p> </section> <section id="CD000204-sec-0080"> <h5 class="title">3. Studies with multiple treatment groups</h5> <p>Where a study involves more than two treatment arms, if relevant we presented the additional treatment arms in comparisons. If data were binary we simply added and combined within the two‐by‐two table. If data were continuous we combined data following the formula in the <i>Cochrane Handbook for Systematic Reviews of Interventions</i> (<a href="./references#CD000204-bbs2-0057" title="HigginsJPT , GreenS (editors) . Cochrane Handbook for Systematic Reviews of Interventions Version 5.0.2 (updated September 2011). The Cochrane Collaboration, 2011. Available from handbook.cochrane.org. ">Higgins 2011</a>)<i>.</i> We did not use data where the additional treatment arms were not relevant. </p> </section> </section> <section id="CD000204-sec-0081"> <h4 class="title">Dealing with missing data</h4> <section id="CD000204-sec-0082"> <h5 class="title">1. Overall loss of credibility</h5> <p>At some degree of loss to follow‐up, data must lose credibility (<a href="./references#CD000204-bbs2-0081" title="XiaJ , AdamsCE , BhagatN , BhagatV , BhoopathiP , El‐SayehH , et al. Loss to outcomes stakeholder survey: the LOSS study. Psychiatric Bulletin2009;33(7):254‐7. ">Xia 2009</a>). We chose that, for any particular outcome, should more than 50% of data be unaccounted for, we would not reproduce these data or use them within analyses. If, however, more than 50% of those in one arm of a study were lost, but the total loss was less than 50%, we addressed this within the 'Summary of findings' table/s by down‐rating quality. We also downgraded quality within the 'Summary of findings' table/s should loss be 25% to 50% in total. </p> </section> <section id="CD000204-sec-0083"> <h5 class="title">2. Binary</h5> <p>In the case where attrition for a binary outcome is between 0% and 50% and where these data are not clearly described, we presented data on a 'once‐randomised‐always‐analyse' basis (an 'intention to treat' analysis). We assumed all those leaving the study early had no improvement. We undertook a sensitivity analysis testing how prone the primary outcomes were to change by comparing data only from people who completed the study to that point to the 'intention to treat' analysis using the above assumptions. </p> </section> <section id="CD000204-sec-0084"> <h5 class="title">3. Continuous</h5> <section id="CD000204-sec-0085"> <h6 class="title">3.1 Attrition</h6> <p>We reported and used data where attrition for a continuous outcome was between 0% and 50%, and data only from people who completed the study to that point were reported. </p> </section> <section id="CD000204-sec-0086"> <h6 class="title">3.2 Standard deviations</h6> <p>If standard deviations were not reported, we first tried to obtain the missing values from the authors. If not available, where there were missing measures of variance for continuous data but an exact standard error and confidence intervals available for group means, and either P value or t value available for differences in mean, we calculated them according to the rules described in the <i>Cochrane Handbook for Systematic Reviews of Interventions</i> (<a href="./references#CD000204-bbs2-0057" title="HigginsJPT , GreenS (editors) . Cochrane Handbook for Systematic Reviews of Interventions Version 5.0.2 (updated September 2011). The Cochrane Collaboration, 2011. Available from handbook.cochrane.org. ">Higgins 2011</a>): when only the standard error (SE) is reported, standard deviations (SDs) are calculated by the formula SD = SE * √(n). Chapters 7.7.3 and 16.1.3 of the <i>Cochrane Handbook for Systematic Reviews of Interventions</i> present detailed formulae for estimating SDs from P, t or F values, confidence intervals, ranges or other statistics (<a href="./references#CD000204-bbs2-0057" title="HigginsJPT , GreenS (editors) . Cochrane Handbook for Systematic Reviews of Interventions Version 5.0.2 (updated September 2011). The Cochrane Collaboration, 2011. Available from handbook.cochrane.org. ">Higgins 2011</a>). If these formulae did not apply, we calculated the SDs according to a validated imputation method which is based on the SDs of the other included studies (<a href="./references#CD000204-bbs2-0052" title="FurukawaTA , BarbuiC , CiprianiA , BrambillaP , WatanabeN . Imputing missing standard deviations in meta‐analyses can provide accurate results. Journal of Clinical Epidemiology2006;59(7):7‐10. ">Furukawa 2006</a>). Although some of these imputation strategies can introduce error, the alternative would be to exclude a given study’s outcome and thus to lose information. We nevertheless examined the validity of the imputations in a sensitivity analysis excluding imputed values. </p> </section> <section id="CD000204-sec-0087"> <h6 class="title">3.3 Assumptions about participants who left the trials early or were lost to follow‐up</h6> <p>Various methods are available to account for participants who left the trials early or were lost to follow‐up. Some trials just present the results of study completers, others use the method of last observation carried forward (LOCF), while more recently methods such as multiple imputation or mixed‐effects models for repeated measurements (MMRM) have become more of a standard. While the last two methods seem to be somewhat better than LOCF (<a href="./references#CD000204-bbs2-0061" title="LeonAC , MallinckrodtCH , Chuang‐SteinC , ArchibaldDG , ArcherGE , ChartierK . Attrition in randomized controlled clinical trials: methodological issues in psychopharmacology. Biological Psychiatry2006;59(11):1001‐5. [PUBMED: 16905632] ">Leon 2006</a>), we feel that the high percentage of participants leaving the studies early and differences in the reasons for leaving the studies early between groups is often the core problem in randomised schizophrenia trials. We therefore did not exclude studies based on which statistical approach had been used. However, we preferred to use the more sophisticated approaches (e.g. MMRM or 'multiple‐imputation') and only presented completer analyses if some kind of ITT data were not available at all. Moreover, we addressed this issue in the item 'Incomplete outcome data' of the 'Risk of bias' tool. </p> </section> </section> </section> <section id="CD000204-sec-0088"> <h4 class="title">Assessment of heterogeneity</h4> <section id="CD000204-sec-0089"> <h5 class="title">1. Clinical heterogeneity</h5> <p>We considered all included studies initially, without seeing comparison data, to judge clinical heterogeneity. We simply inspected all studies for clearly outlying people or situations which we had not predicted would arise and discussed in the text if they arose. </p> </section> <section id="CD000204-sec-0090"> <h5 class="title">2. Methodological heterogeneity</h5> <p>We considered all included studies initially, without seeing comparison data, to judge methodological heterogeneity. We simply inspected all studies for clearly outlying methods which we had not predicted would arise and discussed in the text if they arose. </p> </section> <section id="CD000204-sec-0091"> <h5 class="title">3. Statistical heterogeneity</h5> <section id="CD000204-sec-0092"> <h6 class="title">3.1 Visual inspection</h6> <p>We visually inspected graphs to investigate the possibility of statistical heterogeneity.</p> </section> <section id="CD000204-sec-0093"> <h6 class="title">3.2 Employing the I² statistic</h6> <p>We investigated heterogeneity between studies by considering the I² method alongside the Chi² P value. The I² provides an estimate of the percentage of inconsistency thought to be due to chance (<a href="./references#CD000204-bbs2-0056" title="HigginsJP , ThompsonSG , DeeksJJ , AltmanDG . Measuring inconsistency in meta‐analyses. BMJ2003;327(7414):557‐60. ">Higgins 2003</a>). The importance of the observed value of I² depends on i. magnitude and direction of effects and ii. strength of evidence for heterogeneity (e.g. P value from Chi²  test, or a confidence interval for I²). An I² estimate equal to or greater than around 50% accompanied by a statistically significant Chi² statistic can be interpreted as evidence of substantial levels of heterogeneity (Section 9.5.2 <i>Cochrane Handbook for Systematic Reviews of Interventions;</i><a href="./references#CD000204-bbs2-0057" title="HigginsJPT , GreenS (editors) . Cochrane Handbook for Systematic Reviews of Interventions Version 5.0.2 (updated September 2011). The Cochrane Collaboration, 2011. Available from handbook.cochrane.org. ">Higgins 2011</a>). We explored and discussed in the text potential reasons for substantial levels of heterogeneity (<a href="#CD000204-sec-0096">Subgroup analysis and investigation of heterogeneity</a>). </p> </section> </section> </section> <section id="CD000204-sec-0094"> <h4 class="title">Assessment of reporting biases</h4> <p>Reporting biases arise when the dissemination of research findings is influenced by the nature and direction of results (<a href="./references#CD000204-bbs2-0046" title="EggerM , SmithGD , SchneiderM , MinderC . Bias in meta‐analysis detected by a simple, graphical test. BMJ1997;315(7109):629‐34. ">Egger 1997</a>). These are described in Section 10 of the <i>Cochrane Handbook for Systematic Reviews of Interventions</i> (<a href="./references#CD000204-bbs2-0057" title="HigginsJPT , GreenS (editors) . Cochrane Handbook for Systematic Reviews of Interventions Version 5.0.2 (updated September 2011). The Cochrane Collaboration, 2011. Available from handbook.cochrane.org. ">Higgins 2011</a>). We are aware that funnel plots may be useful in investigating reporting biases but are of limited power to detect small‐study effects. We would not have used funnel plots for outcomes where there were 10 or fewer studies, or where all studies were of similar sizes. In future versions of this review, if funnel plots are possible we will seek statistical advice in their interpretation. </p> </section> <section id="CD000204-sec-0095"> <h4 class="title">Data synthesis</h4> <p>We understand that there is no closed argument for preference of fixed‐effect models over random‐effects models, or vice versa. The random‐effects method incorporates an assumption that the different studies are estimating different, yet related, intervention effects. This often seems to be true to us and the random‐effects model takes into account differences between studies even if there is no statistically significant heterogeneity. There is, however, a disadvantage to the random‐effects model: it puts added weight onto small studies which often are the most biased ones. Depending on the direction of effect, these studies can either inflate or deflate the effect size. We chose the fixed‐effect model for all analyses. </p> </section> <section id="CD000204-sec-0096"> <h4 class="title">Subgroup analysis and investigation of heterogeneity</h4> <section id="CD000204-sec-0097"> <h5 class="title">1. Subgroup analyses</h5> <section id="CD000204-sec-0098"> <h6 class="title">1.1 Primary outcomes</h6> <p>We anticipated one sub‐group analysis to test the hypothesis that the modification of anticholinergic medication is most effective for those with early onset TD (less than five years). We had hoped to present data for this subgroup for the primary outcomes. </p> </section> <section id="CD000204-sec-0099"> <h6 class="title">1.2 Clinical state, stage or problem</h6> <p>We proposed to undertake this review and provide an overview of the effects of anticholinergic medication for people with schizophrenia in general. In addition, however, we had wanted to report data on subgroups of people in the same clinical state, stage and with similar problems. </p> </section> </section> <section id="CD000204-sec-0100"> <h5 class="title">2. Investigation of heterogeneity</h5> <p>We would have reported when inconsistency was high. First we would have investigated whether data were entered correctly. Second, if data were correct, we would have visually inspected the graph and successively removed studies from the company of the rest to see if homogeneity was restored. For this review we decided that should this occur with data contributing to the summary finding of no more than around 10% of the total weighting, we would present data. If not, we would not pool such data but would discuss issues. We know of no supporting research for this 10% cut off but are investigating use of prediction intervals as an alternative to this unsatisfactory state. </p> <p>When unanticipated clinical or methodological heterogeneity were obvious, we simply discussed. We did not undertake sensitivity analyses relating to these. </p> </section> </section> <section id="CD000204-sec-0101"> <h4 class="title">Sensitivity analysis</h4> <section id="CD000204-sec-0102"> <h5 class="title">1. Implication of randomisation</h5> <p>If trials were described in some way as to imply randomisation we undertook a sensitivity analysis for the primary outcomes. We included these studies in the analyses and if there was no substantive difference when the implied randomised studies were added to those with better description of randomisation, then we used relevant data from these studies. </p> </section> <section id="CD000204-sec-0103"> <h5 class="title">2. Assumptions for lost binary data</h5> <p>Where assumptions had to be made regarding people lost to follow‐up (see <a href="#CD000204-sec-0081">Dealing with missing data</a>) we compared the findings of the primary outcomes when we used our assumption compared with 'completer' data only. If there was a substantial difference, we reported and discussed these results but continued to employ our assumption. </p> <p>Where assumptions have to be made regarding missing SDs data (see <a href="#CD000204-sec-0081">Dealing with missing data</a>), we compared the findings on primary outcomes when we used our assumption compared with 'completer' data only. We undertook a sensitivity analysis testing how prone results were to change when 'completer' data only were compared to the imputed data using the above assumption. If there was a substantial difference, we reported and discussed these results but continued to employ our assumption. </p> </section> <section id="CD000204-sec-0104"> <h5 class="title">3. Risk of bias</h5> <p>We analysed the effects of excluding trials that we judged to be at high risk of bias across one or more of the domains of randomisation (implied as randomised with no further details available), allocation concealment, blinding and outcome reporting for the meta‐analysis of the primary outcome. If the exclusion of trials at high risk of bias did not substantially alter the direction of effect or the precision of the effect estimates, we included data from these trials in the analysis. </p> </section> <section id="CD000204-sec-0105"> <h5 class="title">4. Imputed values</h5> <p>Had cluster trials been included, we would have undertaken a sensitivity analysis to assess the effects of including data from trials where we used imputed values for ICC in calculating the design effect. </p> <p>If we found substantial differences in the direction or precision of effect estimates in any of the sensitivity analyses listed above, we did not pool data from the excluded trials with the other trials contributing to the outcome, but presented them separately. </p> </section> <section id="CD000204-sec-0106"> <h5 class="title">5. Fixed and random effects</h5> <p>We synthesised data using a fixed‐effect model; however, we also synthesised data for the primary outcome using a random‐effects model to evaluate whether this altered the significance of the results. </p> </section> </section> </section> </section> </section> <section class="results"> <div class="section-header section-collapse-header" id="CD000204-sec-0107" lang="en"> <h2 class="title section-collapse-title"> Results <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="results" lang="en"> <div class="section-header" id="CD000204-sec-0107"></div> <section id="CD000204-sec-0108"> <h3 class="title">Description of studies</h3> <p>Please see <a href="./references#CD000204-sec-0211" title="">Characteristics of included studies</a>; <a href="./references#CD000204-sec-0212" title="">Characteristics of excluded studies</a>; <a href="./references#CD000204-sec-0213" title="">Characteristics of studies awaiting classification</a>. </p> <section id="CD000204-sec-0109"> <h4 class="title">Results of the search</h4> <p>The 2015 and 2017 update searches were part of an update search of nine Cochrane Reviews; see <a href="#CD000204-tbl-0004">Table 1</a>. The 2015 search retrieved 704 references for 344 studies; see <a href="#CD000204-fig-0004">Figure 4</a> for study flow diagram. After excluding irrelevant references at title and abstract screening, we screened full texts of 31 references (25 studies). As a result of updating the methods and outcomes considered in this review, we have now included two studies that we previously excluded because of a lack of placebo control (<a href="./references#CD000204-bbs2-0001" title="BucciL . The dyskinesias: a new therapeutic approach. Diseases of the Nervous System1971;32(5):324‐7. ">Bucci 1971</a>), and uncertainty around the number of participants (<a href="./references#CD000204-bbs2-0002" title="GreilW , HaagH , RossnaglG , RütherE . Effect of anticholinergics on tardive dyskinesia. A controlled discontinuation study. British Journal of Psychiatry1984;145:304‐10. ">Greil 1984</a>); see <a href="#CD000204-sec-0110">Included studies</a>. These two studies are the only studies included in this review. One study is awaiting classification (<a href="./references#CD000204-bbs2-0025" title="ZhaoxiangZ , FenglianC , LinL . A Clinical Research of Dexetimide and Benzhexol for Treatment of Drug‐induced Tremor. Herald of Medicine1996;15(3):130‐1. ">Zeng 1996</a>). </p> <div class="figure" id="CD000204-fig-0004"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 4</div> </div> <hr class="top"/><img alt="Study flow diagram for 2015 and 2017 searches." data-id="CD000204-fig-0004" src="/cdsr/doi/10.1002/14651858.CD000204.pub2/media/CDSR/CD000204/image_n/nCD000204-AFig-FIG04.png"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Study flow diagram for 2015 and 2017 searches.</p> </div> </div> </div> <p>The 2017 search found eight records (five studies). Editorial base of Cochrane Schizophrenia screened these records and no new studies were relevant to this review. They could be relevant to the other reviews in this series of TD reviews (see <a href="#CD000204-tbl-0004">Table 1</a>), and have been put into 'Studies awaiting classification' of the <a href="./references#CD000204-bbs2-0074" title="Soares‐WeiserK , JoyC . Miscellaneous treatments for neuroleptic‐induced tardive dyskinesia. Cochrane Database of Systematic Reviews2003, Issue 2. [DOI: 10.1002/14651858.CD000208] ">Soares‐Weiser 2003</a> 'miscellaneous treatments' review. </p> </section> <section id="CD000204-sec-0110"> <h4 class="title">Included studies</h4> <p>The review now includes two studies with 30 participants, published in 1971 and 1984.</p> <section id="CD000204-sec-0111"> <h5 class="title">1. Methods</h5> <p>Both studies were stated to be randomised and <a href="./references#CD000204-bbs2-0002" title="GreilW , HaagH , RossnaglG , RütherE . Effect of anticholinergics on tardive dyskinesia. A controlled discontinuation study. British Journal of Psychiatry1984;145:304‐10. ">Greil 1984</a> also reported being double blind. For further details, please see <a href="#CD000204-sec-0127">Risk of bias in included studies</a> (below) on allocation and blinding. </p> </section> <section id="CD000204-sec-0112"> <h5 class="title">2. Design</h5> <p>Both studies presented a parallel longitudinal design.</p> </section> <section id="CD000204-sec-0113"> <h5 class="title">3. Duration</h5> <p>The study by <a href="./references#CD000204-bbs2-0002" title="GreilW , HaagH , RossnaglG , RütherE . Effect of anticholinergics on tardive dyskinesia. A controlled discontinuation study. British Journal of Psychiatry1984;145:304‐10. ">Greil 1984</a> lasted for 7 weeks while <a href="./references#CD000204-bbs2-0001" title="BucciL . The dyskinesias: a new therapeutic approach. Diseases of the Nervous System1971;32(5):324‐7. ">Bucci 1971</a> lasted 40 weeks. </p> </section> <section id="CD000204-sec-0114"> <h5 class="title">4. Participants</h5> <p>Participants, totalling 30 people, were mostly women in their 50s, with diagnoses of chronic schizophrenia. All were reported to have antipsychotic‐induced TD; however, no criteria for the diagnosis of TD were reported. The number of participants ranged from 10 (<a href="./references#CD000204-bbs2-0002" title="GreilW , HaagH , RossnaglG , RütherE . Effect of anticholinergics on tardive dyskinesia. A controlled discontinuation study. British Journal of Psychiatry1984;145:304‐10. ">Greil 1984</a>) to 20 (<a href="./references#CD000204-bbs2-0001" title="BucciL . The dyskinesias: a new therapeutic approach. Diseases of the Nervous System1971;32(5):324‐7. ">Bucci 1971</a>). </p> </section> <section id="CD000204-sec-0115"> <h5 class="title">5. Setting</h5> <p>One study was performed in hospital outpatients in the USA (<a href="./references#CD000204-bbs2-0001" title="BucciL . The dyskinesias: a new therapeutic approach. Diseases of the Nervous System1971;32(5):324‐7. ">Bucci 1971</a>); the other was set in Germany but did not report whether participants were out‐ or inpatients (<a href="./references#CD000204-bbs2-0002" title="GreilW , HaagH , RossnaglG , RütherE . Effect of anticholinergics on tardive dyskinesia. A controlled discontinuation study. British Journal of Psychiatry1984;145:304‐10. ">Greil 1984</a>). </p> </section> <section id="CD000204-sec-0116"> <h5 class="title">6. Interventions</h5> <section id="CD000204-sec-0117"> <h6 class="title">6.1 Anticholinergic medications</h6> <section id="CD000204-sec-0118"> <p><b>6.1.1 Procyclidine</b></p> <p>Procyclidine was used by <a href="./references#CD000204-bbs2-0001" title="BucciL . The dyskinesias: a new therapeutic approach. Diseases of the Nervous System1971;32(5):324‐7. ">Bucci 1971</a> in a 5 mg dose, twice daily. </p> </section> <section id="CD000204-sec-0119"> <p><b>6.1.2 Biperiden</b></p> <p>Biperiden was used by <a href="./references#CD000204-bbs2-0002" title="GreilW , HaagH , RossnaglG , RütherE . Effect of anticholinergics on tardive dyskinesia. A controlled discontinuation study. British Journal of Psychiatry1984;145:304‐10. ">Greil 1984</a> in the same dose that participants received before the trial. This trial compared the withdrawal of biperiden after 1 week and 4 weeks. </p> </section> </section> <section id="CD000204-sec-0120"> <h6 class="title">6.2 Comparison group</h6> <p><a href="./references#CD000204-bbs2-0002" title="GreilW , HaagH , RossnaglG , RütherE . Effect of anticholinergics on tardive dyskinesia. A controlled discontinuation study. British Journal of Psychiatry1984;145:304‐10. ">Greil 1984</a> compared the withdrawal of biperiden over two time periods. <a href="./references#CD000204-bbs2-0001" title="BucciL . The dyskinesias: a new therapeutic approach. Diseases of the Nervous System1971;32(5):324‐7. ">Bucci 1971</a> used isocarboxazid — a monoamine oxidase inhibitor — 10 mg twice per day as a control. </p> </section> </section> <section id="CD000204-sec-0121"> <h5 class="title">7. Outcomes</h5> <section id="CD000204-sec-0122"> <h6 class="title">7.1 TD symptoms</h6> <p>Only one study provided useable data on TD symptoms (<a href="./references#CD000204-bbs2-0001" title="BucciL . The dyskinesias: a new therapeutic approach. Diseases of the Nervous System1971;32(5):324‐7. ">Bucci 1971</a>). This appears to be a clinical assessment and not a validated scale. </p> </section> <section id="CD000204-sec-0123"> <h6 class="title">7.2 Adverse events</h6> <p>Only one study provided useable data on adverse events as a result of medication (<a href="./references#CD000204-bbs2-0001" title="BucciL . The dyskinesias: a new therapeutic approach. Diseases of the Nervous System1971;32(5):324‐7. ">Bucci 1971</a>). This was reported simply as the number of events in both groups. </p> </section> </section> <section id="CD000204-sec-0124"> <h5 class="title">Studies awaiting classification</h5> <p>We identified one study, published in Chinese (<a href="./references#CD000204-bbs2-0025" title="ZhaoxiangZ , FenglianC , LinL . A Clinical Research of Dexetimide and Benzhexol for Treatment of Drug‐induced Tremor. Herald of Medicine1996;15(3):130‐1. ">Zeng 1996</a>). We have contacted the study authors to determine if participants were diagnosed with TD but at the time of preparing this review we had not had a response. </p> </section> <section id="CD000204-sec-0125"> <h5 class="title">Ongoing studies</h5> <p>We have identified no ongoing studies.</p> </section> </section> <section id="CD000204-sec-0126"> <h4 class="title">Excluded studies</h4> <p>There are 22 excluded studies. Twelve studies were not randomised (<a href="./references#CD000204-bbs2-0003" title="CaseyDE , DenneyD . Pharmacological characterization of tardive dyskinesia. Psychopharmacology1977;54(1):1‐8. ">Casey 1977</a>; <a href="./references#CD000204-bbs2-0009" title="GardosG , ColeJO , RapkinRM , LaBrieRA , BaquelodE , MooreP , et al. Anticholinergic challenge and neuroleptic withdrawal. Changes in dyskinesia and symptom measures. Archives of General Psychiatry1984;41(11):1030‐5. ">Gardos 1984</a>; <a href="./references#CD000204-bbs2-0010" title="GerlachJ . The relationship betwen parkisonism and tardive dyskinesia. American Journal of Psychiatry1977;134(7):781‐4. GerlachJ , ThorsenK . The movement pattern of oral tardive dyskinesia in relation to anticholinergic and antidopaminergic treatment. Internal Pharmacopsychiatry1976;11(1):1‐7. ">Gerlach 1976</a>; <a href="./references#CD000204-bbs2-0011" title="GerlachJ , SimmelsgaardH . Tardive dyskinesia during and following treatment with haloperidol, haloperidol and biperiden, thioridazine and clozapine. Psychopharmacology1978;59(2):105‐12. ">Gerlach 1978</a>; <a href="./references#CD000204-bbs2-0012" title="JusK , JusA , GautierJ , VilleneuveA , PiresP , PineauR , et al. Studies on the action of certain pharmacological agents on tardive dyskinesia and on the rabbit syndrome. International Journal of Clinical Pharmacology, Therapy, and Toxicology1974;9(2):138‐45. ">Jus 1974</a>; <a href="./references#CD000204-bbs2-0014" title="KonigP , ChwatalK , HavelecL , RiedlF , SchubertH , SchultesH . Amantadine versus biperiden ‐ a double‐blind study of treatment efficacy in neuroleptic extrapyramidal movement disorders. Neuropsychobiology1996;33(2):80‐4. [MEDLINE: 8927233] ">Konig 1996</a>; <a href="./references#CD000204-bbs2-0015" title="LejoyeuxM , GorwoodP , Stalla‐BourdillonA , AdesJ . Translation and application of the Simpson and Angus Scale of Extrapyramidal Symptoms [Traduction et utilisation de l'echelle de Simpson et Angus de symptomes extra‐pyramidaux]. L'Encéphale1993;19(1):17‐21. ">Lejoyeux 1993</a>; <a href="./references#CD000204-bbs2-0020" title="SmithJS , KilohLG . Six‐month evaluation of thiopropazate hydrochloride in tardive dyskinesia. Journal of Neurology, Neurosurgery and Psychiatry1979;42(6):576‐9. ">Smith 1979</a>; <a href="./references#CD000204-bbs2-0021" title="TammingaCA , SmithRC , EricksenSE , ChangS , DavisJM . Cholinergic influences in tardive dyskinesia. American Journal of Psychiatry1977;134(7):769‐74. ">Tamminga 1977</a>; <a href="./references#CD000204-bbs2-0022" title="WirshingWC , FreidenbergDL , CummingsJL , BartzokisG . Effects of anticholinergic agents on patients with tardive dyskinesia and concomitant drug‐induced parkinsonism. Journal of Clinical Psychopharmacology1989;9(6):407‐11. ">Wirshing 1989a</a>; <a href="./references#CD000204-bbs2-0023" title="WirshingWC , FreidenbergDL , CummingsJL , BartzokisG . Effect of anticholinergic agents on patients with tardive dyskinesia and concomitant drug‐induced parkinsonism. Journal of Clinical Psychopharmacology1989;9(6):407‐11. [MEDLINE: 2574192] ">Wirshing 1989b</a>; <a href="./references#CD000204-bbs2-0024" title="ZwanikkenGJ , OeiTT , KimyaS , AmeryW . Safety and efficacy of prolonged treatment with Tremblex (dexetimide), an antiparkinsonian agent. A controlled study. Acta Psychiatrica Belgica1976;76(3):467‐79. [MEDLINE: 1020682] ">Zwanikken 1976</a>). Four studies were randomised but included participants with schizophrenia but not TD (<a href="./references#CD000204-bbs2-0004" title="DiMascioA , BernardoDL , GreenblattDJ , MarderJE . A controlled trial of amantadine in drug‐induced extrapyramidal disorders. Archives of General Psychiatry1976;33(5):599‐602. DiMascioA , BernardoDL , GreenblattDJ , MarderJE . A controlled trial of amantadine in drug‐induced extrapyramidal disorders. Psychopharmacology Bulletin1977;13(3):31‐3. ">DiMascio 1976</a>; <a href="./references#CD000204-bbs2-0005" title="DoubleDB , WarrenGC , EvansM , RowlandsMP . Efficacy of maintenance use of anticholinergic agents. Acta Psychiatrica Scandinavica1993;88(5):381‐4. ">Double 1993</a>; <a href="./references#CD000204-bbs2-0006" title="ElieR , MorinL , TetreaultM . Effects of ethopropazine and of trihexyphenidyl on several parameters of the neuroleptic syndrome. Encephale1972;61(1):32‐52. ">Elie 1972</a>; <a href="./references#CD000204-bbs2-0007" title="FannWE , LakeCR . Amantadine versus trihexyphenidyl in the treatment of neuroleptic‐induced parkinsonism. American Journal of Psychiatry1976;133(8):940‐3. ">Fann 1976</a>). One study did not report data separately on the minority of participants with TD and the author confirmed that these data are unavailable (<a href="./references#CD000204-bbs2-0013" title="KlettCJ , CaffeyE . Evaluating the long‐term need for antiparkinson drugs by chronic schizophrenics. Archives of General Psychiatry1972;26(4):374‐9. ">Klett 1972</a>). Four studies were cross‐over trials that did not provide data before the first phase before crossing over to the next treatment. We contacted authors of three of these studies and received no data (<a href="./references#CD000204-bbs2-0008" title="FriisT , ChristensenR , GerlachJ . Sodium valproate and biperiden in neuroleptic‐induced akathisia, parkinsonism and hyperkinesia. Acta Psychiatrica Scandinavica1983;67(3):178‐87. ">Friis 1983</a>; <a href="./references#CD000204-bbs2-0016" title="LiebermanJ , PollackS , LesserM , KaneJ . Pharmacologic characterization of tardive dyskinesia. Journal of Clinical Psychopharmacology1988;8(4):254‐60. ">Lieberman 1988</a>; <a href="./references#CD000204-bbs2-0018" title="GerlachJ . Tardive dyskinesia: pathophysiological mechanisms and clinical trials. L'Encephale1988;XIV:227‐32. GerlachJ , AhforsUG , AmthorKF . Effect of different neuroleptics in tardive dyskinesia and parkinsonism. A video‐controlled multicenter study with chlorprothixene, perphenazine, haloperidol and haloperidol and biperiden. Psychopharmacology1986;90(4):423‐9. Nordik Dyskinesia Study Group. Effect of different neuroleptics in tardive dyskinesia and parkinsonism. Psychopharmacology1986;90(4):423‐9. PovlsenUJ , NoringU , MeidahlB , KorsgaardS , WaehrensJ , GerlachJ . Not available [Neuroleptikas virkning pa tardive dyskinesier]. Ugeskr Laeger1987;149(25):1682‐5. ">NDSG 1986</a>). For one of these studies we were not able to identify up‐to‐date contact details, and we consider it is very unlikely that we will receive a reply with data so many years later (<a href="./references#CD000204-bbs2-0019" title="SilverH , GeraisyN , SchwartzM . No difference in the effect of biperiden and amantadine on parkinsonian‐ and tardive dyskinesia‐type involuntary movements: A double‐blind crossover, placebo‐controlled study in medicated chronic schizophrenic patients. Journal of Clinical Psychiatry1995;56(9):435. SilverH , GeraisyN , SchwartzM . No difference in the effect of biperiden and amantadine on parkinsonian‐ and tardive dyskinesia‐type involuntary movements: a double‐blind crossover, placebo‐controlled study in medicated chronic schizophrenic patients. Journal of Clinical Psychiatry1995;56(4):167‐70. ">Silver 1995</a>). One study did not provide any usable data, despite our making contact with the authors (<a href="./references#CD000204-bbs2-0017" title="LudatscherJI . Stable remission of tardive dyskinesia by L‐dopa. Journal of Clinical Psychopharmacology1989;9(1):39‐41. ">Ludatscher 1989</a>). </p> </section> </section> <section id="CD000204-sec-0127"> <h3 class="title">Risk of bias in included studies</h3> <p>Please refer to <a href="#CD000204-fig-0002">Figure 2</a> and <a href="#CD000204-fig-0003">Figure 3</a> for graphical overviews of the risk of bias in the included studies. </p> <section id="CD000204-sec-0128"> <h4 class="title">Allocation</h4> <p>While both studies claimed to be randomised, neither described explicitly how the randomisation sequence was generated or how allocation concealment was ensured. As a result we have rated them as having unclear risk of bias. </p> </section> <section id="CD000204-sec-0129"> <h4 class="title">Blinding</h4> <p>Although <a href="./references#CD000204-bbs2-0002" title="GreilW , HaagH , RossnaglG , RütherE . Effect of anticholinergics on tardive dyskinesia. A controlled discontinuation study. British Journal of Psychiatry1984;145:304‐10. ">Greil 1984</a> was conducted on a double‐blind basis, only blinding of the treatment provider was explicitly described. <a href="./references#CD000204-bbs2-0001" title="BucciL . The dyskinesias: a new therapeutic approach. Diseases of the Nervous System1971;32(5):324‐7. ">Bucci 1971</a> did not mention blinding of providers, participants, or outcome assessors. </p> </section> <section id="CD000204-sec-0130"> <h4 class="title">Incomplete outcome data</h4> <p>In each included study there was one person who did not complete the study. In all cases, however, we tried to ensure that every person randomised was analysed. </p> </section> <section id="CD000204-sec-0131"> <h4 class="title">Selective reporting</h4> <p>All data in this review originates from published reports. The expected outcomes (impact on TD symptoms) were not reported sufficiently by <a href="./references#CD000204-bbs2-0002" title="GreilW , HaagH , RossnaglG , RütherE . Effect of anticholinergics on tardive dyskinesia. A controlled discontinuation study. British Journal of Psychiatry1984;145:304‐10. ">Greil 1984</a>. Both studies did not fully report outcomes that were measured during the study and were rated at high risk of reporting bias. Attempts to contact authors of trials for additional data were unsuccessful. </p> </section> <section id="CD000204-sec-0132"> <h4 class="title">Other potential sources of bias</h4> <p>Both studies had very small sample sizes. There was very little information reported on which to base further concerns regarding risk of bias. </p> </section> </section> <section id="CD000204-sec-0133"> <h3 class="title" id="CD000204-sec-0133">Effects of interventions</h3> <p>See: <a href="./full#CD000204-tbl-0001"><b>Summary of findings for the main comparison</b> Anticholinergic medication compared with placebo for antipsychotic‐induced tardive dyskinesia</a>; <a href="./full#CD000204-tbl-0002"><b>Summary of findings 2</b> Anticholinergic medication compared with other treatments for antipsychotic‐induced tardive dyskinesia</a>; <a href="./full#CD000204-tbl-0003"><b>Summary of findings 3</b> Withdrawal of anticholinergic medication compared to continuing anticholinergic medication for antipsychotic‐induced tardive dyskinesia</a> </p> <section id="CD000204-sec-0134"> <h4 class="title">1. Comparison 1: anticholinergic drugs versus placebo or no treatment</h4> <p>No studies were identified that assessed this comparison.</p> </section> <section id="CD000204-sec-0135"> <h4 class="title">2. Comparison 2: anticholinergic drugs versus other compounds</h4> <section id="CD000204-sec-0136"> <h5 class="title">2.1 TD symptoms</h5> <p>We had chosen 'any improvement in TD symptoms of more than 50% on any TD scale ‒ any time period' as a primary outcome. Although the data we found in trials did not fit this exactly we feel that the outcome 'not improved to a clinically important extent' fits best with what we had hoped to find. </p> <section id="CD000204-sec-0137"> <h6 class="title">2.1.1 Not improved to a clinically important extent</h6> <p>One study found a significant difference on 'no clinically important improvement in TD symptoms favouring isocarboxazid (MAO‐inhibitor) compared with procyclidine (anticholinergic) after 40 weeks' (low‐quality evidence, 1 trial, 20 people; RR 4.20, 95% CI 1.40 to 12.58; <a href="./references#CD000204-fig-0005" title="">Analysis 1.1</a>). </p> </section> <section id="CD000204-sec-0138"> <h6 class="title">2.1.2 Not any improvement</h6> <p>For the outcome of 'not any improvement in TD symptoms', procyclidine resulted in a worse outcome than isocarboxazid after 40 weeks (low‐quality evidence, 1 trial, 20 people; RR 7.00, 95% CI 1.57 to 31.15; <a href="./references#CD000204-fig-0006" title="">Analysis 1.2</a>). </p> </section> </section> <section id="CD000204-sec-0139"> <h5 class="title">2.2 Adverse effects</h5> <section id="CD000204-sec-0140"> <h6 class="title">2.2.1 Any adverse effects</h6> <p>There was no significant difference in the incidence of any adverse effects between procyclidine and isocarboxazid after 40 weeks (very low quality evidence, 1 trial, 20 people; RR 0.33, 95% CI 0.02 to 7.32; <a href="./references#CD000204-fig-0007" title="">Analysis 1.3</a>). </p> </section> </section> <section id="CD000204-sec-0141"> <h5 class="title">2.3 Leaving the study early</h5> <p>Using procyclidine did not significantly affect the chances of a person leaving the study early compared to isocarboxazid after 40 weeks (very low quality evidence, 1 trial, 20 people; RR 0.33, 95% CI 0.02 to 7.32; <a href="./references#CD000204-fig-0008" title="">Analysis 1.4</a>). </p> <p>We did not identify any studies that reported on hospital and service utilisation outcomes, economic outcomes, social confidence, social inclusion, social networks, personalised quality of life, behaviour, or cognitive state. </p> </section> </section> <section id="CD000204-sec-0142"> <h4 class="title">3. Comparison 3: continuation versus withdrawal of anticholinergic drugs</h4> <section id="CD000204-sec-0143"> <h5 class="title">3.1 Leaving the study early</h5> <p>The only usable data showed no significant difference on leaving the study early between withdrawal of biperiden after 1 week compared with continuation of the drug for 4 weeks (very low quality evidence, 1 trial, 10 people; RR 2.14, 95% CI 0.11 to 42.52; <a href="./references#CD000204-fig-0009" title="">Analysis 2.1</a>). </p> <p>We did not identify any studies that reported on TD symptoms, adverse events, hospital and service utilisation outcomes, economic outcomes, social confidence, social inclusion, social networks, personalised quality of life, behaviour, or cognitive state. </p> </section> </section> <section id="CD000204-sec-0144"> <h4 class="title">4. Subgroup analyses</h4> <section id="CD000204-sec-0145"> <h5 class="title">4.1 Clinical stage: recent onset TD</h5> <p>It was not possible to evaluate whether those with recent onset TD responded differently to those with more established problems, since no trial reported data for groups with different durations of TD that could be extracted for separate analyses, and since only one study per comparison was included. </p> </section> <section id="CD000204-sec-0146"> <h5 class="title">4.2 Duration of follow‐up</h5> <p>It was not possible to evaluate whether the effect of anticholinergic drugs changed in relation to duration of follow‐up; only one study per comparison was included. </p> </section> </section> <section id="CD000204-sec-0147"> <h4 class="title">5. Heterogeneity</h4> <p>Only one study per comparison was included. Therefore, investigation into heterogeneity was not relevant, and we could not detect clinical, methodological or statistical heterogeneity as described in <a href="#CD000204-sec-0088">Assessment of heterogeneity</a>. </p> </section> <section id="CD000204-sec-0148"> <h4 class="title">6. Sensitivity analyses</h4> <section id="CD000204-sec-0149"> <h5 class="title">6.1 Implication of randomisation</h5> <p>We aimed to include trials in a sensitivity analysis if they were described in some way as to imply randomisation. We have not undertaken this sensitivity analysis as only one study was included per comparison, and both studies were stated to be randomised. </p> </section> <section id="CD000204-sec-0150"> <h5 class="title">6.2 Assumptions for lost binary data</h5> <p>Where assumptions had to be made regarding people lost to follow‐up (see <a href="#CD000204-sec-0081">Dealing with missing data</a>) we compared the findings when we used our assumption with 'completer' data only. Using 'completer' data only for anticholinergic drugs (procyclidine) versus isocarboxazid, we found that there was no substantial alteration to the direction of effect or the precision of the effect estimates for the primary outcome 'no clinically important improvement' (1 trial, 19 people; RR 3.82, 95% CI 1.30 to 11.26; analysis not shown). </p> </section> <section id="CD000204-sec-0151"> <h5 class="title">6.3 Risk of bias</h5> <p>It was not possible to evaluate whether excluding trials that we judged to be at high risk of bias across one or more of the domains would alter the effect estimate; only one study was included per comparison. </p> </section> <section id="CD000204-sec-0152"> <h5 class="title">6.4 Imputed values</h5> <p>We would have undertaken a sensitivity analysis to assess the effects of including data from cluster randomised trials where we used imputed values for ICC in calculating the design effect. However, no cluster randomised trials were included. </p> </section> <section id="CD000204-sec-0153"> <h5 class="title">6.5 Fixed and random effects</h5> <p>We also synthesised data for the primary outcome using a random‐effects model. This did not alter the results. </p> </section> </section> </section> </section> </section> <section class="discussion"> <div class="section-header section-collapse-header" id="CD000204-sec-0154" lang="en"> <h2 class="title section-collapse-title"> Discussion <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="discussion" lang="en"> <div class="section-header" id="CD000204-sec-0154"></div> <section id="CD000204-sec-0155"> <h3 class="title" id="CD000204-sec-0155">Summary of main results</h3> <section id="CD000204-sec-0156"> <h4 class="title">1. The search</h4> <p>This area of research does not seem to be active. The 2017 update has identified additional data, but all trials predate 1990. This could be because of reasons such as less concern with TD, or less emergence of the problem in research‐active communities because of more thoughtful use of antipsychotic drugs. </p> </section> <section id="CD000204-sec-0157"> <h4 class="title">2. Few data</h4> <p>Only 30 people were included in this review. For this reason it is very likely that real — and important — effects have not been highlighted because of the necessarily wide CIs of the findings. Many outcomes were not measured at all, including several of our pre‐stated outcome measures (see <a href="#CD000204-sec-0165">Overall completeness and applicability of evidence</a>). </p> </section> <section id="CD000204-sec-0158"> <h4 class="title">3. Comparison 1: anticholinergic drugs versus placebo or no treatment</h4> <p>We found no included study that compared the efficacy or safety of an anticholinergic drug compared with placebo or no treatment (<a href="./full#CD000204-tbl-0001">summary of findings Table for the main comparison</a>). </p> </section> <section id="CD000204-sec-0159"> <h4 class="title">4. Comparison 2: anticholinergic drugs versus other compounds</h4> <p>We identified one very small trial reporting few outcomes (<a href="./full#CD000204-tbl-0002">summary of findings Table 2</a>). There were no data on mental state or social outcomes. </p> <section id="CD000204-sec-0160"> <h5 class="title">4.1 TD symptoms</h5> <p>One study found that more participants on isocarboxazid (MAO‐inhibitor) than on procyclidine (anticholinergic) improved to a clinically important level at long term (RR 4.20, 95% CI 1.40 to 12.58; N = 20). However, the quality of the evidence is very low and therefore we have very little confidence in the effect estimate and CIs — the true effect is likely to be substantially different. </p> </section> <section id="CD000204-sec-0161"> <h5 class="title">4.2 Adverse effects</h5> <p>One study found no clear difference in adverse events between procyclidine (anticholinergic) (0/10) and isocarboxazid (MAO‐inhibitor) (1/10) (RR 0.33, 95% CI 0.02 to 7.32; N = 20). Evidence was of very low quality, therefore we are uncertain about the result. </p> </section> <section id="CD000204-sec-0162"> <h5 class="title">4.3 Leaving the study early</h5> <p>One study found no clear difference in leaving the study early between procyclidine (anticholinergic) (0/10) and isocarboxazid (MAO‐inhibitor) (1/10) (RR 0.33, 95% CI 0.02 to 7.32; N = 20). Evidence was of very low quality, therefore we are uncertain about the result. </p> </section> </section> <section id="CD000204-sec-0163"> <h4 class="title">5. Comparison 3. continuation versus withdrawal of anticholinergic drugs</h4> <p>We identified one very small trial reporting few outcomes (<a href="./full#CD000204-tbl-0003">summary of findings Table 3</a>). There were no data on tardive dyskinesia, adverse effects, mental state or social outcomes. </p> <section id="CD000204-sec-0164"> <h5 class="title">5.1 Leaving the study early</h5> <p>One study found no significant difference in leaving the study early between anticholinergic withdrawal after 1 week (1/6) and anticholinergic continuation for 4 weeks (0/4) (RR 2.14, 95% CI 0.11 to 42.52; N = 10). Evidence was of very low quality, therefore we are uncertain about the result. </p> </section> </section> </section> <section id="CD000204-sec-0165"> <h3 class="title" id="CD000204-sec-0165">Overall completeness and applicability of evidence</h3> <section id="CD000204-sec-0166"> <h4 class="title">1. Completeness</h4> <p>Only two small studies with few useable data were included, not sufficient to address whether the use or withdrawal of anticholinergic drugs was associated with an improvement in antipsychotic‐induced TD in people with schizophrenia or other chronic mental illness, let alone to examine whether there was a differential effect among the different anticholinergic drugs. We only identified usable data on TD symptoms from a study comparing anticholinergic medication with another compound, the antidepressant isocarboxazid, a drug which is experimental in the treatment of TD. We found few usable data on adverse events, and none on mental state, social confidence, social inclusion, social networks, or personalised quality of life. If reporting had been better we might have been able to include more data from these studies, and we might have had some data to present from the excluded studies (<a href="./references#CD000204-bbs2-0008" title="FriisT , ChristensenR , GerlachJ . Sodium valproate and biperiden in neuroleptic‐induced akathisia, parkinsonism and hyperkinesia. Acta Psychiatrica Scandinavica1983;67(3):178‐87. ">Friis 1983</a>; <a href="./references#CD000204-bbs2-0016" title="LiebermanJ , PollackS , LesserM , KaneJ . Pharmacologic characterization of tardive dyskinesia. Journal of Clinical Psychopharmacology1988;8(4):254‐60. ">Lieberman 1988</a>; <a href="./references#CD000204-bbs2-0017" title="LudatscherJI . Stable remission of tardive dyskinesia by L‐dopa. Journal of Clinical Psychopharmacology1989;9(1):39‐41. ">Ludatscher 1989</a>; <a href="./references#CD000204-bbs2-0018" title="GerlachJ . Tardive dyskinesia: pathophysiological mechanisms and clinical trials. L'Encephale1988;XIV:227‐32. GerlachJ , AhforsUG , AmthorKF . Effect of different neuroleptics in tardive dyskinesia and parkinsonism. A video‐controlled multicenter study with chlorprothixene, perphenazine, haloperidol and haloperidol and biperiden. Psychopharmacology1986;90(4):423‐9. Nordik Dyskinesia Study Group. Effect of different neuroleptics in tardive dyskinesia and parkinsonism. Psychopharmacology1986;90(4):423‐9. PovlsenUJ , NoringU , MeidahlB , KorsgaardS , WaehrensJ , GerlachJ . Not available [Neuroleptikas virkning pa tardive dyskinesier]. Ugeskr Laeger1987;149(25):1682‐5. ">NDSG 1986</a>; <a href="./references#CD000204-bbs2-0019" title="SilverH , GeraisyN , SchwartzM . No difference in the effect of biperiden and amantadine on parkinsonian‐ and tardive dyskinesia‐type involuntary movements: A double‐blind crossover, placebo‐controlled study in medicated chronic schizophrenic patients. Journal of Clinical Psychiatry1995;56(9):435. SilverH , GeraisyN , SchwartzM . No difference in the effect of biperiden and amantadine on parkinsonian‐ and tardive dyskinesia‐type involuntary movements: a double‐blind crossover, placebo‐controlled study in medicated chronic schizophrenic patients. Journal of Clinical Psychiatry1995;56(4):167‐70. ">Silver 1995</a>). </p> </section> <section id="CD000204-sec-0167"> <h4 class="title">2. Applicability</h4> <p>Trials included both in‐ and outpatients who were mostly women in their 50s with schizophrenia. They were people who would be recognisable in everyday care. The interventions in question — anticholinergic drugs — are readily accessible and most outcomes are understandable in terms of clinical practice. Should anticholinergic drugs have had important effects the findings might well have been applicable. </p> </section> </section> <section id="CD000204-sec-0168"> <h3 class="title" id="CD000204-sec-0168">Quality of the evidence</h3> <p>We cannot draw any robust conclusions regarding the effects of anticholinergic drugs on TD: only two studies with 30 participants could be included, which severely limited the quality of the evidence. The larger trial randomised only 20 people: a trial of this size is unable to detect subtle, yet important, differences due to an intervention with any confidence. In order to detect a 20% difference between groups, probably about 150 people are needed in each arm of the study (alpha 0.05, beta 0.8). Overall the quality of reporting of these trials was poor (see <a href="#CD000204-fig-0003">Figure 3</a>). Allocation concealment was not described, generation of the sequence was not explicit, studies were not clearly blinded, and data were not fully reported. The small sample size and the poor reporting means that we have very little confidence in the effect estimates, and the true effects are likely to be substantially different from the estimates of the effects. </p> </section> <section id="CD000204-sec-0169"> <h3 class="title" id="CD000204-sec-0169">Potential biases in the review process</h3> <section id="CD000204-sec-0170"> <h4 class="title">1. Missing studies</h4> <p>We made every effort to identify relevant trials. However, these studies are both small and it is likely that we have failed to identify other studies of limited power. It is likely that such studies would also not be in favour of the anticholinergics group: if they had been so, it is more likely that they would have been published in accessible literature. We do not, however, think it likely that we have failed to identify large relevant studies. </p> </section> <section id="CD000204-sec-0171"> <h4 class="title">2. Introducing bias</h4> <p>We have tried to be balanced in our appraisal of the evidence but could have inadvertently introduced bias. We welcome comments or criticisms. New methods and innovations now make it possible to report data where, in the past, we could not report data at all or had to report data in a different way. We believe 'Summary of findings' table is a valuable innovation but problematic to those not ‘blind’ to the outcome data: it is possible to ‘cherry pick’ significant findings for presentation in this table. We have tried to decrease the chance of doing this by asking a new reviewer (HB) to select outcomes relevant for this table before becoming familiar with the data. </p> </section> </section> <section id="CD000204-sec-0172"> <h3 class="title" id="CD000204-sec-0172">Agreements and disagreements with other studies or reviews</h3> <p>The only other relevant quantitative review we know of is the previous Cochrane Review (<a href="./references#CD000204-bbs2-0082" title="Soares‐WeiserK , MobsyC , HollidayE . Anticholinergic medication for neuroleptic‐induced tardive dyskinesia. Cochrane Database of Systematic Reviews1997, Issue 2. [DOI: 10.1002/14651858.CD000204] ">Soares‐Weiser 1997</a>). This update identified two studies to include (as discussed in <a href="#CD000204-sec-0109">Results of the search</a> and <a href="#CD000204-sec-0169">Potential biases in the review process</a>), but the very sparse and low‐quality evidence lead to no substantial change in the conclusions. </p> </section> </section> </section> <div class="figures-list"> <div class="figure" id="CD000204-fig-0001"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD000204.pub2/media/CDSR/CD000204/urn:x-wiley:14651858:media:CD000204:CD000204-AFig-FIG01" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD000204.pub2/media/CDSR/CD000204/image_t/tCD000204-AFig-FIG01.png" target="_blank"><b></b></a></p> </div><img alt="Message from one of the participants of the Public and patient involvement consultation of service user perspectives on tardive dyskinesia research." data-id="CD000204-fig-0001" src="/cdsr/doi/10.1002/14651858.CD000204.pub2/media/CDSR/CD000204/image_n/nCD000204-AFig-FIG01.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 1</div> <div class="figure-caption"> <p>Message from one of the participants of the Public and patient involvement consultation of service user perspectives on tardive dyskinesia research. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD000204.pub2/full#CD000204-fig-0001">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD000204.pub2/media/CDSR/CD000204/image_n/nCD000204-AFig-FIG01.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD000204-fig-0002"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD000204.pub2/media/CDSR/CD000204/urn:x-wiley:14651858:media:CD000204:CD000204-AFig-FIG02" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD000204.pub2/media/CDSR/CD000204/image_t/tCD000204-AFig-FIG02.png" target="_blank"><b></b></a></p> </div><img alt="Risk of bias graph: review authors' judgements about each risk of bias item presented as percentages across all included studies." data-id="CD000204-fig-0002" src="/cdsr/doi/10.1002/14651858.CD000204.pub2/media/CDSR/CD000204/image_n/nCD000204-AFig-FIG02.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 2</div> <div class="figure-caption"> <p>Risk of bias graph: review authors' judgements about each risk of bias item presented as percentages across all included studies. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD000204.pub2/full#CD000204-fig-0002">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD000204.pub2/media/CDSR/CD000204/image_n/nCD000204-AFig-FIG02.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD000204-fig-0003"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD000204.pub2/media/CDSR/CD000204/urn:x-wiley:14651858:media:CD000204:CD000204-AFig-FIG03" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD000204.pub2/media/CDSR/CD000204/image_t/tCD000204-AFig-FIG03.png" target="_blank"><b></b></a></p> </div><img alt="Risk of bias summary: review authors' judgements about each risk of bias item for each included study." data-id="CD000204-fig-0003" src="/cdsr/doi/10.1002/14651858.CD000204.pub2/media/CDSR/CD000204/image_n/nCD000204-AFig-FIG03.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 3</div> <div class="figure-caption"> <p>Risk of bias summary: review authors' judgements about each risk of bias item for each included study. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD000204.pub2/full#CD000204-fig-0003">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD000204.pub2/media/CDSR/CD000204/image_n/nCD000204-AFig-FIG03.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD000204-fig-0004"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD000204.pub2/media/CDSR/CD000204/urn:x-wiley:14651858:media:CD000204:CD000204-AFig-FIG04" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD000204.pub2/media/CDSR/CD000204/image_t/tCD000204-AFig-FIG04.png" target="_blank"><b></b></a></p> </div><img alt="Study flow diagram for 2015 and 2017 searches." data-id="CD000204-fig-0004" src="/cdsr/doi/10.1002/14651858.CD000204.pub2/media/CDSR/CD000204/image_n/nCD000204-AFig-FIG04.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 4</div> <div class="figure-caption"> <p>Study flow diagram for 2015 and 2017 searches.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD000204.pub2/full#CD000204-fig-0004">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD000204.pub2/media/CDSR/CD000204/image_n/nCD000204-AFig-FIG04.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD000204-fig-0005"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD000204.pub2/media/CDSR/CD000204/urn:x-wiley:14651858:media:CD000204:CD000204-CMP-001-01" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD000204.pub2/media/CDSR/CD000204/image_t/tCD000204-CMP-001-01.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Anticholinergic medications versus other compounds, Outcome 1 TD symptoms: no clinically significant improvement." data-id="CD000204-fig-0005" src="/cdsr/doi/10.1002/14651858.CD000204.pub2/media/CDSR/CD000204/image_n/nCD000204-CMP-001-01.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.1</div> <div class="figure-caption"> <p>Comparison 1 Anticholinergic medications versus other compounds, Outcome 1 TD symptoms: no clinically significant improvement. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD000204.pub2/references#CD000204-fig-0005">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD000204.pub2/media/CDSR/CD000204/image_n/nCD000204-CMP-001-01.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD000204-fig-0006"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD000204.pub2/media/CDSR/CD000204/urn:x-wiley:14651858:media:CD000204:CD000204-CMP-001-02" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD000204.pub2/media/CDSR/CD000204/image_t/tCD000204-CMP-001-02.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Anticholinergic medications versus other compounds, Outcome 2 TD symptoms: not any improvement." data-id="CD000204-fig-0006" src="/cdsr/doi/10.1002/14651858.CD000204.pub2/media/CDSR/CD000204/image_n/nCD000204-CMP-001-02.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.2</div> <div class="figure-caption"> <p>Comparison 1 Anticholinergic medications versus other compounds, Outcome 2 TD symptoms: not any improvement. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD000204.pub2/references#CD000204-fig-0006">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD000204.pub2/media/CDSR/CD000204/image_n/nCD000204-CMP-001-02.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD000204-fig-0007"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD000204.pub2/media/CDSR/CD000204/urn:x-wiley:14651858:media:CD000204:CD000204-CMP-001-03" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD000204.pub2/media/CDSR/CD000204/image_t/tCD000204-CMP-001-03.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Anticholinergic medications versus other compounds, Outcome 3 Adverse effects." data-id="CD000204-fig-0007" src="/cdsr/doi/10.1002/14651858.CD000204.pub2/media/CDSR/CD000204/image_n/nCD000204-CMP-001-03.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.3</div> <div class="figure-caption"> <p>Comparison 1 Anticholinergic medications versus other compounds, Outcome 3 Adverse effects. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD000204.pub2/references#CD000204-fig-0007">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD000204.pub2/media/CDSR/CD000204/image_n/nCD000204-CMP-001-03.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD000204-fig-0008"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD000204.pub2/media/CDSR/CD000204/urn:x-wiley:14651858:media:CD000204:CD000204-CMP-001-04" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD000204.pub2/media/CDSR/CD000204/image_t/tCD000204-CMP-001-04.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Anticholinergic medications versus other compounds, Outcome 4 Leaving the study early." data-id="CD000204-fig-0008" src="/cdsr/doi/10.1002/14651858.CD000204.pub2/media/CDSR/CD000204/image_n/nCD000204-CMP-001-04.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.4</div> <div class="figure-caption"> <p>Comparison 1 Anticholinergic medications versus other compounds, Outcome 4 Leaving the study early. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD000204.pub2/references#CD000204-fig-0008">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD000204.pub2/media/CDSR/CD000204/image_n/nCD000204-CMP-001-04.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD000204-fig-0009"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD000204.pub2/media/CDSR/CD000204/urn:x-wiley:14651858:media:CD000204:CD000204-CMP-002-01" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD000204.pub2/media/CDSR/CD000204/image_t/tCD000204-CMP-002-01.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 2 Continuation versus withdrawal of anticholinergic medications, Outcome 1 Leaving the study early." data-id="CD000204-fig-0009" src="/cdsr/doi/10.1002/14651858.CD000204.pub2/media/CDSR/CD000204/image_n/nCD000204-CMP-002-01.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.1</div> <div class="figure-caption"> <p>Comparison 2 Continuation versus withdrawal of anticholinergic medications, Outcome 1 Leaving the study early. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD000204.pub2/references#CD000204-fig-0009">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD000204.pub2/media/CDSR/CD000204/image_n/nCD000204-CMP-002-01.png" target="_blank">Open in new tab</a></div> </div> </div> <div class="tables-list"> <div class="table"> <table data-id="CD000204-tbl-0005"> <div class="table-heading"><span class="table-label">Table 2.</span> <span class="table-title">Suggestions for design of future study</span></div> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Methods</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Allocation: randomised, with sequence generation and concealment of allocation clearly described.<br/> Blindness: double, tested.<br/> Duration: 12 months beyond end of intervention at least.<br/> Raters: independent. </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Participants</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>People with antipsychotic‐induced tardive dyskinesia.*<br/> Age: any.<br/> Sex: both.<br/> History: any.<br/> N = 300.** </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Interventions</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1. Anticholinergic withdrawal (N = 150) versus anticholinergic continuation (N = 150).</p> <p>OR</p> <p>2. Specific anticholinergic (N = 150) versus placebo (N = 150).</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Outcomes</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Tardive dyskinesia: any clinically important improvement in TD, any improvement, deterioration.***<br/> Adverse effects: no clinically significant extrapyramidal adverse effects ‒ any time period***, use of any antiparkinsonism drugs, other important adverse events.<br/> Leaving the study early.<br/> Service outcomes: admitted, number of admissions, length of hospitalisation, contacts with psychiatric services.<br/> Compliance with drugs.<br/> Economic evaluations: cost‐effectiveness, cost‐benefit.<br/> General state: relapse, frequency and intensity of minor and major exacerbations.<br/> Social confidence, social inclusion, social networks, or personalised quality of life: binary measure<br/> Distress among relatives: binary measure.<br/> Burden on family: binary measure. </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Notes</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>* This could be diagnosed by clinical decision. If funds were permitting, all participants could be screened using operational criteria; otherwise a random sample should suffice. </p> <p>** Size of study with sufficient power to highlight about a 10% difference between groups for primary outcome.<br/> *** Primary outcome. The same applies to the measure of primary outcome as for diagnosis. Not everyone may need to have operational criteria applied if clinical impression is proved to be accurate. </p> </td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Table 2.</span> <span class="table-title">Suggestions for design of future study</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD000204.pub2/full#CD000204-tbl-0005">Navigate to table in review</a></div> </div> <div class="table"> <table class="summary-of-findings framed" data-id="CD000204-tbl-0001"> <div class="table-heading"><span class="table-label">Summary of findings for the main comparison.</span> <span class="table-title">Anticholinergic medication compared with placebo for antipsychotic‐induced tardive dyskinesia</span></div> <tbody> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>Anticholinergic medication compared with other treatments for antipsychotic‐induced tardive dyskinesia</b> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>Patient or population:</b> patients with antipsychotic‐induced tardive dyskinesia </p> <p><b>Settings:</b> anywhere. </p> <p><b>Intervention:</b> any anticholinergic </p> <p><b>Comparison:</b> placebo </p> </td> </tr> <tr class="table-header separated"> <td align="" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Outcomes</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p><b>Illustrative comparative risks* (CI)</b> </p> </td> <td align="" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Relative effect<br/> (CI)</b> </p> </td> <td align="" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>No of Participants<br/> (studies)</b> </p> </td> <td align="" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Quality of the evidence<br/> (GRADE)</b> </p> </td> <td align="" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Comments</b> </p> </td> </tr> <tr class="table-header separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Assumed risk</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Corresponding risk</b> </p> </td> </tr> <tr class="table-header separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>risk with placebo</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>risk with anticholinergic drugs</b> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Tardive dyskinesia: not improved to a clinically important extent</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>see comment</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>see comment</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>not estimable</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>(0 studies)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>None of the included studies reported on this outcome.</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Tardive dyskinesia: deterioration of symptoms</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>see comment</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>see comment</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>not estimable</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>(0 studies)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>None of the included studies reported on this outcome.</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Mental state</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>see comment</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>see comment</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>not estimable</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>(0 studies)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>None of the included studies reported on this outcome.</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Adverse effect: any adverse effects</b><br/> follow‐up: 40 weeks </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>see comment</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>see comment</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>not estimable</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>(0 studies)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>None of the included studies reported on this outcome.</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Acceptability of the treatment: leaving the study early</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>see comment</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>see comment</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>not estimable</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>(0 studies)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>None of the included studies reported on this outcome.</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Social confidence, social inclusion, social networks, or personalised quality of life</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>see comment</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>see comment</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>not estimable</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>(0 studies)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>None of the included studies reported on this outcome.</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>*The basis for the <b>assumed risk</b> (e.g. the median control group risk across studies) is provided in footnotes. The <b>corresponding risk</b> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its CI).<br/> <b>CI:</b> Confidence interval; <b>MAO</b> : monoamine oxidase; <b>RR:</b> Risk Ratio </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>GRADE Working Group grades of evidence<br/> <b>High quality:</b> Further research is very unlikely to change our confidence in the estimate of effect.<br/> <b>Moderate quality:</b> Further research is likely to have an important impact on our confidence in the estimate of effect and may change the estimate.<br/> <b>Low quality:</b> Further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to change the estimate.<br/> <b>Very low quality:</b> We are very uncertain about the estimate. </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="7"> <div class="table-footnote"> <p><sup>1</sup> Downgraded one level for risk of bias: the included study did not adequately describe randomisation procedure or allocation concealment, and there was no mention of the study being blinded. </p> <p><sup>2</sup> Downgraded two levels for imprecision: very small sample size (n = 20). </p> <p><sup>3</sup> Downgraded two levels for imprecision: very wide CI that includes appreciable benefit for both groups; very small sample size (n = 20). </p> <p><sup>4</sup> Downgraded one level for indirectness: leaving the study early can give an indication, but is not a direct measurement, of treatment acceptability. </p> </div> </td> </tr> </tfoot> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Summary of findings for the main comparison.</span> <span class="table-title">Anticholinergic medication compared with placebo for antipsychotic‐induced tardive dyskinesia</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD000204.pub2/full#CD000204-tbl-0001">Navigate to table in review</a></div> </div> <div class="table"> <table class="summary-of-findings framed" data-id="CD000204-tbl-0002"> <div class="table-heading"><span class="table-label">Summary of findings 2.</span> <span class="table-title">Anticholinergic medication compared with other treatments for antipsychotic‐induced tardive dyskinesia</span></div> <tbody> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>Anticholinergic medication compared with other treatments for antipsychotic‐induced tardive dyskiesia</b> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>Patient or population:</b> chronic schizophrenia patients with antipsychotic‐induced tardive dyskinesia </p> <p><b>Settings:</b> outpatients in the USA. </p> <p><b>Intervention:</b> procyclidine (anticholinergic), 5 mg twice/day </p> <p><b>Comparison:</b> isocarboxazid (MAO‐inhibitor), 10 mg twice/day </p> </td> </tr> <tr class="table-header separated"> <td align="" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Outcomes</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p><b>Illustrative comparative risks* (CI)</b> </p> </td> <td align="" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Relative effect<br/> (CI)</b> </p> </td> <td align="" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>No of Participants<br/> (studies)</b> </p> </td> <td align="" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Quality of the evidence<br/> (GRADE)</b> </p> </td> <td align="" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Comments</b> </p> </td> </tr> <tr class="table-header separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Assumed risk</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Corresponding risk</b> </p> </td> </tr> <tr class="table-header separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>risk with MAO‐inhibitor</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>risk with anticholinergic drugs</b> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Tardive dyskinesia: Not improved to a clinically important extent</b><br/> follow‐up: 40 weeks </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>200 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>840 per 1000</b><br/> (280 to 1000) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>RR 4.20</b> (1.40 to 12.58) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>20<br/> (1 study) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝<br/> <b>very low</b><sup>1 2</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Tardive dyskinesia: deterioration of symptoms</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>see comment</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>see comment</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>not estimable</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>(0 studies)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>None of the included studies reported on this outcome.</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Mental state</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>see comment</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>see comment</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>not estimable</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>(0 studies)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>None of the included studies reported on this outcome.</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Adverse effect: any adverse effects</b><br/> follow‐up: 40 weeks </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>100 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>33 per 1000</b><br/> (2 to 732) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>RR 0.33</b> (0.02 to 7.32) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>20<br/> (1 study) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝<br/> <b>very low</b><sup>1 3</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Acceptability of the treatment: leaving the study early</b><br/> follow‐up: 40 weeks </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>100 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>33 per 1000</b><br/> (2 to 732) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>RR 0.33</b> (0.02 to 7.32) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>20<br/> (1 study) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝<br/> <b>very low</b><sup>1 3 4</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Social confidence, social inclusion, social networks, or personalised quality of life</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>see comment</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>see comment</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>not estimable</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>(0 studies)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>None of the included studies reported on this outcome.</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>*The basis for the <b>assumed risk</b> (e.g. the median control group risk across studies) is provided in footnotes. The <b>corresponding risk</b> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its CI).<br/> <b>CI:</b> Confidence interval; <b>MAO</b> : monoamine oxidase; <b>RR:</b> Risk Ratio </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>GRADE Working Group grades of evidence<br/> <b>High quality:</b> Further research is very unlikely to change our confidence in the estimate of effect.<br/> <b>Moderate quality:</b> Further research is likely to have an important impact on our confidence in the estimate of effect and may change the estimate.<br/> <b>Low quality:</b> Further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to change the estimate.<br/> <b>Very low quality:</b> We are very uncertain about the estimate. </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="7"> <div class="table-footnote"> <p><sup>1</sup> Downgraded one level for risk of bias: the included study did not adequately describe randomisation procedure or allocation concealment, and there was no mention of the study being blinded. </p> <p><sup>2</sup> Downgraded two levels for imprecision: very small sample size (n = 20). </p> <p><sup>3</sup> Downgraded two levels for imprecision: very wide CI that includes appreciable benefit for both groups; very small sample size (n = 20). </p> <p><sup>4</sup> Downgraded one level for indirectness: leaving the study early can give an indication, but is not a direct measurement, of treatment acceptability. </p> </div> </td> </tr> </tfoot> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Summary of findings 2.</span> <span class="table-title">Anticholinergic medication compared with other treatments for antipsychotic‐induced tardive dyskinesia</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD000204.pub2/full#CD000204-tbl-0002">Navigate to table in review</a></div> </div> <div class="table"> <table class="summary-of-findings framed" data-id="CD000204-tbl-0003"> <div class="table-heading"><span class="table-label">Summary of findings 3.</span> <span class="table-title">Withdrawal of anticholinergic medication compared to continuing anticholinergic medication for antipsychotic‐induced tardive dyskinesia</span></div> <tbody> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p><b>Withdrawal of anticholinergic medication compared to continuing anticholigergic medication for antipsychotic‐induced tardive dyskinesia</b> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p><b>Patient or population:</b> chronic schizophrenia patients with antipsychotic‐induced tardive dyskinesia<br/> <b>Setting:</b> Germany (1 study)<br/> <b>Intervention:</b> withdrawal of biperiden (stopping after 1 week)<br/> <b>Comparison:</b> continuing biperiden (stopping after 4 weeks) </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Outcomes</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p><b>Anticipated absolute effects<sup>*</sup> (CI)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Relative effect<br/> (CI)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>№ of participants<br/> (studies)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Quality of the evidence<br/> (GRADE)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Comments</b> </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Risk with continuation of anticholinergic drugs</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Risk with withdrawal of anticholinergic drugs</b> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Tardive dyskinesia: not improved to a clinically important extent</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>see comment</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>see comment</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>not estimable</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0</p> <p>(0 studies)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>None of the included studies reported on this outcome.</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Tardive dyskinesia: deterioration of symptoms</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>see comment</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>see comment</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>not estimable</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0</p> <p>(0 studies)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>None of the included studies reported on this outcome.</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Mental state</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>see comment</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>see comment</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>not estimable</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0</p> <p>(0 studies)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>None of the included studies reported on this outcome.</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Adverse effects</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>see comment</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>see comment</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>not estimable</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0</p> <p>(0 studies)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>None of the included studies reported on this outcome.</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Acceptability of the treatment: leaving the study early</b><br/> follow‐up: 7 weeks </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>0 per 1,000</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>0 per 1,000</b><br/> (0 to 0) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>RR 2.14<br/> (0.11 to 42.52) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>10<br/> (1 RCT) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝<br/> <b>very low</b><sup>1 2 3</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Social confidence, social inclusion, social networks, or personalised quality of life</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>see comment</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>see comment</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>not estimable</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0</p> <p>(0 studies)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>None of the included studies reported on this outcome.</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>*<b>The risk in the intervention group</b> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its CI).<br/> <br/> <b>CI:</b> Confidence interval; <b>RR:</b> Risk ratio </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>GRADE Working Group grades of evidence</b> <br/> <b>High quality:</b> We are very confident that the true effect lies close to that of the estimate of the effect<br/> <b>Moderate quality:</b> We are moderately confident in the effect estimate: The true effect is likely to be close to the estimate of the effect, but there is a possibility that it is substantially different<br/> <b>Low quality:</b> Our confidence in the effect estimate is limited: The true effect may be substantially different from the estimate of the effect<br/> <b>Very low quality:</b> We have very little confidence in the effect estimate: The true effect is likely to be substantially different from the estimate of effect </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="7"> <div class="table-footnote"> <p><sup>1</sup> Downgraded one level for risk of bias: the included study did not adequately describe randomisation procedure or allocation concealment. </p> <p><sup>2</sup> Downgraded one level for indirectness: leaving the study early can give an indication, but is not a direct measurement, of treatment acceptability. In addition, the continuation of anticholinergic medication group stopped biperiden after 4 weeks but the results were measured after 7 weeks. </p> <p><sup>3</sup> Downgraded two levels for imprecision: very wide CI that includes appreciable benefit for both groups; very small sample size (n = 10). </p> </div> </td> </tr> </tfoot> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Summary of findings 3.</span> <span class="table-title">Withdrawal of anticholinergic medication compared to continuing anticholinergic medication for antipsychotic‐induced tardive dyskinesia</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD000204.pub2/full#CD000204-tbl-0003">Navigate to table in review</a></div> </div> <div class="table"> <table data-id="CD000204-tbl-0004"> <div class="table-heading"><span class="table-label">Table 1.</span> <span class="table-title">Other reviews in the series</span></div> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Interventions</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Reference</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Anticholinergic medication</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>This review</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Benzodiazepines</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD000204-bbs2-0034" title="BhoopathiPS , Soares‐WeiserK . Benzodiazepines for neuroleptic‐induced tardive dyskinesia. Cochrane Database of Systematic Reviews2006, Issue 3. [DOI: 10.1002/14651858.CD000205.pub2] ">Bhoopathi 2006</a>; update to be published </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Calcium channel blockers</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD000204-bbs2-0049" title="EssaliA , DeirawanH , Soares‐WeiserK , AdamsCE . Calcium channel blockers for neuroleptic‐induced tardive dyskinesia. Cochrane Database of Systematic Reviews2011, Issue 11. [DOI: 10.1002/14651858.CD000206.pub3] ">Essali 2011</a>; update to be published </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Cholinergic medication</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD000204-bbs2-0077" title="TammenmaaI , McGrathJ , SailasE , Soares‐WeiserK . Cholinergic medication for neuroleptic‐induced tardive dyskinesia. Cochrane Database of Systematic Reviews2002, Issue 3. [DOI: 10.1002/14651858.CD000207; MEDLINE: 22133093] ">Tammenmaa 2002</a>; update to be published </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Gamma‐aminobutyric acid agonists</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD000204-bbs2-0026" title="AlabedS , LatifehY , MohammadHA , RifaiA . Gamma‐aminobutyric acid agonists for neuroleptic‐induced tardive dyskinesia. Cochrane Database of Systematic Reviews2011, Issue 4. [DOI: 10.1002/14651858.CD000203.pub3] ">Alabed 2011</a>; update to be published </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Miscellaneous treatments</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD000204-bbs2-0074" title="Soares‐WeiserK , JoyC . Miscellaneous treatments for neuroleptic‐induced tardive dyskinesia. Cochrane Database of Systematic Reviews2003, Issue 2. [DOI: 10.1002/14651858.CD000208] ">Soares‐Weiser 2003</a>; update to be published </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Neuroleptic reduction and/or cessation and neuroleptics</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD000204-bbs2-0075" title="Soares‐WeiserK , RathboneJ . Neuroleptic reduction and/or cessation and neuroleptics as specific treatments for tardive dyskinesia. Cochrane Database of Systematic Reviews2006, Issue 1. [DOI: 10.1002/14651858.CD000459.pub2] ">Soares‐Weiser 2006</a>; update to be published </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Non‐neuroleptic catecholaminergic drugs</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD000204-bbs2-0047" title="El‐SayehHG , Lyra da SilvaJP , RathboneJ , Soares‐WeiserK . Non‐neuroleptic catecholaminergic drugs for neuroleptic‐induced tardive dyskinesia. Cochrane Database of Systematic Reviews2006, Issue 1. [DOI: 10.1002/14651858.CD000458.pub2] ">El‐Sayeh 2006</a>; update to be published </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Vitamin E</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD000204-bbs2-0076" title="Soares‐WeiserK , MaayanN , McGrathJ . Vitamin E for neuroleptic‐induced tardive dyskinesia. Cochrane Database of Systematic Reviews2011, Issue 2. [DOI: 10.1002/14651858.CD000209.pub2] ">Soares‐Weiser 2011</a>; update to be published </p> </td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Table 1.</span> <span class="table-title">Other reviews in the series</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD000204.pub2/full#CD000204-tbl-0004">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD000204-tbl-0006"> <div class="table-heading"><span class="table-label">Comparison 1.</span> <span class="table-title">Anticholinergic medications versus other compounds</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1 TD symptoms: no clinically significant improvement <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.1 procyclidine vs isocarboxazid</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>20</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>4.2 [1.40, 12.58]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">2 TD symptoms: not any improvement <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.1 procyclidine vs isocarboxazid</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>20</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>7.0 [1.57, 31.15]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">3 Adverse effects <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.1 procyclidine vs isocarboxazid</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>20</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.33 [0.02, 7.32]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">4 Leaving the study early <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>4.1 procyclidine vs isocarboxazid</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>20</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.33 [0.02, 7.32]</p> </td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 1.</span> <span class="table-title">Anticholinergic medications versus other compounds</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD000204.pub2/references#CD000204-tbl-0006">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD000204-tbl-0007"> <div class="table-heading"><span class="table-label">Comparison 2.</span> <span class="table-title">Continuation versus withdrawal of anticholinergic medications</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1 Leaving the study early <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.1 biperiden: withdrawal after 1 week vs withdrawal after 4 weeks</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>10</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>2.14 [0.11, 42.52]</p> </td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 2.</span> <span class="table-title">Continuation versus withdrawal of anticholinergic medications</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD000204.pub2/references#CD000204-tbl-0007">Navigate to table in review</a></div> </div> </div> <noscript> <img height="1" src="/scolaris-auth/report/nonjs/fulltexthtmlreg?doi=10.1002%2F14651858.CD000204.pub2&amp;rf=&amp;articleType=CDSR" style="display:none" width="1"> </img></noscript> <section class="translation-notes-modal" data-modal-class="translation-notes" data-modal-title="Translation notes" data-ok-btn-selector=".ok-btn" style="display: none"> <div class="translation-notes"> <div class="section-language-toggles"> <nav class="section-languages"> <ul> <li class="section-languages-legend">Available in</li> <li class="section-language"> <a class="" href="de#CD000204-note-0001">Deutsch</a> </li> <li class="section-language"> <a class="" href="es#CD000204-note-0002">Español</a> </li> <li class="section-language"> <a class="" href="fa#CD000204-note-0003">فارسی</a> </li> <li class="section-language"> <a class="" href="zh_HANS#CD000204-note-0008">简体中文</a> </li> </ul> </nav> </div> <section class="translation-notes-content"> </section> <button class="btn primary ok-btn pull-right" type="button">Close</button> </div> </section></article> </div> <div class="citation-modal" style="display: none"> <div class="export-citation-header"> <p class="inset-message" data-load-error="Unable to load citation data" id="citeProcText"></p> </div> <div class="export-citation-body row-fluid"> <div class="span12"> <div class="addthis_toolbox addthis_default_style addthis_16x16_style"> <nav class="inline-nav-list is-bordered"> <li> <h4 class="heading">Save citation to:</h4> </li> <li><a class="citation-btn-refworks at300b btn btn-link" href="#" id="refWorksCitationBtn"><span class="citation-icon refworks"></span>RefWorks</a></li> <li><a class="citation-btn-sciwheel at300b btn btn-link disabled" href="#" id="sciWheelCitationBtn" target="_blank"><span class="citation-icon sciwheel"></span>SciWheel</a></li> </nav> </div> </div> </div> <div class="row-fluid"> <div class="span12"> <div class="citation-format"> <h4>Copy or download citation</h4> <a href="/en/help/exporting-search-results" rel="noopener noreferrer" target="_blank">Export help</a> </div> <nav class="inline-nav-list has-dividers"> <li class="citation-option" data-option="plain"><button class="btn btn-link" type="button">Plain text</button></li> <li class="citation-option" data-option="endnote"><button class="btn btn-link" type="button">EndNote</button></li> <li class="citation-option" data-option="refmanager"><button class="btn btn-link" type="button">Reference Manager</button></li> <li class="citation-option" data-option="procite"><button class="btn btn-link" type="button">ProCite</button></li> <li class="citation-option" data-option="bibtex"><button class="btn btn-link" type="button">BibteX</button></li> <li class="citation-option" data-option="csv"><button class="btn btn-link" type="button">CSV (Excel)</button></li> </nav> <div class="citation-content"> <pre data-load-error="Unable to load citation data" id="citationContent" tabindex="0"></pre> </div> <div class="clearfix"> <form class="download-citation-form" data-citation-citeproc-url="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentdisplay_WAR_scolariscontentdisplay&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=citation-citeproc&amp;p_p_cacheability=cacheLevelPage&amp;p_p_col_id=column-1&amp;p_p_col_count=1" method="GET" target="citation-download-iframe"> <input id="siteId" name="siteId" type="hidden" value=""> <input id="downloadType" name="downloadType" type="hidden" value=""> <input id="style" name="style" type="hidden" value=""> <input id="articleId" name="articleId" type="hidden" value=""> <input name="p_p_id" type="hidden" value="scolariscontentdisplay_WAR_scolariscontentdisplay"><input name="p_p_lifecycle" type="hidden" value="2"><input name="p_p_state" type="hidden" value="normal"><input name="p_p_mode" type="hidden" value="view"/><input name="p_p_resource_id" type="hidden" value="citation-download"/><input name="p_p_cacheability" type="hidden" value="cacheLevelPage"/><input name="p_p_col_id" type="hidden" value="column-1"/><input name="p_p_col_count" type="hidden" value="1"/> <button class="btn primary wide pull-right" type="submit">Download</button> <div class="inline-checkbox pull-right"> <label title=" for=" withabstract"=""> <input checked="" class="checkbox" name="withAbstract" type="checkbox"/> <span class="checkbox-label">Include abstract</span> </label> </div> </input></input></input></input></input></input></input></form> <iframe aria-hidden="true" name="citation-download-iframe" src="" style="display: none; visibility: hidden" title="Citation download frame"></iframe> </div> </div> </div> </div> <div class="print-modal" data-modal-title="Print this review" style="display: none;"> <div class="print-options-wrapper"> <p><strong>All sections are selected by default</strong>, please select the sections you do not wish to print or use the select or deselect all button to add or remove sections.</p> <div class="print-options-controls"> <input checked="checked" class="print-options-select-all" title="Select/deselect all" type="checkbox"/> <span class="checkbox-label">Select/deselect all</span> </div> <ul class="print-options checkbox-list"> </ul> <button class="btn primary print-article pull-right"><i aria-hidden="true" class="fa fa-print"></i> Print</button> </div> </div> <div class="download-stats-data-modal" data-modal-title="Download data package" style="display: none;"> <div> <p> The data available are protected by copyright and may only be used in accordance with the <a class="external" href="/about/data-download" target="_blank">Terms and Conditions.</a> </p> <div class="hide-for-zip"> <p> <a class="external" href="https://revman.cochrane.org/#/rm5Converter" target="_blank">RevMan 5 files</a> can be converted to a <a class="external" href="https://links.cochrane.org/review-datapack-userguide" target="_blank">data package.</a> </p> </div> <p> Files in the data package can be imported to <a class="external" href="https://revman.cochrane.org/info" target="_blank">Review Manager software</a> or opened in other tools that support CSV and RIS. </p> <form class="download-stats-data-form" method="GET" target="_blank"> <input name="content-disposition" type="hidden" value="attachment"/> <input name="mime-type" type="hidden" value="application/octet-stream"/> <p class="print-options-controls"> <input aria-label="I agree to these terms and conditions" class="download-stats-data-toc-check-box" type="checkbox"/> <span aria-hidden="true" class="checkbox-label">I agree to these terms and conditions</span> <button class="btn primary download-stats-data pull-right" disabled=""><i aria-hidden="true" class="fa fa-download"></i> Download data</button> </p> </form> </div> </div> <div class="share-modal" data-modal-title="Share this review" style="display:none;"> </div> <div class="viewer-thumbnail-pane-html" style="display:none;"> <div class="figure-viewer-options"> <nav class="inline-nav-list"> <li class="figure-options-btn-container"><button class="btn btn-link" id="figureOptionBtn" type="button">Figures</button></li> <li class="table-options-btn-container"><button class="btn btn-link" id="tableOptionBtn" type="button">Tables</button></li> </nav> </div> <div class="figure-viewer-thumbnails"> <div class="figure-thumbnails is-visible" id="figureThumbnails"></div> <div class="table-thumbnails" id="tableThumbnails"></div> </div> </div> <div class="utilities-html" style="display:none;"> <div class="figure-viewer-utilities"> <a class="figure-viewer-menu-toggle" href="#"> <i class="fa fa-chevron-left"></i><span class="toggle-label" data-figure-hide-text="Hide thumbnails" data-figure-show-text="Show thumbnails" data-table-hide-text="Hide table list" data-table-show-text="Show table list">Hide thumbnails</span> </a> <a class="figure-viewer-navigateback" href="#"> <i class="fa fa-chevron-left"></i> </a> <a class="figure-viewer-rotate" href="#"> <i class="fa fa-undo"></i> </a> <a class="figure-viewer-download" href="#"> <i class="fa fa-download"></i> </a> <a class="figure-viewer-share" href="#"> <i class="fa fa-share-alt"></i> </a> <a class="figure-viewer-zoomin" href="#"> <i class="fa fa-plus"></i><span>zoom in</span> </a> <a class="figure-viewer-zoomout" href="#"> <i class="fa fa-minus"></i><span>zoom out</span> </a> </div> </div> <div class="controls-html" style="display:none;"> <div class="figure-viewer-navigation"> <a class="figure-viewer-nav previous" href="#"> <i class="fa fa-chevron-left"></i><span>left</span> </a> <a class="figure-viewer-nav next" href="#"> <i class="fa fa-chevron-right"></i><span>right</span> </a> </div> </div> <div class="mobile-thumbnail-selector-html" style="display:none;"> <div class="figure-viewer-mobile-thumbnails"> <select class="figure-selection"> <option>Figures</option> </select> <select class="table-selection"> <option>Tables</option> </select> </div> </div> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
</div>
</div>
</div>
<div class="portlet-boundary portlet-boundary_1_WAR_kaleodesignerportlet_ portlet-static portlet-static-end kaleo-designer-portlet" id="p_p_id_1_WAR_kaleodesignerportlet_">
<span id="p_1_WAR_kaleodesignerportlet"></span>
</div>
<form action="#" id="hrefFm" method="post" name="hrefFm">
<span></span>
</form>
</div>
<footer class="footer">
<div class="main-footer">
<div class="main-footer-wrapper container">
<div class="brand">
<p class="brand-name">Cochrane</p>
<a href="http://www.cochrane.org/" title="Cochrane logo">
<img alt="Cochrane logo" class="footer-logo logo-part-1" src="https://www.cochranelibrary.com/cochrane-theme/images/footer-logo-part-1.png"> <img alt="" class="footer-logo logo-part-2" src="https://www.cochranelibrary.com/cochrane-theme/images/footer-logo-part-2.png"> </img></img></a> </div> </div> </div> <div class="aux-footer"> <div class="aux-footer-nav-container container"> <nav class="aux-footer-nav"> <ul class="aux-footer-nav-list"> <li><a class="aux-footer-nav-link" href="https://onlinelibrary.wiley.com/">Browse Publications</a></li> <li><a class="aux-footer-nav-link" href="https://onlinelibrary.wiley.com/">Browse by Subject</a></li> </ul> <ul class="aux-footer-nav-list"> <li><a class="aux-footer-nav-link" href="https://onlinelibrary.wiley.com/advertisers">Advertisers &amp; Agents</a></li> <li><a class="aux-footer-nav-link" href="https://hub.wiley.com/community/support/cochrane-library">Contact Us</a></li> </ul> <ul class="aux-footer-nav-list"> <li><a class="aux-footer-nav-link" href="https://hub.wiley.com/community/support/cochrane-library">Help &amp; Support</a></li> <li><a class="aux-footer-nav-link" href="https://onlinelibrary.wiley.com/terms-and-conditions">Terms &amp; Conditions</a></li> </ul> </nav> </div> <div class="brand"> <div class="brand-container container"> <p class="copyright"> Copyright © 2000 - 2025 by <a class="" href="http://www.wiley.com">John Wiley &amp; Sons, Inc.</a> All Rights Reserved <br> Review our <a href="https://www.wiley.com/privacy"><strong>Privacy Policy</strong></a> <a href="https://www.wiley.com/cookies"><strong>Cookie Policy</strong></a> <a href="#" onclick="Osano.cm.showDrawer('osano-cm-dom-info-dialog-open')"><strong>Cookie Preferences</strong></a> </br></p> <a href="http://eu.wiley.com/"><img alt="Wiley logo" class="logo" src="https://www.cochranelibrary.com/cochrane-theme/images/en-US_wiley-footer-logo.png"/></a> </div> </div> <span class="wiley-semi-circle"></span> </div> <!--BEGIN QUALTRICS WEBSITE FEEDBACK SNIPPET--> <script type="text/javascript"> (function(){var g=function(e,h,f,g){ this.get=function(a){for(var a=a+"=",c=document.cookie.split(";"),b=0,e=c.length;b<e;b++){for(var d=c[b];" "==d.charAt(0);)d=d.substring(1,d.length);if(0==d.indexOf(a))return d.substring(a.length,d.length)}return null}; this.set=function(a,c){var b="",b=new Date;b.setTime(b.getTime()+6048E5);b="; expires="+b.toGMTString();document.cookie=a+"="+c+b+"; path=/; "}; this.check=function(){var a=this.get(f);if(a)a=a.split(":");else if(100!=e)"v"==h&&(e=Math.random()>=e/100?0:100),a=[h,e,0],this.set(f,a.join(":"));else return!0;var c=a[1];if(100==c)return!0;switch(a[0]){case "v":return!1;case "r":return c=a[2]%Math.floor(100/c),a[2]++,this.set(f,a.join(":")),!c}return!0}; this.go=function(){if(this.check()){var a=document.createElement("script");a.type="text/javascript";a.src=g;document.body&&document.body.appendChild(a)}}; this.start=function(){var t=this;"complete"!==document.readyState?window.addEventListener?window.addEventListener("load",function(){t.go()},!1):window.attachEvent&&window.attachEvent("onload",function(){t.go()}):t.go()};}; try{(new g(100,"r","QSI_S_ZN_cGCHHvWNpnJb1zf","https://zncgchhvwnpnjb1zf-wiley.siteintercept.qualtrics.com/SIE/?Q_ZID=ZN_cGCHHvWNpnJb1zf")).start()}catch(i){}})(); </script><div id="ZN_cGCHHvWNpnJb1zf"><!--DO NOT REMOVE-CONTENTS PLACED HERE--></div> <!--END WEBSITE FEEDBACK SNIPPET--> </footer> <div class="scolaris-modal-overlay"></div> <div class="scolaris-modal"> <div class="scolaris-modal-titlebar clearfix"> <p class="scolaris-modal-title"></p> <a class="scolaris-modal-close" href="#"><span>close</span><span class="icon fa fa-times"></span></a> <div class="scolaris-modal-ui"></div> </div> <!-- Static injection of addtoAny as dynamic injection not working properly--> <div class="scolaris-share-modal-content clearfix"> <div class="scolaris-modal-ui clearfix"> <div class="a2a_kit a2a_kit_size_32 a2a_default_style"> <a class="a2a_button_facebook share-button">  Facebook</a> <a class="a2a_button_x share-button">  X(Twitter)</a> <a class="a2a_button_whatsapp share-button">  WhatsApp</a> <a class="a2a_dd share-button">  View more</a> </div> </div> </div> <div class="scolaris-modal-content clearfix"> <div class="scolaris-modal-ui clearfix"></div> </div> <div class="scolaris-modal-ui clearfix"></div> </div> <div class="english-only-modal-wrapper" data-modal-class="english-only-modal" data-modal-title="Feature in English only" style="display: none"> <div class="english-only-modal"> <p class="message"></p> <button class="btn primary ok-btn pull-right" type="button">OK</button> <button class="btn primary border-only cancel-btn pull-right" type="button">Cancel</button> </div> </div> <!--[if gte IE 9]><!--> <script src="/cochrane-theme/vendor/ie9.js?t=1738734064000" type="text/javascript"></script> <!--<![endif]--> <script src="https://www.cochranelibrary.com/cochrane-theme/js/theme.js?t=1738734064000" type="text/javascript"></script> <script src="https://content.readcube.com/cochrane/checkout.js"></script> <script src="https://content.readcube.com/cochrane/epdf_linker.js" type="text/javascript"></script> <script src="https://crossmark-cdn.crossref.org/widget/v2.0/widget.js" type="text/javascript"></script> <script src="https://d1bxh8uas1mnw7.cloudfront.net/assets/embed.js" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/hit-highlighting.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/topics-lookup.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/institution.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/api-manager.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/pico.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/reference-linking.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/rightsLink.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/ui.submit.failed.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/ui.comment.form.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/safety-alerts.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/ui.translation-notes-modal.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/notifications-portlet/notifications/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772751000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-search/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772894000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-topics/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772894000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-language-portlet/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772746000" type="text/javascript"></script> <script type="text/javascript">Liferay.Util.addInputFocus();</script> <script type="text/javascript">Liferay.Portlet.register("scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header_",portletId:"scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3dscolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dnull\x26p_p_col_pos\x3dnull\x26p_p_col_count\x3dnull\x26p_p_static\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD000204\x2epub2\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD000204\x2epub2\x2526type\x253Dcdsr\x2526contentLanguage\x253D\x26templateType\x3dfull\x26urlTitle\x3d\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD000204\x2epub2\x26contentLanguage\x3d\x26type\x3dcdsr\x26doi\x3d10\x2e1002\x252F14651858\x2eCD000204\x2epub2"});Liferay.Portlet.register("scolariscontentdisplay_WAR_scolariscontentdisplay");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_scolariscontentdisplay_WAR_scolariscontentdisplay_",portletId:"scolariscontentdisplay_WAR_scolariscontentdisplay",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3dscolariscontentdisplay_WAR_scolariscontentdisplay\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dcolumn-1\x26p_p_col_pos\x3d0\x26p_p_col_count\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD000204\x2epub2\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD000204\x2epub2\x2526type\x253Dcdsr\x2526contentLanguage\x253D"});Liferay.provide(Liferay.Util,"openKaleoDesignerPortlet",function(c){var b=AUI();var e=Liferay.PortletURL.createURL("https://www.cochranelibrary.com/en/content?p_p_id=2_WAR_kaleodesignerportlet&p_p_lifecycle=0");e.setParameter("mvcPath","/designer/edit_kaleo_draft_definition.jsp");e.setParameter("availableFields",c.availableFields);e.setParameter("availablePropertyModels",c.availablePropertyModels);e.setParameter("ddmStructureId",c.ddmStructureId);e.setParameter("draftVersion",c.draftVersion);e.setParameter("kaleoProcessId",c.kaleoProcessId);e.setParameter("name",c.name);e.setParameter("openerWindowName",c.openerWindowName);e.setParameter("portletResourceNamespace",c.portletResourceNamespace);e.setParameter("propertiesSaveCallback",c.propertiesSaveCallback);e.setParameter("refreshOpenerOnClose",c.refreshOpenerOnClose);e.setParameter("saveCallback",c.saveCallback);e.setParameter("version",c.version);e.setWindowState("pop_up");c.uri=e.toString();var d=c.dialog;if(!d){var f=b.one(Liferay.Util.getOpener()).get("region");d={destroyOnHide:true};c.dialog=d}if(!("align" in d)){d.align=Liferay.Util.Window.ALIGN_CENTER}var a=c.dialogIframe;if(!a){a={closeOnEscape:false};c.dialogIframe=a}Liferay.Util.openWindow(c)},["liferay-portlet-url"]);Liferay.Portlet.register("1_WAR_kaleodesignerportlet");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_1_WAR_kaleodesignerportlet_",portletId:"1_WAR_kaleodesignerportlet",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3d1_WAR_kaleodesignerportlet\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dnull\x26p_p_col_pos\x3dnull\x26p_p_col_count\x3dnull\x26p_p_static\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD000204\x2epub2\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD000204\x2epub2\x2526type\x253Dcdsr\x2526contentLanguage\x253D\x26templateType\x3dfull\x26urlTitle\x3d\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD000204\x2epub2\x26contentLanguage\x3d\x26type\x3dcdsr\x26doi\x3d10\x2e1002\x252F14651858\x2eCD000204\x2epub2"});Liferay.Portlet.register("scolarissearchportlet_WAR_scolarissearch");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_scolarissearchportlet_WAR_scolarissearch_",portletId:"scolarissearchportlet_WAR_scolarissearch",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3dscolarissearchportlet_WAR_scolarissearch\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dnull\x26p_p_col_pos\x3dnull\x26p_p_col_count\x3dnull\x26p_p_static\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD000204\x2epub2\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD000204\x2epub2\x2526type\x253Dcdsr\x2526contentLanguage\x253D\x26templateType\x3dfull\x26urlTitle\x3d\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD000204\x2epub2\x26contentLanguage\x3d\x26type\x3dcdsr\x26doi\x3d10\x2e1002\x252F14651858\x2eCD000204\x2epub2"});Liferay.Portlet.register("scolariscontentlanguagebanner_WAR_scolarislanguageportlet");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_",portletId:"scolariscontentlanguagebanner_WAR_scolarislanguageportlet",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3dscolariscontentlanguagebanner_WAR_scolarislanguageportlet\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dnull\x26p_p_col_pos\x3dnull\x26p_p_col_count\x3dnull\x26p_p_static\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD000204\x2epub2\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD000204\x2epub2\x2526type\x253Dcdsr\x2526contentLanguage\x253D\x26templateType\x3dfull\x26urlTitle\x3d\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD000204\x2epub2\x26contentLanguage\x3d\x26type\x3dcdsr\x26doi\x3d10\x2e1002\x252F14651858\x2eCD000204\x2epub2"});AUI().use("aui-base","liferay-menu","liferay-notice","liferay-poller","liferay-session",function(a){(function(){Liferay.Util.addInputType();Liferay.Portlet.ready(function(b,c){Liferay.Util.addInputType(c)});if(a.UA.mobile){Liferay.Util.addInputCancel()}})();(function(){new Liferay.Menu();var b=Liferay.Data.notices;for(var c=1;c<b.length;c++){new Liferay.Notice(b[c])}})();(function(){Liferay.Session=new Liferay.SessionBase({autoExtend:true,sessionLength:1800,redirectOnExpire:false,redirectUrl:"https\x3a\x2f\x2fwww\x2ecochranelibrary\x2ecom\x2fweb\x2fcochrane",warningLength:0})})()});</script> <script src="https://www.cochranelibrary.com/cochrane-theme/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1738734064000" type="text/javascript"></script> <script type="text/javascript"></script> <div class="mobile-righthand-nav"> <a class="rh-nav-close-btn" href="#"> <span>Close</span> <span class="fa fa-chevron-down"></span> </a> <div class="wrapper"> </div> <a class="rh-nav-open-btn" href="#"> <span>Review tools &amp; navigation</span> </a> </div> <iframe aria-hidden="true" id="printframe" name="printframe" style="position: absolute; left: -2000px; top: 0;" title="Print frame"></iframe> <iframe aria-hidden="true" id="citationExportFrame" name="citationExportFrame" style="position: absolute; left: -2000px; top: 0;" title="scolaris.citation.export.frame"></iframe> <nav> <div class="mobile-navigation"> <div class="close-container"> <a aria-label="Navigate back" class="main-nav-back-btn" href="#"><i class="fa fa-chevron-left"></i></a> <a class="main-nav-close-btn" href="#" title="Close menu">Close menu <i class="fa fa-times"></i></a> </div> <div class="mobile-search basic-search-container"> <div class="portlet-boundary portlet-boundary_scolarissearchportlet_WAR_scolarissearch_ portlet-static portlet-static-end" id="p_p_id_scolarissearchportlet_WAR_scolarissearch_"> <span id="p_scolarissearchportlet_WAR_scolarissearch"></span> <section class="portlet" id="portlet_scolarissearchportlet_WAR_scolarissearch"> <header class="portlet-topper"> <h1 class="portlet-title"> <span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Search\x20Portlet')"> <img alt="" id="ymag__null__null" src="/scolaris-search/icon.png"> <span class="taglib-text hide-accessible">Scolaris Search Portlet</span> </img></span> <span class="portlet-title-text">Scolaris Search Portlet</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolarissearchportlet_WAR_scolarissearch" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="header-search"> <form action="https://www.cochranelibrary.com/en/content?p_auth=xcg9958b&amp;p_p_id=scolarissearchportlet_WAR_scolarissearch&amp;p_p_lifecycle=1&amp;p_p_state=normal&amp;p_p_mode=view&amp;_scolarissearchportlet_WAR_scolarissearch_scolarisAction=redirectSearchResult" method="post"> <input name="searchType" type="hidden" value="basic"> <input name="facetDisplayName" type="hidden" value=""> <input name="facetQueryTerm" type="hidden" value=""/> <input name="facetQueryField" type="hidden" value=""/> <input name="facetCategory" type="hidden" value=""/> <fieldset class="fieldset"> <legend class="sr-only">Basic Search</legend> <div class="select search-by"> <select aria-label="Search by options" class="custom-select-enabled search-type" name="searchBy" title="Search by options"> <option value="1">Title Abstract Keyword</option> <option value="2">Record Title</option> <option value="3">Abstract</option> <option value="4">Author</option> <option value="5">Keyword</option> <option value="6">All Text</option> <option value="7">Publication Type</option> <option value="8">Source</option> <option value="9">DOI</option> <option value="14">Language</option> <option value="10">Accession Number</option> <option value="11">Trial Registry Number</option> <option value="12">Cochrane Group</option> <option value="13">Cochrane Topic</option> </select> </div> <div class="search-select-crg-container select" style="display: none;"> <select class="search-select-crg-list"></select> </div> <div class="search-select-topic-container select" data-topic-list-url="https://www.cochranelibrary.com/en/content?p_p_id=scolaristopics_WAR_scolaristopics&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=topics-list&amp;p_p_cacheability=cacheLevelPage" style="display: none;"> <select class="search-select-topic-list"></select> </div> <div class="search-select-cl-container select" style="display: none;"> <select class="search-select-cl-list"></select> </div> <div class="search-text-container"> <div class="control-group control-group-inline search-input-wrapper"> <input aria-label="Enter search term" class="field browser-search search-text ui-autocomplete-input" id="searchText" name="searchText" placeholder="Search" size="30" type="text" value=""/>
<div id="autocomplete-results"></div>
</div>
<div class="control-group control-group-inline search-button-wrapper">
<button aria-label="Search" class="searchByBtn" type="submit">
<i aria-hidden="true" class="fa fa-search"></i>
</button>
</div>
</div>
</fieldset>
</input></input></form>
</div>
<script>
    window.displayResultURL = 'https://www.cochranelibrary.com/en/content?p_p_id=scolarissearchportlet_WAR_scolarissearch&p_p_lifecycle=2&p_p_state=normal&p_p_mode=view&p_p_resource_id=getSuggestions&p_p_cacheability=cacheLevelPage&_scolarissearchportlet_WAR_scolarissearch_templateType=full&_scolarissearchportlet_WAR_scolarissearch_urlTitle=%2Fcdsr%2Fdoi%2F10.1002%2F14651858.CD000204.pub2&_scolarissearchportlet_WAR_scolarissearch_contentLanguage=&_scolarissearchportlet_WAR_scolarissearch_type=cdsr&_scolarissearchportlet_WAR_scolarissearch_doi=10.1002%2F14651858.CD000204.pub2';
    window.searchByOption = '';
</script>
</div>
</div>
</div>
<div style="display:none">
<input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
<a class="btn secondary" href="/en/browse-by-topic">Browse </a>
<a class="btn secondary advanced-search-button" href="/en/advanced-search">Advanced search</a>
</div>
<div class="menu-items parent">
<div>
<div class="nav-root-item parent">
<a class="language-selection-title-link" href="#" title="Select language">
<span class="mobile-nav-language-title">Select your preferred language </span></a> <span class="icon fa fa-caret-down"></span>
<div class="mob-child">
<div class="portlet-boundary portlet-boundary_scolarislanguageselector_WAR_scolarislanguageportlet_ portlet-static portlet-static-end" id="p_p_id_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_mobilenav_">
<span id="p_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_mobilenav"></span>
<section class="portlet" id="portlet_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_mobilenav">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Language\x20Selector')">
<img alt="" id="fdkn__null__null" src="/scolaris-language-portlet/icon.png"> <span class="taglib-text hide-accessible">Scolaris Language Selector</span> </img></span> <span class="portlet-title-text">Scolaris Language Selector</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_mobilenav" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="language-display" data-content-languages="[de, en, es, fa, fr, hi, hr, id, ja, ko, hu, ms, nl, pl, pt, ru, ro, ta, th, zh_HANT, zh_HANS]"> <a class="language-select-mobile" href="#" title="Select your preferred language"> <i class="fa fa-file-text"></i> English </a> <a class="language-select-mobile" href="#" title="Select your preferred language"> <i class="fa fa-globe"></i> English </a> </div> <div class="form-content language-selector-modal child"> <div class="row-fluid"> <h3><i class="fa fa-file-text"></i> Cochrane review language</h3> <p>Select your preferred language for Cochrane reviews and other content. Sections without translation will be in English.</p> <div class="dropdown-trigger" id="active-content-language"> <span>English</span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="language-selector-dropdown"> <a class="content-language-selector" data-languagecode="de" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=de">Deutsch</a> <a class="content-language-selector is-active" data-languagecode="en" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=en">English</a> <a class="content-language-selector" data-languagecode="es" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=es">Español</a> <a class="content-language-selector" data-languagecode="fa" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=fa">فارسی</a> <a class="content-language-selector" data-languagecode="fr" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=fr">Français</a> <a class="content-language-selector" data-languagecode="hi" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=hi">हिन्दी</a> <a class="content-language-selector" data-languagecode="hr" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=hr">Hrvatski</a> <a class="content-language-selector" data-languagecode="id" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=id">Bahasa Indonesia</a> <a class="content-language-selector" data-languagecode="ja" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ja">日本語</a> <a class="content-language-selector" data-languagecode="ko" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ko">한국어</a> <a class="content-language-selector" data-languagecode="hu" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=hu">Magyar</a> <a class="content-language-selector" data-languagecode="ms" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ms">Bahasa Malaysia</a> <a class="content-language-selector" data-languagecode="nl" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=nl">Nederlands</a> <a class="content-language-selector" data-languagecode="pl" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=pl">Polski</a> <a class="content-language-selector" data-languagecode="pt" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=pt">Português</a> <a class="content-language-selector" data-languagecode="ru" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ru">Русский</a> <a class="content-language-selector" data-languagecode="ro" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ro">Română</a> <a class="content-language-selector" data-languagecode="ta" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ta">தமிழ்</a> <a class="content-language-selector" data-languagecode="th" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=th">ภาษาไทย</a> <a class="content-language-selector" data-languagecode="zh_HANT" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=zh_HANT">繁體中文</a> <a class="content-language-selector" data-languagecode="zh_HANS" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=zh_HANS">简体中文</a> </div> </div> <div class="row-fluid"> <h3 class="portal-language-header"><i class="fa fa-globe"></i> Website language</h3> <p>Select your preferred language for the Cochrane Library website.</p> <div class="dropdown-trigger" id="active-portal-language"> <span>English</span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="language-selector-dropdown"> <a class="portal-language-selector is-active" data-portallanguage="en" href="/en/cdsr/doi/10.1002/14651858.CD000204.pub2/full/en">English</a> <a class="portal-language-selector" data-portallanguage="es" href="/es/cdsr/doi/10.1002/14651858.CD000204.pub2/full/es">Español</a> </div> </div> <a class="btn secondary ok-btn pull-right" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage">Save</a> </div> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
</div>
<div class="parent">
<a class="mobile-link signin" data-redirect="false" href="https://www.cochranelibrary.com/c/portal/login?p_l_id=20757&amp;redirect=%2Fcdsr%2Fdoi%2F10.1002%2F14651858.CD000204.pub2%2Ffull" rel="nofollow">
                        Sign In
                    </a>
</div>
</div>
<div class="menu-items-footer">
<div class="utility-links">
<a class="cochrane-link" href="http://www.cochrane.org/" target="_blank">Visit Cochrane.org</a>
</div>
</div>
</div>
<div class="menu-items child"></div>
</div>
</nav><div class="basic-login-form-content" data-modal-title="Sign in" style="display: none;">
<div class="form-content">
<div class="row-fluid">
<div class="span12">
<div class="portlet-boundary portlet-boundary_58_ portlet-static portlet-static-end portlet-login" id="p_p_id_58_INSTANCE_MODAL_">
<span id="p_58_INSTANCE_MODAL"></span>
<section class="portlet" id="portlet_58_INSTANCE_MODAL">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Sign\x20In')">
<img alt="" id="dbam__null__null" src="https://www.cochranelibrary.com/cochrane-theme/images/spacer.png" style="background-image: url('https://www.cochranelibrary.com/sprite/html/icons/_sprite.png'); background-position: 50% -592px; background-repeat: no-repeat; height: 16px; width: 16px;"> <span class="taglib-text hide-accessible">Sign In</span> </img></span> <span class="portlet-title-text">Sign In</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_58_INSTANCE_MODAL" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <form action="https://www.cochranelibrary.com/en/content?p_p_id=58_INSTANCE_MODAL&amp;p_p_lifecycle=1&amp;p_p_state=normal&amp;p_p_mode=view&amp;_58_INSTANCE_MODAL_struts_action=%2Flogin%2Flogin" autocomplete="on" class="form sign-in-form" id="_58_INSTANCE_MODAL_fm" method="post" name="_58_INSTANCE_MODAL_fm"> <fieldset class="input-container" disabled="disabled"> <legend class="sr-only">Cochrane Login</legend> <input name="_58_INSTANCE_MODAL_formDate" type="hidden" value="1740715239142"> <input class="field" id="_58_INSTANCE_MODAL_saveLastPath" name="_58_INSTANCE_MODAL_saveLastPath" type="hidden" value="false"> <input class="field" id="_58_INSTANCE_MODAL_redirect" name="_58_INSTANCE_MODAL_redirect" type="hidden" value="/cdsr/doi/10.1002/14651858.CD000204.pub2/full"> <input class="field" id="_58_INSTANCE_MODAL_doActionAfterLogin" name="_58_INSTANCE_MODAL_doActionAfterLogin" type="hidden" value="false"> <div class="control-group input-text-wrapper"> <label class="control-label" for="_58_INSTANCE_MODAL_login"> Email Address </label> <input class="field clearable" id="_58_INSTANCE_MODAL_login" name="_58_INSTANCE_MODAL_login" type="text" value=""> </input></div> <div class="control-group input-text-wrapper"> <label class="control-label" for="_58_INSTANCE_MODAL_password"> Password </label> <input class="field" id="_58_INSTANCE_MODAL_password" name="_58_INSTANCE_MODAL_password" type="password" value=""/> </div> <span id="_58_INSTANCE_MODAL_passwordCapsLockSpan" style="display: none;"> Caps Lock is on. </span> <div class="clearfix"> <div class="checkbox-list pull-left"> <div class="checkbox-list-item"> <div class="control-group form-inline input-checkbox-wrapper"> <label for="_58_INSTANCE_MODAL_rememberMeCheckbox"> <input id="_58_INSTANCE_MODAL_rememberMe" name="_58_INSTANCE_MODAL_rememberMe" type="hidden" value="true"/> <input checked="" class="field" id="_58_INSTANCE_MODAL_rememberMeCheckbox" name="_58_INSTANCE_MODAL_rememberMeCheckbox" onclick="Liferay.Util.updateCheckboxValue(this); " type="checkbox" value="true"/> Remember Me </label> </div> </div> </div> <div class="pull-right"> <a href="https://onlinelibrary.wiley.com/user/forgottenpassword" target="_blank">Forgotten password?</a> </div> </div> <div class="login-form-footer clearfix"> <div class="pull-left"> <button class="btn primary" type="submit">Sign in</button> <a class="btn secondary" href="https://onlinelibrary.wiley.com/user-registration" target="_blank">Register</a> </div> <div class="pull-right"> <a class="institutional-login-form-button" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentdisplay_WAR_scolariscontentdisplay&amp;p_p_lifecycle=0&amp;p_p_state=normal&amp;p_p_mode=view&amp;_scolariscontentdisplay_WAR_scolariscontentdisplay_action=institution-access">Institutional login</a> </div> </div> </input></input></input></input></fieldset> </form> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
</div>
</div></div>
<div class="institution-login-form-content" data-modal-title="Institutional login" style="display: none;">
<div class="form-content">
<div class="row-fluid access-content-wrapper">
<div class="span12">
<div class="section">
<div class="portlet-boundary portlet-boundary_scolariscontentdisplay_WAR_scolariscontentdisplay_ portlet-static portlet-static-end scolaris-content-display-portlet" id="p_p_id_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_combinedloginform_">
<span id="p_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_combinedloginform"></span>
<section class="portlet" id="portlet_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_combinedloginform">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Content\x20Display')">
<img alt="" id="obft__null__null" src="/scolaris-content-display/icon.png"> <span class="taglib-text hide-accessible">Scolaris Content Display</span> </img></span> <span class="portlet-title-text">Scolaris Content Display</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_combinedloginform" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="access-content-section"> <div class="section-content"> <p>Search for your institution's name below to login via Shibboleth</p> <form action="/shibboleth" id="institutionLoginForm" method="post"> <div class="fieldset"> <div class="form-group access-input-wrapper"> <div class="ui-widget ui-front"> <label class="sr-only" for="institutionName">Institution name</label> <input class="field" id="institutionName" name="institutionName" type="text" value=""/>
</div>
<button class="btn primary" name="button" type="submit">Go</button>
</div>
<div class="message error" id="institutionLookupErrorDiv" style="display:none">
                        '<span id="enteredInstitionNameSpan"></span>' is not set up for this type of access on Wiley Online Library. Please contact your institution's administrator to ask about access.
                    </div>
</div>
<input id="entityId" name="entityId" type="hidden" value=""/>
</form>
<h4>Previously accessed institutions</h4>
<ul class="plain" id="previousInstitutions">
<li>(none)</li>
</ul>
</div>
<div class="section-content">
<div class="open-athens-login">
                Login using <a href="/openathens">OpenAthens</a>
</div>
</div>
</div>
</div>
</div>
</div>
<div style="display:none">
<input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
<div class="portlet-boundary portlet-boundary_58_ portlet-static portlet-static-end portlet-login" id="p_p_id_58_INSTANCE_4_">
<span id="p_58_INSTANCE_4"></span>
<section class="portlet" id="portlet_58_INSTANCE_4">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Sign\x20In')">
<img alt="" id="joiu__null__null" src="https://www.cochranelibrary.com/cochrane-theme/images/spacer.png" style="background-image: url('https://www.cochranelibrary.com/sprite/html/icons/_sprite.png'); background-position: 50% -592px; background-repeat: no-repeat; height: 16px; width: 16px;"> <span class="taglib-text hide-accessible">Sign In</span> </img></span> <span class="portlet-title-text">Sign In</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_58_INSTANCE_4" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <p>If you have a <strong>Wiley Online Library</strong> institutional username and password, enter them here.</p> <form action="https://www.cochranelibrary.com/en/content?p_p_id=58_INSTANCE_4&amp;p_p_lifecycle=1&amp;p_p_state=normal&amp;p_p_mode=view&amp;_58_INSTANCE_4_struts_action=%2Flogin%2Flogin" autocomplete="on" class="form sign-in-form" id="_58_INSTANCE_4_fm" method="post" name="_58_INSTANCE_4_fm"> <fieldset class="input-container" disabled="disabled"> <legend class="sr-only">Cochrane Login</legend> <input name="_58_INSTANCE_4_formDate" type="hidden" value="1740715239146"> <input class="field" id="_58_INSTANCE_4_saveLastPath" name="_58_INSTANCE_4_saveLastPath" type="hidden" value="false"> <input class="field" id="_58_INSTANCE_4_redirect" name="_58_INSTANCE_4_redirect" type="hidden" value="/cdsr/doi/10.1002/14651858.CD000204.pub2/full"> <input class="field" id="_58_INSTANCE_4_doActionAfterLogin" name="_58_INSTANCE_4_doActionAfterLogin" type="hidden" value="false"> <div class="control-group input-text-wrapper"> <label class="control-label" for="_58_INSTANCE_4_login"> Username </label> <input class="field clearable" id="_58_INSTANCE_4_login" name="_58_INSTANCE_4_login" type="text" value=""> </input></div> <div class="control-group input-text-wrapper"> <label class="control-label" for="_58_INSTANCE_4_password"> Password </label> <input class="field" id="_58_INSTANCE_4_password" name="_58_INSTANCE_4_password" type="password" value=""> </input></div> <input class="field" id="_58_INSTANCE_4_institutionalLogin" name="_58_INSTANCE_4_institutionalLogin" type="hidden" value="true"/> <span id="_58_INSTANCE_4_passwordCapsLockSpan" style="display: none;"> Caps Lock is on. </span> <div class="login-form-footer clearfix"> <div class="pull-left"> <button class="btn primary" type="submit">Sign in</button> </div> </div> </input></input></input></input></fieldset> </form> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
</div>
</div>
</div></div>
<div class="get-access-form-content" data-modal-title="Unlock gold-standard Cochrane evidence" style="display: none;">
<div class="portlet-boundary portlet-boundary_scolariscontentdisplay_WAR_scolariscontentdisplay_ portlet-static portlet-static-end scolaris-content-display-portlet" id="p_p_id_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_getaccessform_">
<span id="p_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_getaccessform"></span>
<section class="portlet" id="portlet_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_getaccessform">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Content\x20Display')">
<img alt="" id="wpdq__null__null" src="/scolaris-content-display/icon.png"> <span class="taglib-text hide-accessible">Scolaris Content Display</span> </img></span> <span class="portlet-title-text">Scolaris Content Display</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_getaccessform" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="readcube-checkout-container-outer"> <div class="row-fluid access-content-wrapper"> <div class="span6 access-left-content"> <div class="section"> <div class="section-content"> <p>Improve your health decisions with access to trusted, independent evidence from the Cochrane Library. Unlock this review for uninterrupted access.</p> <p>Still deciding? <a href="https://m.info.wiley.com/webApp/cochranenewsletter"> Sign up to our newsletter to learn more </a> </p> </div> </div> <div class="section"> <div class="access-content-section"> <h3 class="title">Institutional users</h3> <div class="section-content"> <p>Search for your institution's name below to login via Shibboleth</p> <form action="/shibboleth" id="institutionLoginForm" method="post"> <div class="fieldset"> <div class="form-group access-input-wrapper"> <div class="ui-widget ui-front"> <label class="sr-only" for="institutionName">Institution name</label> <input class="field" id="institutionName" name="institutionName" type="text" value=""/> </div> <button class="btn primary" name="button" type="submit">Go</button> </div> <div class="message error" id="institutionLookupErrorDiv" style="display:none"> '<span id="enteredInstitionNameSpan"></span>' is not set up for this type of access on Wiley Online Library. Please contact your institution's administrator to ask about access. </div> </div> <input id="entityId" name="entityId" type="hidden" value=""/> </form> <h4>Previously accessed institutions</h4> <ul class="plain" id="previousInstitutions"> <li>(none)</li> </ul> </div> <div class="section-content"> <div class="open-athens-login"> Login using <a href="/openathens">OpenAthens</a> </div> </div> </div> </div> <div class="section"> <div class="access-content-section"> <h3 class="title"> Other access options </h3> <div class="section-content"> <ul class="plain"> <li> <a class="get-access-individual-login-button" href="/c/portal/login"> Individual access - via Wiley Online Library </a> </li> </ul> </div> </div> </div> </div> <div class="span6 access-right-content readcube-checkout-container"> <div class="section"> </div> </div> </div> </div> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/> <input id="openlabel" name="openlabel" type="hidden" value="Open access"/> </div> </section> </div> </div> <!-- Scolaris Version: --> <script type="text/javascript">if(window._satellite){_satellite.pageBottom()};</script> </div> <script>(function(){function c(){var b=a.contentDocument||a.contentWindow.document;if(b){var d=b.createElement('script');d.innerHTML="window.__CF$cv$params={r:'918d823f1987f446',t:'MTc0MDcxNTIzOS4wMDAwMDA='};var a=document.createElement('script');a.nonce='';a.src='/cdn-cgi/challenge-platform/scripts/jsd/main.js';document.getElementsByTagName('head')[0].appendChild(a);";b.getElementsByTagName('head')[0].appendChild(d)}}if(document.body){var a=document.createElement('iframe');a.height=1;a.width=1;a.style.position='absolute';a.style.top=0;a.style.left=0;a.style.border='none';a.style.visibility='hidden';document.body.appendChild(a);if('loading'!==document.readyState)c();else if(window.addEventListener)document.addEventListener('DOMContentLoaded',c);else{var e=document.onreadystatechange||function(){};document.onreadystatechange=function(b){e(b);'loading'!==document.readyState&&(document.onreadystatechange=e,c())}}}})();</script></body> </html> 